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Colorectal cancer is the second most frequent cancer among females after breast cancer and the 
third most common cancer among males, after prostate and lung cancer1. In 2010, 12755 patients 
were diagnosed with colorectal cancer in the Netherlands. Of these, 3667 (29%) were located in the 
rectum2. The incidence is rising, partly due to growth and ageing of the population. 
Rectal cancer is associated with a relatively poor prognosis due to the high risk of local recurrence 
and distant metastases. After 5 years, approximately 60% of patients are still alive. The diagnosis and 
optimal treatment of rectal cancer is a multidisciplinary team effort made by the gastroenterologist, 
radiologist, radiation oncologist, medical oncologist, surgeon and pathologist. In the past two decades 
our understanding of the locoregional spread of rectal cancer has improved substantially leading to 
major improvements in preoperative staging, surgical technique, histopathological aspects and to the 
introduction of preoperative (chemo)radiotherapy. This has decreased local recurrence (LR) rates from 
15-45% to approximately 10%. Distant metastases occurring in 20%-30% of patients have now become 
the event determining outcome which requires priority in future research.
DEFINITION OF THE RECTUM
Anatomically, the rectum emerges from the sigmoid colon about 12-15 cm from the anal verge 
(illustrated in Figure 1), where it curves posteriorly and descends within the bony pelvis. The rectum is 
surrounded by a fatty envelop, the mesorectum. At about 2-3 cm from the anal verge the levator muscle 
complex cones in and closely encases the rectum, replacing the fatty mesorectum. The mesorectum 
contains a powerful prognosticator in rectal cancer, the regional lymph nodes, and is circumferentially 
enclosed by the mesorectal fascia (MRF) (illustrated in Figure 2). Regarding the lymph drainage, the 
upper rectum drains into the inferior mesenteric system, while the middle and lower rectum may also 
drain directly into other lymph node stations, for example the internal iliac or the presacral nodes.
DEFINITION OF LOCALLY ADVANCED RECTAL CANCER
About 10% of patients present themselves at a later stage with more advanced locoregional disease, 
termed locally advanced rectal cancer (LARC): the tumour threatens or invades the MRF, sometimes 
even infiltrating surrounding structures and organs, and (more) pathologic lymph nodes may have 
developed (illustrated in Figure 2). The definition of locally advanced rectal cancer varies in the 
literature and differs in different geographical regions. Generally, North-Western Europe1;3 reserves 
this definition for only those “ugly” tumours threatening or invading the MRF, invading surrounding 
organs, those with more than 3 mesorectal lymph node metastases or with enlarged lateral pelvic 
lymph nodes. In Mediterranean countries4-6 and the US7;8 the definition is applied less vigorously and 





Figure 1: the left drawing depicts the gastrointestinal tract starting with the stomach, which becomes the small 
intestine (removed in this illustration), the colon and then the rectum and anus. Dotted lines depict two areas: the 
upper area is resected during a low anterior resection, implemented for mid and upper rectal tumours. In case of 
a low rectal tumour, situated close to the anal sphincter, an abdominoperineal resection is performed whereby 
both areas are resected. The right drawing shows a sagittal or lateral view of the female rectum, enveloped by the 
mesorectal fat tissue. Dotted lines depict the plane of resection during a low anterior resection according to the 
principles of total mesorectal excision. Lymph nodes are coloured in green. Drawings by H. van’t Hof.
Figure 2: On the left a schematic representation of an axial image of the rectum of a male, showing 4 examples of 
primary tumour growth: a clinical T2 (cT2) tumour which stays confined to the muscular layer, a cT3 that invades 
the mesorectal fat and does (red arrow) or does not threaten the mesorectal fascia (MRF) or a cT4 tumour which 
invades the prostate. The red dotted line shows the MRF along which total mesorectal excision (TME) is performed. 
The blue arrow demonstrates pathologically enlarged mesorectal lymph nodes. On the right a slice of magnetic 
resonance imaging (MRI) depicting a tumour with infiltration of the MRF on the anterior side (red arrow). This 
tumour is classified as a cT3 with an involved MRF, thereby classifying it as a locally advanced tumour requiring 




Preoperative staging of rectal cancer is an important aspect of clinical management, particularly in 
determining indications for neoadjuvant therapy. Diagnosis of rectal cancer follows after pathological 
confirmation of biopsies taken from the tumour during endoscopy. The height of the tumour can 
be estimated from the anal verge which aids the choice in type of surgical resection. The classical 
way to evaluate the extent of a rectal tumour is by digital rectal examination (DRE). However, clinical 
terms such as fixed or mobile are difficult to interpret and inter-observer bias is high. Furthermore, 
information gained with DRE does not reflect the relationship between the tumour and the underlying 
structures like the mesorectal fascia. Therefore, further imaging of the pelvis to stage local disease 
follows, whereby depth of primary tumour invasion (T-stage) and the presence of lymph node 
metastases (N-stage) are important factors9. Regarding the accuracy of the different staging tools at 
hand, Bipat10 reported the results of a meta-analysis of 90 studies investigating staging accuracy. In 
summary, endoluminal-ultrasound (EUS) has an important role in the staging of superficial tumours 
and is preferred over MRI to differentiate between T1 and T2 tumours. The abdominal multi-slice 
CT was traditionally implemented for more locally advanced tumours but following improvements in 
resolution of the MRI, the MRI has now become the cornerstone of staging for non-superficial rectal 
cancer (cT3-4) giving more information, in addition to tumour depth and height. Advantages of the 
MRI include the ability to visualize the relationship between the tumour and the MRF (illustrated in 
Figure 2) and predict MRF involvement accurately11;12. This relationship affects preoperative treatment 
planning significantly, enabling a more patient tailored approach. The preoperative identification of 
lymph node metastases is difficult but improvements have been made with the introduction of the 
MRI, whereby size, inhomogeneity and border contour seem to be predictive factors13. However, nodal 
staging remains unreliable and is in need of further development in the future. Another recent and 
promising finding is the ability to identify extra-mural vascular invasion of the tumour on MRI14, which 
has proven to be a prognostic factor predicting locally advanced disease and associated poor outcome. 
However, more evidence is required to embed this factor into standard MRI staging in daily clinical 
practice and the definition of LARC.
Another important aspect of preoperative staging involves screening of systemic dissemination. A CT-
scan of the abdomen or ultrasound of the liver, and X-ray or CT-scan of the thorax can evaluate the 
occurrence of distant metastases, at diagnosis and during follow-up. Positron emission tomography 
(PET) using 18-flurodeoxyglucose tracer is increasingly being applied to evaluate metastatic or 
recurrent disease but presently has no role in initial preoperative staging15. As resolution improves 
and combinations between imaging modalities become possible (like PET-MRI) staging will become 
more complex and expensive, but hopefully lead to more accuracy. 
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1 IMPROVEMENTS IN SURGICAL TECHNIQUE 
Surgery remains the cornerstone of rectal cancer treatment. Up to the early 1990’s, population-
based and randomized studies reported LR rates up to 45% after conventional “blunt” surgery16. 
Heald was the first European surgeon to publish superior local control resulting from a new surgical 
technique: total mesorectal excision (TME)17. He acknowledged the importance of the mesorectum by 
incorporating embryologically determined planes into surgery. Instead of the blunt dissection of the 
perirectal fascia, he advocated sharp dissection under direct vision of the “holy plane”, an avascular 
plane formed by the mesorectal fascia. In doing so the surgeon provided the pathologist with a surgical 
specimen with an intact mesorectum, as illustrated in Figure 3, resulting in a lower rate of positive 
resection margins. Additionally, the pelvic autonomous nerves could be spared, thereby reducing 
urinary and sexual dysfunction. Heald18 reported a LR rate of 6% after 5 years and this was confirmed 
by other single-centre series like Enker et	al19 reporting a LR rate of 7%. These clearly superior results 
led to the consensus-based introduction of TME as standard of care in rectal cancer without awaiting 
further evidence from a randomized study. 
The Dutch TME trial20 was designed in the Netherlands as part of a nationwide initiative to introduce 
TME and optimize and standardize treatment of rectal cancer. Workshops were held and instructor 
surgeons were appointed to teach fellow surgeons. A total of 1861 patients were included between 
1996 and 1999 and quality of surgery and pathology was studied and assured. Results confirmed 
low LR rates of 11% after TME alone with a negative CRM being a powerful predictor. An APR was 
also associated with a higher LR rate compared to a low anterior resection (LAR). In-depth analysis 
demonstrated that an APR was associated with a higher CRM positive rate of 30%21, probably due to 
the fact that anatomically, the mesorectal fat disappears in the distal rectum, misleading the surgeon 
to “cone in” and cause a positive margin. This has led to a change in surgical approach for distal rectal 
cancer by maintaining a “cylindrical” resection distal from the levator muscles to retain adequate 
circumferential margins. Overall, the introduction and training of TME over the years has decreased 
LR after 2 years (after TME only) from 16% to 9% and increased overall survival from 77% to 86% in 
the Netherlands22.
DEVELOPMENTS IN (NEO)ADJUVANT STRATEGIES
In the last decades, perioperative or (neo)adjuvant treatments have been added to the surgical 
treatment of rectal cancer to further improve prognosis. At present preoperative or neoadjuvant 
therapy is given with two goals in mind: short-course radiotherapy (SCRT, 5x5 Gy), for the eradication 
of pelvic micro-metastases which is followed directly by TME, and long-course chemoradiotherapy 
(CRT) for downsizing of locally advanced tumours to facilitate radical resection 6-8 weeks later. To 





Figure 3 depicts a macroscopic complete rectal resection specimen after TME surgery. Reprinted with permission 
© 2013 American Society of Clinical Oncology23. All rights reserved. 
The Swedish Rectal Cancer Trial24 which included patients in the pre-TME era, showed that SCRT 
administered 1 week prior to conventional surgery was capable of reducing 5-year local recurrence 
rates (27% vs. 11%) and improving 5-year overall survival (48% vs. 58%) compared with conventional 
(non-TME) surgery alone. After a median of 13 years these differences maintained significance25. 
The abovementioned Dutch TME trial followed with a similar design and investigated the additive 
value of this regimen when TME surgery was performed. It confirmed that neoadjuvant SCRT 
decreased the long-term LR rates from 11% with TME surgery only, to 6% after 5x5 Gy RT and TME, 
but found no difference in survival26. An important finding was that SCRT followed directly by TME 
does not compensate for tumour positive resection margins27. Patients at risk for a positive CRM 
should therefore be selected preoperatively to achieve preoperative downsizing of the tumour with 
a conventional radiotherapy schedule in order to facilitate radical surgery. In patients with LARC, 
the addition of chemotherapy to long-course radiotherapy (CRT, 45-50 Gy) followed by delayed 
surgery results in increased downsizing and downstaging and a reduction in local recurrences 
compared with either neoadjuvant radiation without chemotherapy or CRT delivered in the 
postoperative setting4;28-30. However, no effect on overall survival was found in any of these studies. 
Two studies, a Polish and an Australian randomized trial, later compared CRT followed by delayed 
TME and SCRT followed by direct TME in resectable rectal cancer and observed more downstaging 
after CRT, but found no significant difference in local recurrence, DFS or OS31;32. However, both 
studies were underpowered, making it difficult to draw firm conclusions. To answer the question 
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1 whether delaying TME after SCRT will facilitate downstaging, the Stockholm III trial is presently randomizing patients between SCRT followed by direct TME, delayed TME or long-course RT and 
delayed TME. 
Other on-going discussions over future neoadjuvant strategies include whether an increase in 
tumour response should be a goal of research. Ways do attain this would be to increase total dose 
of radiotherapy, for instance by using an integrated boost or brachytherapy, or by adding other 
(combinations of) chemoradiosensitizers to the radiotherapy to optimize response to radiotherapy. 
However, the latter seems to increase toxicity without significant increases in response33. Lastly, one 
could intensify the role of chemotherapy, for instance by starting with neoadjuvant chemotherapy, 
followed by SCRT or CRT and delayed surgery. A possible reason to increase response would be to be 
able to limit surgical intervention necessary for cure, a concept discussed in the following paragraph. 
MODERN ORGAN-PRESERVING APPROACHES 
After TME, whether an APR or LAR is performed, life-altering changes in (bowel) function, with or 
without a stoma, occur which affect quality of life. As a result there is an active interest in applying 
less invasive methods for management of rectal cancer, but oncological safety must be guaranteed. 
Local excision has been investigated in the treatment of early rectal cancer. Recent reports of stage 
T1N0 rectal tumours resected using transanal endoscopic microsurgery (TEM), instead of a TME, 
indeed show lower rates of morbidity and mortality, but at a cost of increased local recurrence rates 
of more than 20%34;35. Of note, salvage surgery for these patients and survival upon diagnosis of a local 
recurrence proved to be dismal due to the development of distant metastases in 39%36 and emphasize 
potential dangers of less invasive surgical treatment.
In a German randomized trial investigating the treatment of cT3-4 or node-positive disease, all 
patients undergoing neoadjuvant CRT and TME 6 weeks later were evaluated for response to therapy. 
Ten percent of patients had a pathologic complete response (pCR) with no viable tumour identified 
after resection30. No patients with a pCR developed local recurrence of disease, and these patients 
experienced superior disease-free survival than did those with a lesser response to neoadjuvant 
therapy. In the literature pCR rates of up to 30% have been described with subsequent excellent 
outcome6;37;38 which has led to investigations into a non-operative `wait and see` policy37. Assessment 
of clinical response is done using digital and endoscopic rectal examination with biopsies taken from 
suspicious areas, CT scan of the abdomen and EUS, whereby patients showing a clinical complete 
response are selected for less invasive surgery or omission of surgery all together. These patients are 
monitored in an intensified follow up scheme. Habr-Gama et	al39 have published encouraging results 
after omitting TME, which have been confirmed by another smaller series40. However, concerns have 
been expressed by others41 demonstrating that only 30% of patients with a clinical complete response 
actually have a pCR. Advanced imaging techniques, such as diffusion weighted MRI42 might improve 
accuracy. The data on this interesting topic is sparse and limited to single centres and together 
with the inaccuracy of standard imaging tools to assess response and nodal disease, needs further 
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1validation. Another option consisting of full thickness TEM in responding tumours after CRT, has recently gathered interest with advantages of tissue sampling for valuable histopathological analysis 
and results in acceptable short-term local control rates 43;44. 
Long-term outcome will determine possible indications for these conservative approaches as potential 
tumour deposits or lymph node metastases in the mesorectum are not assessed or treated in this 
way and may affect prognosis drastically. The importance of clinically undetectable residual tumour 
deposits in the mesorectum has not yet been clarified. The risk of lymph node involvement increases 
with depth of wall penetration. In a population based study of non-irradiated patients, lymph node 
involvement was observed in 6-14% of T1 tumours, in 17% to 23% ofT2 tumours, and in 49% to 66% 
of T3 tumours, respectively45. In a series of 121 patients receiving neoadjuvant CRT46, lymph node 
metastases occurred in 8% in ypT0, 0% in ypT1, 19% in ypT2, 49% in ypT3 and 75% in ypT4 disease. 
The risks of under-treatment and subsequent residual disease require further investigation before one 
can safely embark local excision policies. On the other hand overtreatment of those unresponsive to 
CRT, resulting in unnecessary toxicity, is also an issue. 
DEMARCATION OF TUMOURS IN THE RECTUM
External beam radiotherapy is the “main delivery technique” in radiotherapy. Endorectal 
brachytherapy, a promising new option based on contact x-ray therapy as described in the early 1970’s, 
is given through a flexible multi-channel applicator placed in the rectum. Utilizing their radiopaque 
characteristics, endoclips have been used to mark tumours or anatomical structures to facilitate 
intervention radiology47 and radiotherapy48;49 or to locate the tumour intra-operatively50. A modern 
indication is the use to aid correct positioning of the endorectal applicator, for tumour location but 
also for target volume delineation purposes during brachytherapy. Furthermore, as CRT results in 
complete remission in up to 30% of patients, demarcation of the tumour location will become more 
important in the future. Different types of clips have been developed which facilitate a better grasp 
of the tissue thereby probably improving retention rates. Retention rates have, however, only been 
evaluated in canines and pigs and have not yet been reported in the human gastrointestinal tract. 
ADVERSE EFFECTS ASSOCIATED WITH THE TREATMENT OF RECTAL CANCER
As prognosis of rectal cancer treatment improves, adverse effects and quality of life become more 
important issues that need to be weighed up against potential advantages resulting from the different 
improvements. Adverse effects of surgery include surgical complications and long-term pelvic organ 
dysfunction while adverse effects of (C)RT include short- and long-term toxicity. The combined 
modality treatment causes mixed and sometimes additive toxicity.
A symptomatic anastomotic leakage after a LAR, which is the most feared complication, occurs in 
10%51 and can lead to abdominal sepsis and even death, while intra-abdominal abscesses delay 
postoperative recovery. In a Swedish randomized controlled trial, a deviating stoma after LAR decreased 
the number of symptomatic anastomotic leakages from 28% to 10%52. However, stoma reversal is also 
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1 associated with morbidity and mortality
53 and is not possible in a fifth of patients54. Perineal wound 
complications after abdominoperineal resection (APR) occur in up to 34%55 of patients and represent a 
challenging management problem, with associated pain, unpleasant odour and unexpected drainage 
seriously affecting quality of life. After neoadjuvant CRT, anastomotic leak rates of up to 27% have 
been reported55, but this has not been reproduced in the randomized controlled trials4;30;56. However, 
complication rates are not endpoints of randomized controlled trials and definitions used for scoring 
complications are seldomly reported in retrospective series, which indicate lack of actual complication 
rates after CRT followed by delayed TME. 
With regards to long-term adverse effects of surgery and subsequent quality of a life, a recent 
comparative study found APR to be comparable to LAR, with 72% of LAR patients experiencing a 
degree of faecal incontinence while sexual dysfunction was higher in the APR group57. An analysis of 
long-term adverse effects of TME in the Dutch TME trial reported both urinary incontinence and faecal 
incontinence developing in almost 40% of patients58, while sexual dysfunction occurs in more than 
half of patients59 after TME only. This study demonstrated that TME itself, causing nerve damage and 
anatomical changes, seems to be the main cause of functional morbidity after rectal cancer treatment. 
Regarding short-term toxicity during SCRT, negligible additional toxicity was reported in the Dutch 
TME trial during the 5 days of SCRT60. The German Rectal Cancer Study Group trial30 demonstrated 
that neoadjuvant CRT with 5-FU in patients with LARC resulted in fewer short- and long-term adverse 
effects than after postoperative CRT. With regards to long-term adverse effects, no difference was 
found between CRT and SCRT in the Australian study randomizing between SCRT followed by direct 
TME and CRT followed by delayed TME32. However, in the Dutch TME trial, at 5 years after treatment, 
faecal incontinence was reported by 62% of patients after SCRT and TME versus 39% after TME only61. 
Sexual dysfunction occurred more frequently in the radiotherapy arm59. In conclusion, additional 
radiotherapy increases local control but adds adverse effects in comparison to TME alone.
As the age of the population increases the treatment of the elderly plays an increasingly important 
role. Patient tailored treatment is needed in this fragile patient category known to have higher post-
operative six-month mortality rates62. Of note, the mortality as a consequence of anastomotic leakage 
is much higher than in younger patients, while the leakage rate is equal. Rutten et	al62 went on to 
contemplate that treatments that keep extent of surgery and associated morbidity to a minimum 
and optimize the use of radiotherapy might be more suitable for elderly patients with diminished 
physiological reserves and co-morbidity. 
OPTIMIZING TARGET VOLUMES IN RADIOTHERAPY
One of the principle goals in the radiotherapeutic field includes maximizing efficacy and minimizing 
damage of healthy tissue with subsequent toxicity. To achieve this, great accuracy and a well-defined 
target volume is required. Three different target volumes are important in radiotherapy, the gross 
tumour volume (GTV), the clinical target volume (CTV) and the planning target volume (PTV). The GTV 
in rectal cancer is defined as the actual visible primary tumour and any involved lymph nodes. The 
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1CTV is the GTV plus the volume that is suspected to contain microscopic tumour deposits. However, in radiotherapy more uncertainties prevail and include day to day variation (of the CTV) within a patient 
due to organ motion and with respect to the setup on the treatment machine63. These uncertainties 
are taken into account by expanding the CTV with a safety margin to a PTV64. The larger the PTV 
margin, the more certain it is that the CTV will receive the prescribed dose; however, the more healthy 
tissue will be included in the field of radiation, resulting in unnecessary toxicity. 
As microscopic tumour deposits are undetectable on imaging, anatomical guidelines for CTV definitions 
have been developed65 based on (non-irradiated) patterns of local recurrence. A recent 3D analysis of 
local recurrences of the Dutch TME trial reported very few recurrences above the S2-S3 interface 
leading to lowering of the cranial border of the CTV in patients with expected pN0 and CRM negative 
disease66. The CTV is typically defined by manual delineation on a planning CT-scan and presently 
encompasses the (meso)rectum and the lymph nodes of the presacral, obturator and internal iliac 
region. Cranially, the (meso)rectum CTV is bordered by the sigmoid curve while the caudal border 
depends on the planned operation. In case of an APR the perineum is included, while for all other 
tumours the entire mesorectum is delineated down to at least 4 cm under the tumour. For the coming 
years the challenge will be to describe the complete CTV more extensively and finally reach consensus 
on CTV delineation. 
The most important organs at risk during RT for rectal cancer are the small bowel, followed by 
the sphincter complex. Over the years, developments in RT delivery and planning have decreased 
irradiation to the small bowel by increasing the number of angles, size and different shapes of the 
beam. Conventional RT has been replaced by 3- or 4- field techniques to spare healthy tissue without 
compromising treatment of the target volume. With the introduction of the multi-leaf collimator 
the shape of each beam can be adapted to the actual shape of the PTV, resulting in conformal RT. 
Nowadays, we have the ability to deliver the RT dose using intensity modulated radiotherapy where, 
for instance, 7 beams from different angles can be subdivided into segments, with variable intensity. 
However, as a result, dose fall-off becomes steeper and therefore margins need to be accurate and 
variations accounted for, to avoid under dosage. To assure correct patient position during RT a low 
dose CT scan can be made during treatment (so called cone beam CT). Still, more insight in organ 
motion is needed to guarantee adequate treatment delivery. 
THE INCREASING ROLE OF THE PATHOLOGIST
Pathology plays an important role in rectal cancer staging and prediction of prognosis. Rectal cancer 
is staged according to the Tumour Node Metastases (TNM) classification9. As illustrated in Figure 2, a 
T1 tumour stays confined to the (sub)mucosa, a T2 invades the muscularis propria, and a T3 invades 
further through the muscular layer into the mesorectal fat tissue, while a T4 tumour grows through 
the serosa or invades surrounding organs. The nodal stage includes N0, meaning lymph node negative 
disease; N1 includes metastases in 1-3 regional lymph nodes; while N2 includes more than 3 positive 
regional lymph nodes. The presence of distant (systemic, peritoneal or lymph node) metastases is 
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1 shown by the M, whereby M1 entails distant metastases. The TNM stage is defined as pTNM when based on pathology and as cTNM when based on (preoperative) clinical findings. When preoperative 
therapy may have induced a response (for instance after chemoradiotherapy) it becomes ypTNM. 
Subsequent versions of the TNM have been introduced over the years, dividing a category into 
subcategories, in an attempt to further refine prognosis. Refinements in the TNM classification every 
5–7 years, however, mean that comparisons across studies and clinical trials that have been performed 
using earlier editions of the TNM system are no longer possible without first revising the pathology 
using the new version. Therefore, but also due to its higher reproducibility, Dutch national guidelines1 
state that the 5th TNM version9 (instead of the recently introduced 7th) should be used for the staging 
of rectal cancer.
In the last decades, the role of the pathologist in the treatment of rectal cancer has evolved 
tremendously. The pathologist has become a key player in assessing quality of surgery and giving 
feedback to the multidisciplinary team. The improvements in preoperative staging and surgical 
technique are the result of an increased understanding of the microscopic locoregional spread of 
rectal cancer in the mesorectum. In 1943, Dukes67 presented his presidential address on pathological 
aspects of rectal cancer demonstrating the prognostic importance of tumour characteristics like depth 
of invasion, location, venous invasion, lymphatic spread and tumour-free margins. Forty years later, 
extensive pathologic research by Quirke68 has revealed the importance of the lateral or circumferential 
resection margin (CRM) as a prognostic factor for local recurrence. Patients with tumour in the inked 
CRM but also those with tumour cells approaching the CRM within 1 mm were at risk and developed 
a LR in 80%. A positive CRM, as shown in Figure 4, is defined as primary tumour or a positive lymph 
node found ≤ 1 mm from the CRM. These results confirmed the findings by Heald69 implementing TME 
in the same period and led to fewer positive margins and less residual disease. In a review, Nagtegaal 
et	al70 demonstrated that after the introduction of TME, and even more so after the introduction of 
neoadjuvant therapy, CRM remains a powerful prognosticator, predicting LR, distant metastases and 
overall survival. In LARC patients undergoing CRT, local recurrence occurs in only 8% of the patients 
with a negative CRM compared with 43% in case of CRM involvement71. 
After the introduction of neoadjuvant (C)RT histological alterations occur of which the prognostic value 
is yet to be defined73. In up to 30% of patients a pathological complete response (pCR) is observed after 
CRT, with no viable primary tumour cells in the specimen. The pCR rate may also vary due to differences 
in the pathology protocol used to exclude residual disease. Incompletely understood entities include 
the heterogeneous response observed after CRT, the meaning of the formation of fibrosis, residual 
tumour deposits and tumours that are replaced by acellular mucin lakes. The histopathological 
regression of tumour to the CRT is assessed by semi-quantitatively scoring the relative proportion 
of residual tumour to stromal fibrosis (tumour regression grade74 or TRG), and has been correlated 
with outcome. Since reproducibility of several commonly used five tiered tumour regression grading 
systems is notoriously poor, no system has gained acceptance in practice. More subgroups, in poor 




Figure 4: Schematic representation of the macroscopic histopathological view of the circumferential resection 
margin in resection specimens. In A and C a positive lymph node is situated close to the CRM, as indicated by the 
arrow. In B and D the primary tumour invades into the perirectal fat tissue close to the CRM, as indicated by the 
arrow. Reprinted with permission © 2013 American Society of Clinical Oncology70 and American Journal of Surgical 
Pathology72. All rights reserved.
DISTANT METASTASES IN RECTAL CANCER
Following the improvements in local control, distant metastases occurring in up to 30% of patients 
remain a problem and govern outcome in rectal cancer26;75. Adjuvant systemic chemotherapy (CT) 
seems to be the obvious means of attacking micro-metastases to prevent these metastases, but 
evidence for its efficacy in rectal cancer is poor and much less than in colon cancer76-78. Furthermore, 
no significant gain in survival was observed when adding CT to RT followed by surgery in rectal cancer 
patients4;29. In the QUASAR study, conducted in predominantly low-risk colorectal cancer patients in 
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1 Western countries in the pre-neoadjuvant therapy era, an improvement in survival was observed
79, 
while in another study in the same period benefit was found in colonic cancer but not for rectal 
cancer80. A recent Cochrane meta-analysis showed a reduction of 17% in the risk of death after adjuvant 
CT in comparison to surgery alone, once again, in the pre-neoadjuvant therapy era81. In contrast, an 
exploratory analysis of an EORTC trial suggested that for patients responding to neoadjuvant treatment 
with a ypT0-2 result, adjuvant CT improved survival82 while those not responding to CRT also do 
not benefit from adjuvant CT. A recent European Consensus Conference failed to reach consensus 
regarding the benefit of postoperative CT after CRT, because of insufficient evidence83. In the Dutch 
rectal cancer guidelines, adjuvant chemotherapy is administered only in trial setting. Results from the 
recently closed Dutch randomized SCRIPT trial which addresses this question are awaited. In other 
countries, national guidelines support adjuvant CT as standard of care. The benefit in those with a 
complete response or those with a ypN0 stage has, however, been questioned84. 
Peritoneal carcinomatosis (PC) is another location for distant metastases present in approximately 10% 
of patients with colorectal cancer at the time of diagnosis and in about 25% of patients with recurrent 
disease. PC seems to behave differently than the systemic metastases to the liver and lungs. It has 
been suggested that if distant metastases are limited to the peritoneal cavity, PC should be regarded 
as locoregional disease progression rather than systemic progression. Prolonged survival using a new 
treatment technique, cytoreduction followed by hyperthermic intra-peritoneal chemotherapy (HIPEC) 
has been reported85. The concept entails cytoreductive surgery whereby all macroscopic disease 
is removed by organ resection or peritoneal stripping. The intra-operative intra-peritoneal lavage 
with chemotherapy then eradicates microscopic disease, while hyperthermia improves peritoneal 
permeability and cytotoxicity. Verwaal et	 al86 published the only randomized controlled trial to 
date, demonstrating improved survival after cytoreduction followed by HIPEC compared to systemic 
treatment in patients with PC. As a result of the randomized trial, cytoreduction followed by HIPEC has 
been introduced in the Netherlands and since then more than 1000 procedures have been performed 
over 5 institutes. 
Cytoreduction is attempted only in those in which a complete cytoreduction is probable, as otherwise 
patients do not benefit from the treatment. As present day imaging cannot detect PC accurately, 
exploration of the abdomen is the only way to gain information on extent of disease. Different scoring 
systems are in use to score extent of disease upon opening the abdomen but evidence is lacking to 
support one in particular. 
QUALITY ASSURANCE IN RECTAL CANCER
From the above it is clear that the treatment of rectal cancer has evolved from a mono-disciplinary 
surgical approach to multidisciplinary team work. Variability in care inevitably causes variability in 
quality of care. Improving surgical quality therefore also implies reducing variability among surgeons. 
Total mesorectal excision is a technically demanding operation and quality is surgeon-dependent with 
regards to volume and case-mix87. With regards to daily practice, the multimodality character and 
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1different treatment approaches have made the treatment of rectal cancer complex for health care professionals. An optimal patient-tailored decision-making process requires adequate interdisciplinary 
communication and coordination. Burton	 et	 al	 confirmed this hypothesis, demonstrating that 
multidisciplinary team discussion and implementation of a MRI-guided preoperative treatment 
strategy resulted in significantly reduced positive CRM rates in rectal cancer patients3. Evidence based 
rectal cancer treatment guidelines1 for the Netherlands were introduced in 2004 and recommend 
that all patients be discussed by a MDT, irrespective of tumour stage or treatment plan. At the MDT 
meeting, patients are stratified according to risk of a positive CRM, and subsequent local recurrence, 
and treated accordingly. Patients with a mobile, resectable tumour (cT2-3N0-1) undergo SCRT followed 
directly by TME while those with LARC undergo neoadjuvant CRT followed by TME 6-8 weeks later. 
Possible benefits of a more standardized approach to preoperative and histopathological staging are 
that certain parameters for quality assurance and possibilities for direct feedback to the MDT arise. 
With regards to quality assurance, the first nationwide initiative to improve quality in rectal cancer 
started in 1993 in Norway with the Norwegian Rectal Cancer Project. Centralized treatment was 
implemented “top-down”, TME was taught to participating surgeons and the national cancer registry 
collected information, thereby facilitating comparisons over the different periods. All participating 
institutions received feedback on their own results, benchmarking with the national average. More 
than 99% of patients operated for rectal cancer were included. After 4 years the results of this audit 
were remarkable: the proportion of TME surgery rose from 78% to 92% and the local recurrence rate 
dropped from 28% to 7%88. As a consequence, the concept of a surgical audit was established and 
in the meantime several European countries have embarked on a surgical audit. In 2009 the Dutch 
Surgical Colorectal Audit (DSCA) was initiated by the cancer care providers themselves to maximize 
transparency in quality of care from a “bottom up” perspective. First publications already show an 
increase in quality of care for these patients89. In addition, collaboration between different modalities 
has led to the publication of the SONCOS document in 2012, containing minimal requirements that 
need to be met by different departments of hospitals aiming to provide cancer care. Amongst others, 
an active MDT is required, modern imaging tools must be implemented, an annual volume of 20 TME’s 
need to be performed and LARC has been centralized. Under supervision of the government health 
board, insurance companies determine financial compensations to be awarded to the hospitals on the 
basis of these quality care indicators.
Chapter 1
24
1 OUTLINE OF THE THESIS
Remaining questions and current goals in the treatment of rectal cancer include optimizing staging 
accuracy, establishing the optimal neoadjuvant strategy to be implemented in the different stages 
of rectal cancer and possibly leading to the evidence-based introduction of organ sparing and 
non-operative strategies in selected patients. Furthermore, adverse effects of new multi-modality 
treatments need to be investigated to properly inform patients. Correlating histopathological 
response to outcome will provide information on efficacy of new neoadjuvant therapies, factors 
governing distant metastases and potential consequences of scaling down treatment approaches to 
avoid surgery. The aim of this thesis, addressing the different modalities, was to evaluate these aspects 
concerning the multidisciplinary treatment of rectal cancer in general, with the focus on patients with 
locally advanced rectal cancer in particular. 
As the treatment of rectal cancer has evolved it is important to introduce these improvements in 
all hospitals treating rectal cancer thereby maximizing patient benefit. In Chapter 2 an overview of 
the adherence to treatment guidelines for rectal cancer is presented in the form of a population-
based study with the aim of improving the exposure of all patients to modern rectal cancer treatment. 
Particular attention was paid to present staging accuracy and the additional value of the discussion 
of patients in a multidisciplinary team. The 3rd Chapter captures developments in the delivery of 
target volumes in radiotherapy and reports results from a prospective repeat-CT study to describe 
full 3D shape variation for the entire clinical target volume for rectal cancer during short-course 
radiotherapy and chemoradiotherapy. This chapter also describes and validates a pragmatic approach 
to translate clinical target volume shape variation into a planning target volume margin with the aim 
to decrease radiation dose to surrounding healthy tissues. In Chapter 4 acute toxicity and surgical 
complications were evaluated in patients with locally advanced rectal cancer. Results are presented 
from a relatively large series of patients treated uniformly with neoadjuvant chemoradiotherapy with 
capecitabine followed by total mesorectal excision 6-8 weeks later. Chapter 5 reports the results after 
central revision of the histopathology of the patients discussed in chapter 4. Objective of this study 
was to evaluate which factors determine outcome, focusing on the contribution of histopathological 
response after chemoradiotherapy and the possible consequences for a “wait and see” policy. The 6th 
Chapter describes demarcation of the rectal tumour with endoclips placed around the tumour during 
sigmoidoscopy before radiotherapy treatment. Results are shown of our evaluation of long-term 
attachment of two different endoclips in the human gastrointestinal tract. Chapter 7 concerns patients 
with peritoneal carcinomatosis of colorectal origin who underwent cytoreduction and HIPEC. In this 
study three different scorings systems used to quantify extent of tumour load at laparotomy were 
compared. In Chapters 8 - 10 the thesis is concluded with a general discussion and future perspectives, 
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ABSTRACT
BACKGROUND
The purpose of the present study was to evaluate the value of discussing rectal cancer patients in a 
multidisciplinary team (MDT).
METHODS
All treated rectal cancer patients (>T1M0) diagnosed in 2006–2008 were included. According to the 
national guidelines, neoadjuvant (chemo)radiotherapy should be given to all rectal cancer patients. 
Patients were scored as ‘‘discussed’’ (MDT+) only if documented proof was available. The primary 
endpoint was the number of positive circumferential resection margins (CRM ≤1 mm).
RESULTS
Of the 275 patients included, 210 were analysed (exclusions: (recto)sigmoid tumour, acute 
laparotomy, and inoperability). Neoadjuvant treatment was applied in 174 (83%) patients and 
followed by total mesorectal excision in 171 (81%) patients. Patients considered not to require 
downstaging, received short-course radiotherapy (SCRT) (n = 116) or no radiotherapy (no RT) (n = 
36), whereas 58 more advanced patients received chemoradiotherapy (CRT). The MDT discussion 
took place in 116 cases (55%). In the MDT+ group an MRI was used more often (p = 0.001) and TNM 
staging was more complete (p<0.001). The proportion of patients with advanced disease was higher 
in the MDT+ group (88% ≥T3/N+ versus 68%; p = 0.001). The overall CRM+ rate was 13% and did not 
differ between the MDT+ and the MDT– group (p = 0.392). In patients receiving SCRT or no RT, the 
CRM+ rate was 10%, whereas the rate was 20% for patients receiving CRT.
CONCLUSION 
Although no difference in CRM+ rate was found for those patients who were discussed and those 
who were not, our results demonstrate room for improvement, especially in the selection of 
patients for SCRT or no RT. We advocate standardized documentation of treatment decisions and 
pathology reports.




Over the last 10-15 years, the treatment of rectal cancer has evolved tremendously. Results of 
randomized controlled trials20;30;90 have led to the introduction of “total mesorectal excision” (TME)69 
and preoperative (chemo)radiotherapy in Western Europe. Further research has established the 
role of the pathologist and radiologist in optimizing the multidisciplinary treatment of rectal cancer. 
Identification of tumour ≤ 1 mm from the circumferential resection margin (CRM+) has proven to be 
a strong predictor of local recurrence, distant metastases and survival, resulting in a new surrogate 
endpoint of rectal cancer treatment70;91-93. Meanwhile, two radiological studies11;94 demonstrated that 
MRI can accurately predict involvement of this surgical CRM, thereby shifting the importance of an 
accurate T-stage on MRI to the more clinically appealing mesorectal fascia (MRF) at risk for a positive 
CRM after TME. 
With regards to daily practice, the multimodality character and different treatment approaches have 
made the treatment of rectal cancer complex for health care professionals. An optimal patient-tailored 
decision-making process requires adequate interdisciplinary communication and coordination. 
Burton et	al have shown that a MRI directed multidisciplinary team (MDT) discussion of rectal cancer 
patients with implementation of a preoperative stratification significantly reduced the CRM+ rate3. In 
certain patients groups, MDT discussion is increasingly becoming standard of care, but evidence of its 
direct effect on the quality of cancer care remains limited95. Rectal cancer treatment guidelines for 
the Netherlands were introduced in 2004 and recommend that all patients be discussed by a MDT, 
irrespective of tumour stage or treatment plan. At the MDT meeting, patients are stratified according 
to risk of a positive CRM, and subsequent local recurrence, and treated accordingly. Possible benefits 
of a more standardized approach to preoperative and histopathological staging are that certain 
parameters for quality assurance and possibilities for direct feedback to the MDT arise. For instance, 
patients receiving short-course radiotherapy (SCRT) or TME only should all have a negative CRM after 
TME, as otherwise chemoradiotherapy (CRT) was the preferred preoperative treatment to induce 
preoperative downstaging. 
We studied surgical outcome after the introduction of TME with the administration of (chemo)
radiotherapy in selected cases of rectal cancer in the greater Amsterdam region. The aim of this 
population-based study was to evaluate the additional value of discussing rectal cancer patients in a 
MDT, with the occurrence of a positive CRM as endpoint. Additional aims were to audit preoperative 







All patients diagnosed with cT2-4, N0-2 rectal cancer (TNM, 5th edition9) in one of six referring 
hospitals and one cancer referral centre in the greater Amsterdam region, between January 2006 and 
January 2008, were included in the study. Exclusion criteria included patients with low risk cancer 
(cT1N0) receiving local excision only, previous invasive cancers, a tumour located above the peritoneal 
deflection or more than 15 cm from the anal verge, or patients with metastasized disease. 
DATA COLLECTION
The Comprehensive Cancer Centre Amsterdam (CCCA) is an independent regional, population-based 
cancer registry with complete coverage of a population of approximately 3 million inhabitants. 
Following histopathological diagnosis, cancer patients are identified from the nationwide pathology 
registry (PALGA) and prospectively entered into the registry. This pathology registry also assures 
complete coverage of all patients diagnose in the region enabling a true population based study. 
Registration clerks routinely extract data on tumour stage, treatment and follow-up from hospital 
and outpatient records. Additional information, not routinely collected, was collected retrospectively 
by the registration clerks of the CCCA or by one of the authors (HAMS and EGP) and included type of 
imaging for preoperative staging, discussion by a MDT, treatment decisions and treatment outcome.
MDT
In the regional referral network of the cancer institute, patients are discussed in a multidisciplinary 
oncology meeting at the referring hospital. During an MDT discussion patient history, clinical and 
psychological condition, comorbidity, modes of work-up, clinical staging and optimal treatment 
strategies are discussed. The multidisciplinary team members present include a consulting oncologic 
surgeon, a radiation oncologist and a medical oncologist (all from the cancer institute), the treating 
specialists (surgical oncologist, medical oncologist) as well as a radiologist, a pathologist and a 
specialized nurse (nurse practioner or case manager). If the MDT at the referring hospital decides to 
treat the patient with neoadjuvant radiotherapy, the patient is referred to the cancer institute. In case 
of doubt, when the optimal treatment approach is queried by the radiation oncologist at the cancer 
institute, or when a locally advanced tumour is suspected, the patient is also discussed in the cancer 
institute’s specialized gastrointestinal cancer MDT.
Patients were scored as “discussed” (MDT+) only if documented proof was available that the patient 
had been discussed preoperatively at a MDT meeting, either in a referring institute or in the cancer 
institute. 




In the Netherlands, patients are stratified into three risk groups, each with a different treatment 
approach based on the risk of a positive CRM and subsequent local recurrence. Low-risk patients, 
defined as those with superficial tumours (T1N0) where treatment with local excision suffices, were 
excluded from the study. The intermediate risk group consists of patients with mobile resectable 
tumours (T2 and small T3, N0-1), suitable for treatment with preoperative 5x5 Gy radiotherapy (short-
course radiotherapy, SCRT) followed directly by TME. In patients with small proximal tumours without 
clinical node metastasis, where the additional value of radiotherapy is under debate, preoperative SCRT 
may be withheld after discussion in a MDT. The high-risk group includes patients with locally advanced 
tumours, where the MRF and consequent surgical CRM is threatened or involved, or where extensive 
lymph node involvement is expected. In this group, the treatment of choice consists of preoperative 
downstaging with long-course radiotherapy (25x2 Gy) in combination with fluoropyrimidine-based 
chemotherapy4;29;30;96, followed by TME 6-8 weeks later. Standard chemotherapy in the study period 
was capecitabine, 825mg/m2, bid on days 1-33. In three patients, bevacizumab (5mg/kg i.v. on days 
-14, 1, 15 and 29) was added in trial setting. Four patients received 50 Gy only as chemotherapy was 
contraindicated. 
PATHOLOGY
An involved CRM (CRM+) was defined as tumour or an involved lymph node ≤1 mm from the CRM. If 
the CRM was not mentioned in the report (n=81), additional investigation of the CRM was performed 
by a pathologist (MLV). 
STATISTICAL ANALYSIS
Data were entered into a database and analysed using the Statistical Package for the Social Sciences 
(version 15.0 for Windows; SPSS, Chicago, Illinois, USA). To determine significance in differences 
between groups of patients, chi-square tests were used for categorical variables unless stated 
otherwise, while the t-test and Mann-Whitney test were used for continuous variables. A p-value of < 
0.05 (two-sided) was regarded statistically significant.
RESULTS
Initially, 275 patients with intermediate or high-risk rectal cancer were identified. Inoperable patients 
(n=24), patients undergoing non-elective surgery (n=1) or those with a (recto)sigmoid	tumour (n=40) 
were excluded, leaving 210 patients suitable for analysis. Fifty-five per cent (116/210) of all patients 
were discussed by a MDT. In Table 1, baseline patient and treatment characteristics are shown for all 
patients and also for MDT+ and MDT- groups. Of the discussed patients, 50% were discussed at the 
referring hospital only, 20% were discussed both at the referring hospital and at the cancer institute, 




Table 1: Patient and Treatment characteristics according to discussion by a MDT
Total MDT + MDT –
 n= % a n= %a n= %a p-value
Total patients 210 100 116 55b 94 45b 0.147c
Sex Male 122 58 63 54 59 63 0.217
Female 88 42 53 46 35 37
Age Median 70 69 70 0.312
Range 37-89 37-87 41-89
Tumour location 0-5cm 75 36 52 45 23 24 0.002
6-10 89 42 46 40 43 46
>10 45 21 17 15 28 30
Unknown 1 1 1 1 0 0
MRI Yes 175 83 106 91 69 73 0.001
No 35 17 10 9 25 27
Clinical tumour stage (cT) 1 6 3 2 2 4 4 0.001d
2 47 22 20 17 27 29
3 103 49 67 58 36 38
4 30 14 25 22 5 5
Unknown 24 11 2 2 22 23
Clinical node stage (cN) 0 108 51 55 47 53 56 0.014d
1 69 33 40 34 29 31
2 17 8 15 13 2 2
Unknown 16 8 6 5 10 11
Advanced stage  
(≥T3 or N+)
n=198
Yes 149 81 99 88 50 68 0.001
No 36 20 13 12 23 32
Type of preoperative
treatment
None 36 17 7 6 29 31 <0.001e
SCRT 116 55 61 53 55 59
CRT 58 27 48 41 10 11
Type of surgery LAR 115 55 48 41 67 71 <0.001f
Hartmann 28 13 20 17 8 9
APR 64 31 46 40 18 19




0 9 4 8 7 1 1 0.262d
1 20 10 11 10 9 10
2 68 32 35 31 33 35
3 102 49 56 49 46 49




0 73 64 57 61 0.437b
1 26 23 24 26
2 15 13 11 12
Unknown 0 0 1 1
Abbreviations:	SCRT:	short-course	radiotherapy.	CRT:	chemoradiotherapy.	LAR:	low	anterior	resection.	
APR:	abdominoperineal	resection.	Pt:	patients.	a)	Percentages	are	column	percentages	unless	stated	







Of the 210 patients, 178 (85%) had a clinical TNM stage, including both T and N-stage, reported. 
In the MDT+ group, staging was more complete (94% versus 73%, p<0.001) while a MRI was also 
performed more often (p=0.001). In addition, the proportion of patients with advanced disease (≥T3 
and/or N+) was higher (p=0.001) in the MDT+ group. Correlation of the clinical and pathological T 
and N stages of the subgroup of patients receiving SCRT or TME only (to exclude downstaging effects 
of CRT) revealed a staging accuracy for T-stage of 57% (Table 2) and N-stage of 63%. In Table 2 only 
patients with complete cT and pT were included. No significant difference in tumour or nodal staging 
accuracy (understaging, accurate, overstaging) was found between MDT+ and MDT- groups (p= 0.139 
and 0.902). 
TREATMENT
Preoperative (chemo)radiotherapy was applied in 174 (83%) patients. Three patients did not proceed 
to surgery due to death during CRT, poor performance status and local progression, respectively. Thirty-
six patients underwent TME only. Patients receiving preoperative (chemo)radiotherapy were discussed 
more often in a MDT than those undergoing TME only (63% versus 19%, p<0.001). Furthermore, 
patients with distal tumours (≤5 cm from the anal verge) were more likely to be discussed in a MDT 
than those with more proximal (6-15 cm) tumours (69% versus 47% MDT+, p=0.002). 
OUTCOME
The CRM was initially reported in 126 (61%) and additionally measured in 71 (34%) of the 207 resected 
patients, while in 10 patients the CRM remained unknown. In total, in 24 patients a positive CRM was 
documented after resection, while in one patient the tumour was irresectable after CRT, resulting 
in an overall CRM+ rate of 13% (25/198). An APR was not associated with significantly more CRM+ 
resections (18% versus 10% after sphincter saving resections, p=0.093). Increasing pathological T- and 
N- stage were both associated with increasing CRM+ rates (p=<0.001 and p=0.001, respectively). 
The flow diagram in Figure 1 illustrates outcome after different treatment strategies. The CRM+ rate for 
intermediate risk patients (i.e. receiving SCRT or no radiotherapy) was 10% (14/143) while it was  20% 
(11/55) after CRT (including one irresectable patient). Furthermore, in the intermediate risk subgroup, 
distal tumours were associated with more CRM+ resections (8/38 CRM+, p=0.011) compared to those 




Figure 1: Flow diagram of treatment and CRM+ rate
Table 3 shows CRM involvement according to MDT discussion. The overall CRM+ rate did not differ 
significantly between the MDT+ (14%, 16/111) and the MDT- (10%, 9/87) group (p=0.392), even when 
patients with a positive CRM determined by an involved node were excluded from the comparison 
(p=0.198). When analysing the subgroup of intermediate risk patients (receiving SCRT or no RT) only, 
the CRM+ rate remained similar (12% versus 8%, respectively; p=0.385). The root-cause analysis in 
Table 4 describes the characteristics and treatment of those patients with a CRM+ outcome after TME 
only or SCRT. Of these 14 patients with a positive CRM, not treated with CRT, discussion in a MDT 
could not prevent the positive CRM in eight patients, while six patients were not discussed by a MDT. 
Strikingly, in non-discussed patients with a positive CRM 3 patients had a pathological T4 tumour that 
was not recognized during preoperative staging.
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Table 2: Correlation of the clinical and pathological T stages of the subgroup of patients not receiving CRT.
pT
Total
1 2 3 4
cT
1 3 3 0 0 6
2 10 22 10 1 43
3 3 22 45 2 72
4 0 1 2 1 4
Total 16 48 57 4 125
Table 3: shows CRM involvement according to MDT discussion
























None 6 (100) 0 0 1 24 (92) 1 (4) 1 (4) 3 36
SCRT 52 (87) 7 (12) 1 (2) 1 47 (92) 3 (6) 1 (2) 4 116
CRT 37 (82) 7 (16) 1 (2) 1 7 (70) 2* (20) 1 (10) 0 56
Total 95 (86) 14 (13) 2 (2) 3 78 (90) 6 (7) 3 (3) 7 208*
*	Including	1	irresectable	tumour.	Abbreviations:	MDT	+:	Discussed	by	a	multidisciplinary	team.	MDT-:	
Not	discussed.	 CRM:	 circumferential	 resection	margin.	 CRT:	 chemoradiotherapy.	 SCRT:	 short-course	
radiotherapy.	uk:	unknown
DISCUSSION
This population based study represents daily practice in the Netherlands in the era following the TME 
trial. Only half of the patients diagnosed with rectal cancer in our region are discussed by a MDT. As 
predominantly advanced patients were selected for discussion, this may have influenced the study 
outcome whereby no significant benefit was found for MDT discussion on the CRM+ rate. We found an 
overall CRM+ rate of 13%, while for the subgroup of patients in which preoperative downstaging was 
not deemed necessary, the rate was 10%. Documenting the CRM in the pathology report has not yet 




Table 4: CRM positive patients: a root-cause analysis.
Pt nr Tumour height (cm)









node at CRM TN stage
1 0-5 - No None Hartmann 0 Tumour cT4Nx, pT4N0
2 0-5 - Yes SCRT LAR 0 Lymph node cT3N1, pT3N1
3 0-5 - Yes SCRT LAR ≤1 Tumour cT3N1, pT3N0
4 0-5 Referring  hospital Yes SCRT Hartmann ≤1 Tumour cT3N0, pT3N2
5 0-5 Referring  hospital Yes SCRT APR ≤1 Tumour cT2N0, pT3N0
6 0-5 Referring  hospital Yes SCRT APR ≤1 Tumour cT2N1, pT2N0
7 0-5 Referring hospital Yes SCRT APR 0 Tumour cT3N1, pT2N2
8 0-5 Cancer Institute Yes SCRT APR ≤1 Lymph node cT2N2, pT2N2
9 6-10 - Yes SCRT LAR 0 Tumour cT2N0, pT4N2
10 6-10 - Yes SCRT APR 0 Tumour cT3N1, pT4N0
11 6-10 Referring hospital Yes SCRT LAR 0 Tumour cT3N1, pT3N1
12 6-10 Both Yes SCRT LAR 0 Tumour cT3N0, pT3N1
13 >10 - No None LAR ≤1 Lymph node cTxN0, pT3N1
14 >10 Cancer Institute Yes SCRT Hartmann ≤1 Tumour cT3N0, pT3N1
No	 information	 on	 the	 completeness	 of	 the	 surgical	 specimen	was	 available.	 Abbreviations:	MDT:	
multidisciplinary	team,	CRM:	circumferential	resection	margin,	CRT:	chemoradiotherapy,	SCRT:	short-
course	radiotherapy,	APR:	abdominoperineal	resection,	LAR:	low	anterior	resection.	
CRM + RATES IN THE LITERATURE
In the TME trial, patients with resectable rectal cancer were randomized between TME alone and 
SCRT followed by TME within 10 days. In this quality controlled study undertaken in the era preceding 
the use of MRI, the reported CRM+ rates after macroscopic complete resection were 18% and 16%, 
respectively27. The CRM rate of 10% in patients receiving SCRT or TME only in our study reflects 
progression in this field; but it also illustrates room for further improvement in patient selection, 
especially in patients receiving SCRT (11% CRM+). In the MRC CR07 study, a study comparable to the 
TME trial, the CRM+ rates were 10% of those undergoing a macroscopic complete resection in the 
SCRT arm and 12% in the TME alone arm90. During this study period the MRI was being introduced 
as selection tool, with 41% of patients staged with MRI, indicating the advantages of MRI on patient 
selection.
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EFFECT OF THE MDT DISCUSSION
Dutch rectal cancer treatment guidelines recommend discussing all patients in a MDT meeting. As 
mentioned above, our study shows that this is not yet the case in our region. 
Despite the fact that recording the results of the MDT discussion is mandatory in the Netherlands, it 
is possible that we underestimated the number of patients discussed due to a lack of documentation. 
The use of a pro forma for all patients would facilitate more complete documentation of the 
discussion or the reason why a patient was not discussed. Burton3 evaluated the effects of regional 
implementation of a MDT discussion and reported a CRM+ rate of 13%, which is equal to ours. In 
contrast to our study, they showed that discussion by a MDT was associated with a significantly 
lower CRM+ rate (26% versus 8%). At re-audit one year later, after introduction of compulsory MDT 
discussion for all rectal cancer patients, 96% were discussed and the CRM+ rate was decreased to 7% 
overall, which emphasizes the importance and effect of multidisciplinary interaction in their region. 
Due to a selection of advanced patients for discussion a true comparison between MDT+ and MDT- 
patients in our series is difficult, especially because advanced patients have a higher a-priori risk of a 
CRM+ resection, thereby undermining the value of the MDT. Although acceptable CRM+ rates were 
obtained with this selective discussion approach, there is room for improvement. In fact, six CRM+ 
patients, who were not discussed and received SCRT or no RT, might have benefitted from a discussion 
by a MDT. This is underscored by the fact that three of these patients had a pT4 tumour, indicating that 
CRT was absolutely necessary. We therefore advocate discussion of all rectal cancer patients in a MDT. 
Regarding the MDT itself, eight patients discussed in a MDT received SCRT but ended up with a positive 
CRM, indicating that the MDT itself also needs improvement. However, another confounding factor 
may be the quality of the surgical specimen (Table 4). 
PRE-TREATMENT STAGING
With regards to preoperative staging, T-staging accuracy with MRI was 57%, similar to that of the 
MERCURY group in their national MRI implementation program (53%)97. Inaccuracy in distinguishing 
T1 from a T2 (34% in our study) and T2 from a T3 (32%) reported in this study is in line with the 
literature and indicate that MRI does have its limits in T and N staging11. However, recent studies11;94 
have shown that a shift in staging has taken place from primarily an accurate T-stage on MRI to a 
more clinically important mesorectal fascia (MRF) at risk for a positive CRM after TME. In our study, 
treatment stratification was based on the risk of a positive CRM (<2 mm at risk), but exact distances to 
the MRF on MRI were not documented. Twelve of the 14 patients with a positive CRM after SCRT or 
TME only were staged with MRI, indicating that more attention is needed to accurately select patients 
at risk. A pro forma with standardized quantification of margins, tumour infiltration depth, and size 
and aspects of nodes might facilitate further optimization of staging. Furthermore, a MRI based MDT 
discussion will lead to a better understanding of the anatomy of the rectal tumour which is important 





In the 11 patients with a positive resection margin after CRT, a complete resection was not possible 
indicating that sufficient downstaging after chemoradiotherapy is not always achieved. Re-staging 
after chemoradiotherapy, which was not standard of care during this study period, might have 
optimized treatment by enabling the surgeon to plan the resection according to the (lack of) response 
or to even decide to delay surgery to optimise response. However, on MRI microscopic tumour 
deposits remain difficult to distinguish from benign desmoplastic reaction. Possibly, PET scanning will 
aid the identification of vital and metabolically active tumour cells in the future. Other possibilities 
to further decrease the CRM+ rate after CRT include centralisation of the treatment and further 
optimisation of the synergistic effect of chemoradiotherapy on tumour downstaging with either 
intensified chemoradiotherapy or tumour specific biologicals, like VEGF inhibitors. However, whether 
this approach will really lead to better clinical outcome remains to be seen. In the ACCORD 12 trial33, 
T3-4M0 rectal cancer patients were randomised between 45 Gy RT with capecitabine or 50 Gy RT 
with capecitabine and oxaliplatin. A significant decrease in CRM+ resections with intensified CRT (19% 
versus 10%, p=0.02) was observed. Whether this was due to the increased radiotherapy dose or the 
addition of oxaliplatin remains speculative. 
STUDY LIMITATIONS
Due to the retrospective population based nature of this study; some limitations need to be 
addressed. We only scored patients as MDT+ if documented proof was available that the patient had 
been discussed preoperatively at a MDT meeting. It is possible that the number of patients discussed 
in a MDT has been underreported. Exact details on and reasons underlying treatment decisions (for 
instance: patient unfit for chemo(radiotherapy)) were not available. Regarding patient outcome, 
follow-up was not long enough to be able to demonstrate the prognostic importance of a positive 
CRM with regards to the (local) recurrence rate or overall survival.
CONCLUSION
In conclusion, in our region MRI based preoperative stratification has led to a selective approach to MDT 
with 55% of patients being discussed. Even though national guidelines state that all patients should be 
discussed in a MDT before starting treatment this is not yet the case in clinical practice. Interestingly, 
even though the group of patients discussed consisted of patients with higher risk for a positive CRM 
due to their advanced stage of disease, this did not result in more CRM positivity in comparison to 
the group of patients not discussed by a MDT with predominantly less advanced disease. In this latter 
group one would expect less positive CRM resections. The CRM+ rate of 10% in patients not receiving 
CRT indicates room for improvement. The message of this study is clear; the implementation of MRI 
in optimizing patient selection has not yet reached its full potential. Standardized staging (MRI and 
histopathology) in all rectal cancer patients will lead to improvement of rectal cancer treatment and 
create opportunities for feedback to the MDT.
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ABSTRACT
BACKGROUND
To quantify the inter-fraction shape variation of the CTV in rectal cancer patients treated with 5 x 5 
(SCRT) and 25 x 2 Gy (LCRT) and derive PTV margins.
METHODS 
Thirty-three SCRT with daily repeat CT scans and 30 LCRT patients with daily scans during the first 
week followed by weekly scans were included. The CTV was delineated on all scans and local shape 
variation was calculated with respect to the planning CT. Margin estimation was done using the local 
shape variation to assure 95% minimum dose for at least 90% of patients. 
RESULTS
Using 482 CT scans, systematic and random CTV shape variation was heterogeneous, ranging from 
0.2 cm close to bony structures up to 1.0 cm SD at the upper-anterior CTV region. A significant 
reduction in rectal volume during LCRT resulted in an average 0.5 cm posterior shift of the upper-
anterior CTV. Required margins ranged from 0.7 cm close to bony structures up to 3.1 and 2.3 cm in 
the upper-anterior region for SCRT and LCRT, respectively.
CONCLUSIONS
Heterogeneous shape variation demands anisotropic PTV margins. Required margins were 
substantially larger in the anterior direction compared to current clinical margins. These larger 
margins were, however, based on strict delineated CTVs, resulting in smaller PTVs compared to 
current practice.




The standard of care for early-stage and locally-advanced rectal cancer has evolved to preoperative 
short-course radiotherapy (RT) followed by a total mesorectal excision (TME) and long-course chemo-
RT followed by a TME, respectively24;26;90;98;99. The side-effects of RT can be reduced by advanced 
treatment delivery techniques such as intensity modulated RT (IMRT)100;101. To assure clinical target 
volume (CTV) coverage with IMRT a proper planning target volume (PTV) margin should be applied 
accounting for all geometric uncertainties. The known dominant uncertainties in RT of rectal cancer 
are CTV shape- and delineation-variation with systematic and random errors up to 1 cm SD. Despite 
the size and impact of these uncertainties, only few publications are available describing them102-108, 
with the limitation of small numbers and only a part of the CTV investigated. Furthermore, there is 
no recipe available to calculate the required PTV margin to account for these variations. Available 
margin recipes are only valid for translations of rigid CTV structures64;109. In clinical practice often a too 
small uniform 1 cm PTV margin is used, for which the radiation oncologist often delineates the CTV 
generously to compensate for shape variation106. 
The purpose of this study was to evaluate the shape variation of the clinical target volume in both 
early- and advanced-stage rectal cancer and to establish subsequent planning target volume margins. 
The data were gathered in a prospective repeat CT (rCT) study.
PATIENTS AND METHODS
PATIENTS, SCANS AND TREATMENTS
The study was initiated in the Netherlands Cancer Institute (NKI) and expanded to the Leiden University 
Medical Centre (LUMC). For patients with short-course RT (SCRT) of 5 x 5 Gy, daily rCT scans were 
acquired. For patients with long-course RT (LCRT) of 25 x 2 Gy, daily rCT scans were acquired in the 
first week followed by weekly scans. The study was designed to include 40 SCRT and 40 LCRT patients, 
20 male and 20 female each. Previous surgery or RT in the pelvic area and supine positioning (e.g. due 
to stoma) were exclusion criteria. 
All CT scans were acquired in prone position, on a flat table, ranging from the L2-L3 junction to below 
the perineum. A rotated knee support was placed under the lower legs for immobilization. When 
clinically feasible, intravenous contrast enhancement was used for the planning CT (pCT) only. No 
rectal contrast was used. All patients received instructions to empty the bladder and subsequently 
drink 350 ml water 1 h before the pCT and every treatment fraction. The rCT scans were planned 
before the treatment fraction.
STUDY DELINEATIONS
On each CT scan the following structures were delineated: bladder, rectum, and the CTV divided into 




obturatorial lymph node regions left and right (LN_L, LN_R) (Figure 1). The rectum was delineated 
from the dentate line up to the sigmoidal curve. 
The MesoRect included the sphincter complex and the mesorectum with borders defined by the 
external sphincter, the mesorectal fascia, and had the cranial border at the same level as the rectum. 
In the cranial region where the mesorectal fascia could not be identified, the anterior border was 
delineated 0.5 cm anterior of the rectum, excluding small bowel loops.
Figure 1: Example of the delineated structures on the planning CT of a male patient. On the left axial views at two 
different levels are shown, on the right a sagittal view. The delineated structures are the bladder, the rectum, the 
MesoRect including the sphincter complex, the presacral region and the lymph node regions left and right.
The LN_L and LN_R regions included the internal iliac, the lateral sacral, and the superior gluteal 
artery. The caudal border was where the obturator artery entered the obturator canal. The cranial 
border was the division of the common iliac artery in the external and internal artery. The borders 
were defined by the ureters anteriorly, the bones/muscles laterally, the MesoRect, seminal vesicles, 
uterus, neurovascular bundle medially. 
The Presacr delineation connects the LN_L and LN_R from the cranial border of the MesoRect and 
includes the superior rectal artery. Small bowel loops were excluded from all delineations. All structure 
definitions were the same for SCRT and LCRT patients. The GTV was not delineated. All scans of a 
patient were delineated by one of five observers. The structures were first delineated on the pCT 
Repeat CT assessed CTV variation and PTV margins for short- and long-course preoperative RT
45
3
and discussed among the observers and one radiation oncologist. The rCT scans were subsequently 
delineated after bony anatomy registration, using the pCT delineations as example. 
SHAPE VARIATION
To compare the CTV shape variation between patients the following model was used. The MesoRect 
and Presacr delineation were added together (MesoPresacr) to create the central, cylinder-like, part of 
the CTV. The pCT MesoPresacr was sliced into 80 slices containing 100 equidistant dots per slice, with 
the first dot of each slice at the dorsal side. LN_L and LN_R were analysed separately, using 40 slices 
and 50 dots per slice, numbered starting at the mid-lateral side of the slices. The shape variation was 
calculated by measuring signed distances to the surfaces of the rCT CTVs perpendicular to the surface 
of the pCT delineation for each point. For each point the average distance and the standard deviation 
over the distances were calculated. 
The assumption was made that the ordered points were comparable between patients, such that 
corresponding points could be used to calculate the local group mean (GM), systematic (∑), and 
random (σ) shape variation by means of the average of the averages, the SD over the averages, and 
the root-mean-square of the SD’s, respectively. For long-course RT a normalized weighted average and 
SD were calculated for each patient by using a weight of 1 for the scans in the 1st week and a weight 
of 5 for the following scans. 
MARGINS
In order to calculate the PTV margins for shape variation of the CTV, the margin recipe for rigid CTV 
motion of van Herk et	al64 was adapted. The aim was to define a margin recipe using the local group 
mean, systematic, and random shape variation surface maps assuring a minimum CTV dose (Dmin) of 
95% of the prescribed dose for at least 90% of the patients. In the rigid setting the PTV margin can be 
calculated by mPTV = α * ∑ + β * √(σ
2 + σp
2) – β * σp + GM with the SD to describe the penumbra width 
(σp) in the pelvic area taken as 0.32 cm, α = 2.5 and β = 1.64 to meet our demands. Adaptation of the 
formula was needed because in a rigid setting, systematic translations always result in a movement out 
of the high dose region on one side, while the other side of the CTV moves within the high dose region. 
The effect of systematic shape variation depends on the correlation between the shape variations on 
different areas of the surface of the CTV110;111. Group mean errors are generally small and discarded, 
but when significant time-trends are present they can be included by simple adding to the PTV margin, 
taking the margin directions into account. 
The effect of random errors in the setting of rigid motion or shape variation is the same, namely 
blurring of the dose to the CTV as a local effect. For random shape variation 1.64 * √(σ2 + 0.322) – 1.64 
* 0.32 was used. 
To estimate the remaining unknown factor α, the factor was varied between 2.0 and 4.0 in steps of 0.1 




and a penumbra described by σp = 0.32 cm, resulting in a 95% isodose line at the edge of the PTV
64. 
Within each dose distribution the surface dose to the CTV was accumulated by slicing each rCT CTV 
into 80 slices with 100 dots per slice. The dose was accumulated over the corresponding points and 
the Dmin was calculated for each patient. The α-factor assuring Dmin of 95% of the prescribed dose for 
90% of the patients was finally used in the adapted margin recipe. 
All calculations described above were performed perpendicular to the pCT CTV surface. Most treatment 
planning systems are not capable of this type of expansion and use rolling ball like algorithms. To 
get the rolling ball expansions the shortest distance from each PTV surface to its corresponding CTV 
surface was calculated locally. The median distance over corresponding points in the patient groups 
was taken to derive the required local rolling ball PTV margin. 
Finally, sub-volumes of the CTV were visually derived based on the heterogeneity of locally defined 
margins. For each sub-volume a clinically applicable margin was defined in orthogonal directions. The 
PTVs created with these margins were dosimetrically analysed by generating ideal dose distributions 
and accumulation of the dose over the rCT delineations. Finally, a volumetric comparison to the actual 
clinical PTVs, which were based on generously delineated CTVs and a 1 cm PTV margin, was done to 
estimate the impact of strictly delineated CTVs plus the newly derived margins in clinical practice. 
STATISTICAL ANALYSIS
For all delineations the absolute volume and the volume relative to the pCT was calculated. The 
relative volumes were tested to be different from 1 using a 2-sided student T-test for each rCT time 
point. Systematic shape variation errors between the groups were compared using a 2-sided F-test 
on corresponding points resulting in a p-value surface map. The GM shape errors were tested on 
difference from 0 using a T-test. For random errors a 2-sided T-test was used to test the means as a 
surrogate for the root-mean-square. In the analysis four different groups were compared, being the 
male and female SCRT, and the male and female LCRT patients. Significance level was set to p < 0.05.
RESULTS
PATIENTS
Between October 2008 and March 2011 63 patients (40 male, 23 female) were included in the study 
(Table 1), 60 NKI, and three LUMC. The intended 40 female patients were not reached due to more 
prevalence of exclusion criteria, more refusals, and less prevalence compared to male patients. 
For six SCRT patients one rCT scan was missing. For LCRT one rCT scan was missing for three patients 
and two female patients withdrew from the study after the 1st and 2nd week, respectively. This resulted 
in a total of 63 pCT scans and 419 rCT scans. The rCT scans were taken on average 25 min before the 
treatment fraction. 




The average bladder volume on the pCT was about 300 cc and comparable between the different 
groups (Table 2). The bladder volumes in the rCT scans were significantly smaller compared to the 
pCT scan, except for the first week scans of the LCRT female patients (Figure 2). A significant negative 
time trend in rectal volume was present in the LCRT groups, more predominant in male than in female 
patients (Figure 2) with a rectal volume reduction of approximately 35% at the end of treatment. The 
average CTV volume on the pCT was 508 cc for female patients and 580 cc for male patients (Table 2). 
SHAPE VARIATION
The local GM, ∑, and σ surface maps for each patient group were projected on the average CTV shape 
for visualization (Figure 3). The negative time trend in rectal volume resulted in a negative GM error 
at the upper-anterior border of the MesoRect for both LCRT groups. The GM error was significantly 
different from 0 for the male patients (p < 0.01) and borderline significant for the female patients (p 
= 0.06). Combining all LCRT patients resulted in a significant negative GM error of 0.5 cm (p < 0.01). 
Table 1: Clinical and pathological characteristics
5 x 5 Gy 25 x 2 Gy
Age (yrs) Median (range) 65 (44-85) 64.5 (44-81)
Sex Male 20 20
Female 13 10
Distance from anus <   5 cm 7 16
5 – 10 cm 15 12
> 10 cm 11 2
Resection type LAR 26 17
APR 7 13




cN-stage N0 22 3
N1 9 17
N2 2 10
cM-stage M0 31 29
M1 2 1
The ∑ was comparable between the groups. In general the maximum ∑, of approximately 1.0 cm SD, 
was found at the upper-anterior region of the MesoRect. Only for the male LCRT patients the maximum 




were only significant at the edges of the high variable upper-anterior CTV region of the LCRT group 
(Figure 4). Differences in ∑ between male and female LCRT were not significant. Random errors were 
comparable between the groups (no significant differences), similar in heterogeneity compared to the 
∑, but slightly smaller (max 0.8 cm SD).
Table 2: Average volumes delineated/calculated on the planning CT (1SD)
5x5 Gy 25x2 Gy
Female Male Female Male
Bladder 322 cc (204) 301 cc (189) 298 cc (193) 243 cc (158)
Rectum 116 cc (49) 125 cc (56) 121 cc (28) 138 cc (52)
CTV 509 cc (154) 579 cc (101) 507 cc (110) 581 cc (93)
Current clinical PTV 1316 cc (290) 1484 cc (285)
Proposed PTV (Table 3) 1107 cc (200) 1128 cc (127)
MARGINS
To reach a Dmin of 95% of the prescribed dose for 90% of the patients a factor α of 3.2 needed to be 
applied to the systematic errors (Figure 5). The rolling ball margins were calculated with factor α = 3.2 
for SCRT and LCRT groups separately (Figure 6), because of the difference in GM error (Figure 3) and 
the significant difference in ∑ error between the male patients in both groups (Figure 4). The average 
PTV volumes were 997 cc (1SD = 184) and 944 cc (1SD = 127) for SCRT and LCRT (p = 0.19), respectively. 
The CTV was divided into six sub-regions to define more practical orthogonal PTV margins (Table 3). 
The sub-regions were the earlier defined LN_L, LN_R, and presacral regions, and a division of the 
MesoRect in the sphincter region (caudal 4 cm) and an upper and lower half of the remainder of the 
MesoRect. 
The proposed margins (Table 3) were also applied to the dataset to re-evaluate the accumulated Dmin 
to the CTV, which resulted in a Dmin of 95% of the prescribed dose to 94% of the patients. The average 
PTV volumes were 1233 cc (1SD = 198) and 1186 cc (1SD = 131) for SCRT and LCRT, respectively. 
The actual clinical PTVs that were used during treatment had an average volume of 1316 cc (1SD = 
290) and 1484 cc (1SD = 285) for SCRT and LCRT, respectively (Table 2). The proposed PTVs (Table 2), 
adapted to the same cranial and caudal border as the clinical PTVs, were significantly smaller with 
on average 1107 cc (1SD = 200) and 1128 cc (1SD = 127) (p < 0.0001) for SCRT and LCRT, respectively 
(Table 2).
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Figure 2: Relative bladder and rectum volume on the repeat CT scans with respect to the planning CT for the four 





Figure 3: Left anterior view of the group mean (top), systematic (middle) and random (bottom) errors for the four 
groups of patients.
Figure 4: Anterior view of the systematic error for the 5x5 Gy male patients (left), 25x2 Gy male patients (middle) 
and the p-value results (right) of a locally calculated 2-sided f-test where only regions with systematic error 
differences of ≥ 0.2 cm were taken into account. 
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Figure 5: Minimum dose to the clinical target volume for the total dataset of 63 patients. This when applying mPTV 
= α * ∑ + 1.64 * √(σ2 + 0.322) – 1.64 * 0.32 + GM when applying the ∑, σ and GM errors shown in Figure 1 for each 
group separately. With α=3.2, 90% of patients assured a minimum dose of 95% of the prescribed dose to the CTV.
 




Table 3: Required PTV margins for sub-regions of the CTV to assure a Dmin of 95% of the prescribed dose to at least 
90% of the patients. 
25 x 2 Gy treatment schedule
Anterior Posterior Left Right Cranial Caudal
LN_L 1.5 cm 0.7 cm 0.7 cm 1.0 cm 1.0 cm 1.0 cm
LN_R 1.5 cm 0.7 cm 1.0 cm 0.7 cm 1.0 cm 1.0 cm
Presacral 1.5 cm 0.7 cm 0.7 cm 0.7 cm 1.0 cm 1.0 cm
MesoRect upper half 2.4 cm 0.7 cm 0.7 cm 0.7 cm 1.0 cm 1.0 cm
MesoRect lower half 1.5 cm 0.7 cm 0.7 cm 0.7 cm 1.0 cm 1.0 cm
Sphincter 1.0 cm 1.4 cm 1.0 cm 1.0 cm 1.0 cm 1.0 cm
5 x 5 Gy treatment schedule 
LN_L 1.5 cm 0.7 cm 0.7 cm 1.0 cm 1.0 cm 1.0 cm
LN_R 1.5 cm 0.7 cm 1.0 cm 0.7 cm 1.0 cm 1.0 cm
Presacral 1.5 cm 0.7 cm 0.7 cm 0.7 cm 1.0 cm 1.0 cm
MesoRect upper half 3.2 cm 0.7 cm 0.7 cm 0.7 cm 1.0 cm 1.0 cm
MesoRect lower half 1.8 cm 0.7 cm 1.0 cm 1.0 cm 1.0 cm 1.0 cm
Sphincter 1.0 cm 1.1 cm 1.0 cm 1.0 cm 1.0 cm 1.0 cm
Bold	numbers	indicate	the	differences	between	both	groups
DISCUSSION
The first aim of this study was to evaluate shape changes of the clinical target volume during pre-
operative RT of early- and advanced-stage rectal cancer patients. With a dataset of 483 CT scans in a 
group of 63 patients we have shown that shape variation of the CTV is a substantial and heterogeneous 
geometric uncertainty. In long-course RT a volumetric negative time trend could be found for the CTV 
(Figure 2), as well as a significant difference in systematic error between the male patients in both 
groups (Figure 4). 
The second aim was to establish PTV margins for CTV shape variation. With an adapted version of 
the van Herk margin recipe64 it was shown that a multiplication factor of 3.2 for the systematic shape 
variation error could be used to reach a 95% Dmin for 90% of the patients (Figure 5). The acquired locally 
defined PTV margins were pragmatically translated into clinically applicable margins for sub-regions 
of the CTV (Table 3) with sufficient CTV coverage and smaller PTV volumes compared to clinical PTVs. 
CTV SHAPE VARIATION 
In LCRT, Nuyttens et	al107 described the motion of the anterior border of the CTV, ranging from 0.4 cm 
SD at the anus, to 1.0 cm SD at 10 cm from the anus, which is similar to our results. Shape variation 
in LCRT was also described by Tournel et	al108 with a mean shift of 0.2 cm (1SD = 0.7 cm) and 0.04 cm 
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(1SD = 0.4 cm) in anterior and posterior directions, respectively. These results were averaged over all 
measurements on the cranio-caudal axis and over all patients, ignoring the heterogeneity of shape 
variation and the influence of inter-patient variation. The 0.7 and 0.4 cm SD in anterior and posterior 
directions do confirm that shape variation is substantial and heterogeneous.
In two previous studies we investigated the shape variation of the mesorectal part of the CTV during 
SCRT using CBCT scans104;105. We found heterogeneous shape variation with up to 0.8 cm ∑ and 0.7 cm 
σ at the anterior part of the mesorectum. In the current study repeat CT imaging was chosen instead 
of CBCT, because of better image quality and the ability to investigate the entire CTV. When comparing 
the systematic and random SD for the same regions in the current study, results are comparable in 
terms of heterogeneity and size. Where systematic errors in the CBCT studies were slightly larger for 
female patients104;105, differences in the current study were not statistically significant. 
One major significant difference comparing the four groups was the negative time trend in rectal 
volume for the LCRT (Figure 2). The negative time-trend in rectal volume was previously shown in 
repeat-CT studies on prostate cancer patients, indicating a RT dose-effect on rectal volume112;113. The 
LCRT patients in the current study also received chemotherapy, which might also have influenced the 
rectal volume. 
In addition, we found a difference in systematic errors between both male groups (Figure 4), which 
might be explained by a difference in tumour location. In SCRT more upper rectal tumours were 
present, in LCRT more low seated. When evaluating the first week scans of all 63 patients divided 
into low-, mid-, and high seated tumours, high seated tumours showed statistically significant larger 
systematic errors at the anterior side of the CTV compared to mid- and low-seated tumours (data not 
shown). A more elaborated multi-variate analysis is needed, since tumour stages and treatment types 
were differently distributed in the three groups.
MARGINS
PTV margins to account for CTV shape variation in rectal cancer patients have been previously estimated 
by Tournel et	al108 and Brierly et	al102, for the mesorectal part of the CTV. In both papers the shape 
variation of the mesorectum was averaged over the cranio-caudal axis and over all patients. Doing so, 
the different effects of ∑ and σ on the Dmin to the CTV were ignored, as well as the heterogeneity of 
systematic and random shape variation. 
An important additional issue is that margins for shape variation should take the correlation of 
variation in different regions of the CTV into account110;111. Attempts have been made to estimate 
correlation by use of principal component analysis114 and by a point distribution model based on 
corresponding points modelled using spherically parameterized and canonical aligned outlines115. 
Due to the complexity of these models and the lack of clinical implementation we have chosen for a 
more pragmatic approach calculating local ∑ and σ position variability and deriving a margin recipe by 




The derived margin recipe included a ∑ multiplication factor α of 3.2 based on the total group of 63 
patients. When estimating α for the 4 groups separately a range of 3.2, 2.8, 3.0, and 3.4 was found 
for LCRT male and female and SCRT male and female, respectively, with smaller statistical certainty. 
The small range of α with the extremes coming from the small female groups with only 10 and 13 
patients suggests the applicability of the margin formula to other rectal cancer patients, but validation 
on a completely independent dataset is preferred. Note that applying a fixed multiplication factor to 
the heterogeneous systematic errors does not necessarily lead to the smallest possible PTV volumes. 
Increasing the multiplication factor in the least variable regions will substantially increase local 
coverage, while the PTV volume will only increase moderately. The gain in coverage could be used to 
decrease the multiplication factor in more variable regions, resulting in a larger reduction of the PTV 
volume.
In the current study ideal dose distributions were used to calculate CTV coverage. In clinical practice it 
is very hard to get the 95% isodose line on the edge of the PTV, especially in the anterior region where 
the horse-shoe shape results often in a somewhat broader dose distribution. The proposed clinical 
margins (Table 3) resulted in a 95% Dmin to 94% of the patients, which was higher than the intended 
90% of patients. These results do not include intra-fraction setup errors, intra-fraction shape variation, 
and delineation variation. We previously described intra-fraction setup errors in SCRT being 0.24, 0.10, 
and 0.06 cm ∑ and 0.22, 0.10 and 0.10 cm σ in LR, CC and AP directions, respectively105. We simulated 
the effect of intra-fraction setup errors on the proposed clinical margins (Table 3) using a Monte Carlo 
simulation. This resulted in a 95% Dmin probability for 92% of simulated treatments, being closer to the 
intended 90%. 
The difference in required margin between SCRT and LCRT patients was mainly due to the negative 
time trend in rectal and subsequent CTV volume in LCRT patients, for which the margin can simply be 
reduced.
Intra-fraction shape variation needs real-time imaging and is not easily performed. To our knowledge 
it has never been investigated and can therefore not be included in the analyses. However, we do 
assume that intra-fraction motion of the bladder and rectum is small compared to inter-fraction 
motion. 
CTV delineation variation in rectal cancer is found to be comparable to shape variation errors when 
evaluating inter-observer variation103;106. In the current study observer variation was minimized by 
having one observer per patient, discussion of pCT delineations before delineation of the rCT scans, 
and availability of the pCT delineations during rCT delineation. Intra-observer variation using this 
approach was previously shown to be in the order of 0.2-0.3 cm SD for delineation of the Mesorectum 
on CBCT scans104, for which the image quality is generally inferior to CT scans. 
The proposed PTV margins (Table 3) are larger than current clinical margins of 1 cm. Despite the 
margin increase, PTV volumes were smaller compared to the clinical PTV volumes, with 16% and 
24% volume reduction for SCRT and LCRT, respectively (Table 2). A strictly delineated CTV plus larger 
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margins therefore resulted in a smaller PTV, compared to observer based generous delineation of 
the CTV plus a 1 cm PTV margin. An advantage of using strict anatomical borders instead of observer 
dependent generous delineations for the CTV is the possible reduction in inter-observer variation106. 
It is important to realize that the derived results are mainly of advantage when using IMRT. With 
conventional 3- or 4-field conformal techniques dose outside the PTV will minimize the PTV volume 
reduction effect. 
Another factor is that a large part of the CTV will contain only microscopic disease, at most. It is 
therefore questionable if the Dmin of 95% of the prescribed dose is really needed for the entire CTV. 
Unfortunately, it is currently not possible to define the exact GTV within the CTV. Until further advances 
in GTV definition have been made it is unsafe to relax the constraints on the CTV coverage. 
LIMITATIONS OF THE STUDY
The study is based on rCT data taken on average 25 minutes before the actual treatment fractions 
resulting in significantly smaller bladder volumes (Figure 2). In an earlier study we investigated the 
correlation between bladder and rectum volume changes and CTV shape variation105, and demonstrated 
that shape variation is mainly driven by rectal filling, and not by bladder filling. Influence of the scan 
timing was therefore expected to be limited.
The number of female patients in the study was limited due to low accrual. Differences between male 
and female patients might therefore lack statistical power, as was already seen in the derivation of the 
α-factor. This is, however, the largest available study so far.
In order to combine data of different patients a corresponding point model was used based on fixed 
amount of slices and points per structure. Variation was measured perpendicular to the surface of the 
reference structures. This model is dependent on the definition of the different structures. Results 
are therefore only applicable to rectal cancer patients where the CTV is delineated according to the 
guidelines in the current study. All derived results are of course not applicable to patients meeting the 
exclusion criteria of previous surgery or RT in the pelvic area. 
CONCLUSIONS
Clinical target volume shape variation is a major geometric uncertainty both in short- and long-course 
radiotherapy of rectal cancer patients. The shape variation was heterogeneous, with systematic shape 
variation ranging from 0.2 cm SD close to bony structures to 1.0 cm SD at the anterior-cranial end of 
the mesorectum. To assure 95% of the prescribed dose to the CTV for 90% of the patients mPTV = 3.2 
* ∑ + 1.64 * √(σ2 + 0.322) – 1.64 * 0.32 + GM was established, where shape variation is determined 
perpendicular to the surface of planning CT CTV delineation. The derived margins were pragmatically 
translated to orthogonal margins for sub-regions of the CTV ranging from 0.7 cm margin in posterior 
direction up to 2.3 and 3.1 cm PTV margin at the upper anterior region of the mesorectum for long- 




negative time trend in rectal volume. The proposed larger PTV margins in combination with a strict 
CTV delineation resulted in significant PTV reduction compared to the current clinical PTVs based on 
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ABSTRACT
BACKGROUND 
Capecitabine is an attractive radiosensitizer. In this study acute toxicity and surgical complications 
were evaluated in patients with locally advanced rectal cancer following total mesorectal excision 
(TME) after preoperative chemoradiotherapy (CRT) with capecitabine.
METHODS
Between 2004 and 2008, consecutive patients with clinical tumour category (cT) 3–4 (with a 
threatened circumferential resection margin or cT3 within 5 cm of the anal verge) or clinical node 
(cN) category 2 rectal cancer were treated with preoperative CRT (25 × 2 Gy, capecitabine 825 
mg/m2 twice daily, days 1–33). TME followed 6 weeks later. Toxicity was scored according to the 
Common Terminology Criteria (version 3.0) and Radiation Therapy Oncology Group scoring systems. 
Treatment-related surgical complications were evaluated up to 30 days after discharge from hospital 
using the modified Clavien–Dindo classification.
RESULTS
Some 147 patients were analysed. The mean cumulative dose of capecitabine was 95% and 98% 
of patients received at least 45 Gy. One patient died from sepsis following haematological toxicity. 
Grade 3–5 toxicity developed in 32 patients (21.8%), especially diarrhoea (10.2%) and radiation 
dermatitis (11.6%). There were no deaths within 30 days. Anastomotic leakage and perineal wound 
complications developed after 13 of 47 low anterior resections and 23 of 62 abdominoperineal 
resections. Surgical reintervention was required in 30 patients. Twenty-seven patients (20%) were 
readmitted within 30 days after initial hospital discharge.
CONCLUSION 
Preoperative CRT with capecitabine is associated with acceptable acute toxicity, significant surgical 
morbidity but minimal postoperative mortality. 




Over the past two decades, local control of resectable rectal cancer has improved tremendously as 
a result of the introduction of total mesorectal excision (TME) and preoperative radiotherapy26;116;117. 
Where the circumferential resection margin (CRM) is threatened by tumour infiltration or extensive 
nodal involvement is present (N2), however, poor local control continues to pose a problem21. 
Randomized controlled trials4;29;30;118 have shown that preoperative chemoradiotherapy (CRT) with 
5-fluorouracil (5-FU) leads to downstaging and downsizing, facilitating a higher probability of a 
tumour-free CRM118 after resection in these patients. Possible drawbacks of this treatment regimen 
are surgical delay (especially in non-responders), overtreatment and toxicity due to the addition of 
chemotherapy. 
Capecitabine, an oral prodrug of 5-FU, has been introduced over the past decade, and proven 
to be effective in the metastatic and adjuvant setting in colorectal cancer119. It mimics continuous 
5-FU infusion. Advantages over continuous 5-FU include avoidance of complications associated with 
continuous intravenous administration and convenience to the patient. The question remains whether 
capecitabine is a worthy substitute as radiosensitizer in terms of toxicity, perioperative complications 
and efficacy. Phase II series120-128 have shown that capecitabine is promising with respect to acute 
toxicity. However, in the literature little attention has been paid to the surgical complications following 
neoadjuvant CRT, especially when capecitabine is used as radiosensitizer. Anastomotic leakage 
following low anterior resection (LAR) remains an important and potentially fatal surgical complication. 
After neoadjuvant CRT, anastomotic leak rates of up to 27% have been reported55, but this has not 
been reproduced in the randomized controlled trials4;30;56. Perineal wound complications after 
abdominoperineal resection (APR) represent a challenging management problem, with associated 
pain, unpleasant odour and unexpected drainage seriously affecting quality of life. Rates of 35% have 
been reported in patients receiving preoperative (chemo)radiotherapy55;90 and historically in up to 57% 
of patients after APR in general129. 
These days, surgical complications are, among others, increasingly becoming healthcare quality 
outcome parameters130. To ensure uniform documentation and enable interinstitutional comparison, 
strict definition of complications is required. Surgical complications are mostly recorded as the 30-day 
complication rate, but sometimes manifest themselves more than 30 days after surgery52, suggesting 
that the treatment-related complication rate is as important as the 30-day complication rate. 
The aim of this study was to evaluate toxicity and surgical complications in patients with locally 
advanced rectal cancer following TME surgery after neoadjuvant CRT with capecitabine in a single 
institute. The results and use of definitions were compared with those reported by others. 
METHODS
Between June 2004 and February 2008, consecutive patients with clinical tumour category (cT) 3–4 (T3 




category (cN) 2 primary rectal cancer were registered prospectively and treated with preoperative 
CRT in the Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital. Magnetic resonance 
imaging (MRI) was used to evaluate tumour infiltration and the presence of lymph nodes larger than 
1 cm or with clinical characteristics suspicious of metastases. Superficial tumours were excluded by 
endorectal ultrasonography (EUS). CT of the abdomen and X-ray or CT of the thorax were used to 
evaluate dissemination. 
RADIOTHERAPY
Preoperative radiotherapy consisted of 50 Gy in 25 fractions on week days. The clinical target volume 
included the primary tumour and the mesentery with vascular supply, containing the perirectal, 
presacral and internal iliac nodes. The recommended upper border was at the level of the promontory. 
The perineum was included if an APR was planned, whereas the lower border was 3 cm above the anal 
verge if the planned operation was LAR. From April 2006 onwards, intensity-modulated radiotherapy 
(IMRT) substituted the three-field, three-dimensional conformal technique (90 versus 57 patients). 
Four patients received intraoperative brachytherapy with a 5-mm thick flexible intraoperative 
template. The radiation dose at 1 cm from the surface of the template was 7.5 or 10 Gy.
CAPECITABINE AS RADIOSENSITIZER
Capecitabine was administered orally and twice daily at a dose of 825 mg/m², on days of radiotherapy 
but also over weekends, adding up to 33 days of chemotherapy. From May 2007 onwards, patients 
were screened for a gene mutation (DPYD*2A mutation) which has been linked to a dihydropyrimidine 
dehydrogenase (DPD) enzyme deficiency and associated with severe 5-FU-related toxicity. One of the 
48 patients evaluated showed this mutation and received a dose reduction.
SURGERY
All patients underwent surgery according to the TME technique, as advocated by Heald131. Surgery was 
performed in the Netherlands Cancer Institute – Antoni van Leeuwenhoek hospital or in one of ten 
regional hospitals (median 11 patients per hospital), approximately 6 weeks after neoadjuvant therapy 
had been completed. A diverting stoma was constructed at the discretion of the surgeon.
ACUTE TOXICITY AND POSTOPERATIVE COMPLICATIONS
During CRT, toxicity was evaluated once or twice weekly and subsequently discussed at a weekly 
multidisciplinary meeting. Adverse events were graded according to the National Cancer Institute 
Common Terminology Criteria (NCI-CTC, version 3.0)132. Acute radiation-induced skin toxicity was 
scored according to the Radiation Therapy Oncology Group scoring system133. Postoperative surgical 
complications were scored using pre-specified definitions (Table 1). General complications were 
scored as cardiovascular, pulmonary, neurological or renal. The severity of surgical complications was 
scored using the validated modified Clavien–Dindo classification of surgical complications134;135. To 
Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer
63
4
analyse treatment-related toxicity accurately, complications were not only evaluated during hospital 
admission but also during the first 30 days after discharge. 




Any fluid collection around the anastomosis; clinical suspicion confirmed by surgery 
or diagnosed on CT or fluoroscopy.
Perineal wound 
complications (APR)
Wound dehiscence resulting from underlying infection, wound necrosis, prolonged 
admission after 3 weeks for wound care and professional wound care after 
discharge from hospital into the home environment.
Intra-abdominal abscess Any fluid collection unrelated to the anastomosis or perineal wound.
Fistula Enterocutaneous, enterovaginal, vesicovaginal, enterovesical connections.
Ileus Need for (re)placement or delayed removal of nasogastric tube, absence of bowel 
sounds or defecation, all after 5 days following surgery.
Abdominal wound 
complications
Fascial dehiscence, superficial wound infection, open abdomen treatment, vacuum-
assisted therapy.
Intestinal necrosis Any bowel ischemia.
Urological Ureter leakage, urinary incontinence, ureter stenosis, suprapubic or transurethral 
catheter-related complications, urosepsis.
Bleeding Gastrointestinal haemorrhage, decrease in haemoglobin level directly after surgery 
treated conservatively with or without blood transfusion or by reintervention.
LAR,	low	anterior	resection;	CT,	computed	tomography;	APR,	abdominoperineal	resection.
STATISTICAL ANALYSIS
The association between clinical variables and two key surgical complications (perineal wound 
complications and anastomotic leakage) was investigated using univariable analysis. The clinical 
variables included general patient and tumour characteristics, as well treatment-related variables such 
as any toxicity of grade 3 or more, at least grade 3 skin toxicity (only patients having APR), symptoms 
of obstruction requiring diversion before starting CRT, diverting stoma (only patients undergoing LAR), 
IMRT, duration of radiotherapy, interval between the beginning and end of radiotherapy, and resection 
and resection of a structure other than the mesorectum. Two-sided χ2 or Fisher’s exact test was used 
for categorical variables, and linear regression analysis for continuous variables. Because of the low 
number of events in each group, no multivariable analysis was performed. P ≤ 0.050 was regarded 
statistically significant.
RESULTS
A total of 147 patients with locally advanced rectal cancer were analysed, 86 men and 61 women, 
with a median age of 64 (range 37–83) years. Patient and tumour characteristics are shown in Table 2. 
MRI-directed staging was implemented in 133 patients (90.5%); the remaining 14 were staged by EUS 




Table 2: Patient and treatment demographics
No. of patients (n = 147)*
Age (years)† 64 (37–83)
Sex ratio (M : F) 86 : 61




Tumour distance from the anal 
verge (cm)
≤ 5 83 (56.5)
6–10 46 (31.3)
> 10 18 (12.2)






cN unknown 3 (2.0)
cM0 131 (89.1)
cM1 16 (10.9)
Diverting stoma before CRT Yes 54 (36.7)
No 93 (63.3)
Surgery Low anterior resection 47 (32.0)
Hartmann procedure 22 (15.0)
Abdominoperineal resection 62 (42.2)
No resection 7 (4.8)
No surgery 9 (6.1)
Diverting stoma after low 
anterior resection (n = 47)
Yes 35 (74)
No 12 (26)










pN unknown 2 (1.5)
*With	percentages	 in	parentheses	unless	 indicated	otherwise;	†values	are	median	 (range).	‡World	
Health	 Organization	 (WHO)	 classification136;	 International	 Union	 Against	 Cancer	 tumour	 node	
metastasis	(TNM)	classification,	fifth	edition9.	CRT,	chemoradiotherapy.
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CHEMORADIOTHERAPY AND ASSOCIATED ACUTE TOXICITY
The mean cumulative dose of capecitabine was 95% (range 32–100). Thirty-one patients (21.1%) 
requested or needed adjustments to the capecitabine intake; intake was stopped prematurely in 18 
patients (12.2%) a median of 5 (range 1–23) days before the end of radiotherapy, interrupted in six 
(4.1%) for a median of 3 (range 1–12) days, and dose reduction was performed in seven patients 
(4.8%).
Some 98.0% of patients received at least 45 Gy radiotherapy. Six patients (4.1%) did not complete all 
radiotherapy fractions owing to gastric perforation after 44 Gy (1), parastomal abscess outside of the 
radiation portal after 48 Gy (1), (fatal) pancytopenia after 42 Gy (1) and patient’s request (3, after 28 
Gy in one patient and after 48 Gy in 2 patients).
Thirty-one patients (21%) experienced grade 3 toxicity; diarrhoea (10.2%) and radiation dermatitis 
(11.6%) were the most prominent (Table S1, supporting information). No grade 4 toxicity was 
documented, but one patient died (grade 5) in the last week of CRT from pancytopenia, mucositis 
and associated septic complications. The DPD enzyme activity was unknown in this patient. Patients 
receiving a diverting stoma because of obstructive symptoms (before CRT) experienced more toxicity 
of at least grade 3 than those with no stoma (18 of 54 versus 15 of 93; P = 0.016). No differences 
in grade 3–5 toxicity were observed between patients receiving IMRT versus three-dimensional 
conformal radiotherapy (P = 0.625).
SURGERY 
After a median of 44 (range 22–87) days after the end of CRT, 138 of the 147 patients underwent a 
laparotomy. At laparotomy, resection was possible in 131 patients. Fig. 1 shows the types of surgery 
performed and reasons for exclusion.
HISTOPATHOLOGICAL EXAMINATION
Histopathological examination revealed microscopic tumour cells in the resection margin (R1) in 
seven (5.5%) of 127 patients for whom a report was available. The CRM was reported in 94 (71.8%) of 
131 patients whose tumour was resected, and measured 1 mm or less in 16 (17%). In four of the 16 
patients a tumour-positive lymph node determined the CRM (3 after sphincter-sparing surgery and 1 
after APR). APR was associated with a higher overall rate of R1 resection (P = 0.050), whereas a trend 
was found for more CRM-positive resections (P = 0.082; including those with tumour-positive nodes 
determining the positive CRM). In an analysis of the subgroup in which the primary tumour extended 
to within 1 mm of the CRM, an abdominoperineal resection was also significantly associated with 
more CRM-positive resections (positive CRM in 10 patients after APR and 2 after sphincter-saving 




Figure 1: Flow diagram of treatment. Abbreviations: CRT: chemoradiotherapy, TME: Total mesorectal excision
TREATMENT-RELATED POSTOPERATIVE COMPLICATIONS
The median duration of the primary surgical admission for patients who underwent tumour resection 
was 14 (range 6–200) days, and 15 patients (11.5%) were admitted for more than 30 days. Twenty-
seven (19.6%) of 138 patients who had a laparotomy were readmitted within 30 days after initial 
discharge from hospital. There were no deaths within 30 days after surgery. One patient died 3.5 
months after an APR, as a result of enterocutaneous fistula following treatment for a large perineal 
defect. Surgical reintervention was required in 30 (21.7%) of 138 patients. Treatment-related 
complications are summarized in Table 3. Major general complications included myocardial infarction 
and a stroke in two patients with previous cardiovascular disease.
Anastomotic leakage developed in 13 (28%) of 47 patients following LAR, of whom 11 required surgical 
reintervention. In two of 13 patients, the anastomotic leakage manifested itself after discharge from 
hospital. Anastomotic leakage was distributed equally between men and women (7 of 26 and 6 of 21 
respectively). Five of 12 patients without a diverting stoma developed anastomotic leakage versus 
eight of 35 with a diverting stoma (P = 0.269). Univariable analysis revealed that increasing age 
correlated with decreasing numbers of anastomotic leakages (P = 0.033). 
A perineal wound complication developed in 23 (37%) of the 62 patients undergoing APR. In 11 of 
23 patients, the perineal wound complication became evident after discharge from hospital. Eight of 
the 23 patients required surgical reintervention (including vacuum-assisted therapy). A poorer World 
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Health Organization (WHO) performance status136 at diagnosis (2 versus 0–1) and extent of surgery 
(TME alone versus extended TME) were both associated with the development of perineal wound 
complications (P = 0.016 and P = 0.044 respectively). There were no differences in rates of perineal 
wound complications (P = 0.168), anastomotic leakage (P = 0.333) or other major postoperative 
complications (P = 0.850) between patients receiving IMRT versus three-dimensional conformal 
radiotherapy.
DISCUSSION
This study investigated the acute toxicity and postoperative complications of CRT with capecitabine 
followed by TME surgery in a relatively large series of patients with locally advanced rectal cancer. 
The preoperative CRT was tolerable, with a mean cumulative chemotherapy dose of 95% and 98% of 
patients receiving at least 45 Gy of the planned radiotherapy. The postoperative morbidity rate was 
significant, but this did not translate into postoperative mortality. Histopathological analysis showed 
a promising efficacy in this series characterized by 38.1% cT4 tumours, with an R1 resection rate of 
only 5.5%. 
Nine phase II trials120-128 were reviewed on toxicity and surgical complications (Table S2, supporting 
information). The trials described, incorporating capecitabine as radiosensitizer in more than 50 
patients, generally included all cT3–4 N0–2 disease, whereas in the present series the treatment was 
limited to those with a CRM at risk of incomplete resection and those with extensive nodal disease 
(cN2). Capecitabine was generally taken continuously and 59–99% received the dose as planned, as 
in the present series (78.9%). With grade 3–4 toxicity developing in 21.1% of patients during CRT, the 
results are comparable with those of other phase II studies incorporating capecitabine (range 11–23%). 
With the intention of using capecitabine to optimize radiosensitivity, prescribing capecitabine on days 
of radiotherapy only could be considered an option in the future, to further optimize tolerability.
Anastomotic leakage is a potentially fatal surgical complication after LAR. In the present series, no 
patient died as a result of an anastomotic leak, but it was diagnosed in 28% of patients undergoing 
LAR. This seems much higher than reported rates of about 10% in the randomized controlled 
trials4;26;29;30;52;56;60;90;96;117;118;137;138 evaluating radiotherapy or CRT with 5-FU (Table S3, supporting 
information). A plausible reason for this difference could be the more advanced nature of the tumours 
in this series. Kerr and colleagues55 have recently described a retrospective series of 189 patients, with 
similar disease characteristics (50% cT4) and definitions, and reported anastomotic leakage in 27% of 
patients after LAR. Interestingly, they found a relationship between decreasing rates of anastomotic 
leakage and increasing interval between CRT and surgery, and suggested delaying surgery beyond 8 
weeks. As only five patients in the present series had a delay beyond 8 weeks, this finding could not 
be confirmed. Of the nine phase II trials120-128 reviewed (Table S2, supporting information), only four 
reported anastomotic leakage rates120;121;124;127. Rates ranged between 0 and 3%, suggesting a different 
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explanation involves the (discretional) use of a diverting stoma to protect the anastomosis. Recently, 
a randomized controlled trial52 with clinical anastomotic leakage as primary endpoint randomized 
patients after uncomplicated rectal cancer surgery to a diverting stoma or not. A significant reduction in 
clinical anastomotic leakage rate from 28 to 10% was demonstrated with the use of a diverting stoma. 
Furthermore, two recently published meta-analyses139;140 and a pooled analysis51 have combined 
published data from randomized controlled trials and showed a reduced rate of anastomotic leakage 
with a diverting stoma. In the present study, the anastomotic leak rate was reduced from five of 12 
to eight of 35 with the use of a diverting stoma, although the difference was not significant, possibly 
owing to the small numbers. 
Impaired postoperative wound healing is a well-recognized risk following radiotherapy141. In the 
present series, 37% of patients developed perineal wound complications, which is in line with rates of 
up to 35% in the preoperative radiotherapy arms in randomized controlled rectal cancer trials (Table 
S3, supporting information). However, in these studies, as well as in the phase II studies reviewed 
incorporating capecitabine as radiosensitizer (Table S2, supporting information), the reported perineal 
wound complication rates vary enormously. In the present study, both poor performance status 
(WHO performance status 2) at diagnosis and extent of surgery were associated with perineal wound 
complications, suggesting a role of both patient reserves and size of the surgical wound in wound 
healing. Another important issue is the fact that a perineal wound may seem to heal normally initially, 
but subsequently manifest itself as a complication after discharge from hospital. Almost half of the 23 
perineal wound complications were diagnosed or became evident at readmission within 30 days after 
discharge. This underlies the importance of thorough follow-up in this patient group and may warrant 
adaptation of currently used definitions in clinical trials.
Regarding the definition of anastomotic leakage and perineal wound complications, it is remarkable 
how the reported definitions vary in the reviewed phase II studies123;125;126 and European randomized 
trials in rectal cancer (Tables S2 and S3, supporting information)4;24;30;52;56;60;90;96;117;137;138. The scope of 
a definition and the way it is implemented largely determine the reported complication rate. It is 
comprehensible that surgical complications are underreported when they are not well defined or do 
not form the primary endpoint of a (large) multicentre study. Over the years, the instigators of the 
modified Clavien–Dindo classification have validated a severity classification of complications in a 
cohort of 6336 patients and confirmed its value in an international survey among 144 surgeons. This 
classification was used in the present study and showed that almost 40% of the 129 surgical events 
experienced required surgical, radiological or endoscopic (re)intervention under general anaesthesia 
(grade 3b). Of these, only 39% were due to anastomotic leakage or perineal wound complications.
Of equal importance in allowing interinstitution comparison is the definition per complication. For 
example, anastomotic leakage may be reported incorrectly as a percentage of all laparotomies 
instead of those with an anastomosis, as was the case in two phase II studies125;126. Only recently, the 
International Study Group of Rectal Cancer142 published an extensive review on all reported definitions 




system consisting of three grades (grade C requiring a laparotomy). However, no period in which the 
complications were to be scored was mentioned. In general, the high readmission rate within 30 days 
after discharge suggests that treatment-related complications (up to 30 days after discharge) could be 
a more realistic representation of morbidity after CRT and surgery than in-hospital or 30-day morbidity. 
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Table S1: Chemoradiotherapy-related toxicity in 147 patients










Gastric perforation 1 (1)
 Obstruction 1 (1)
Nausea 1 (1) 
Vomiting 1 (1)
Hand and foot syndrome 1 (1)
 Rash 1 (1)
Radiotherapy related 17
Skin dermatitis (RTOG) 17 (12)
Other toxicity 3
Ileus 1 (1)
Transient ischaemic attack 1 (1)
Stoma revision 1 (1)
Total events 57 0 1 58
No. of patients with grade 3 or  more toxicity 32 (22)
Values	in	parentheses	are	percentages.	RTOG,	radiation	Therapy	Oncology	Group133.






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Tumour regression grading after CRT for locally 
advanced rectal cancer: a near pathologic complete 
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ABSTRACT
BACKGROUND
After preoperative chemoradiotherapy (CRT) for rectal cancer, some rectal tumours undergo 
complete tumour regression (pCR). Clinically undetectable residual tumour deposits or pathologic 
lymph nodes may remain in the mesorectum. The consequences thereof are still unknown. The 
aim of this study was to report histopathological effects of CRT and factors affecting outcome in a 
uniformly treated series of strictly defined locally advanced rectal cancer (LARC) patients.
METHODS
Between 2004-2008, 107 consecutive patients with cT3 (threatening the mesorectal fascia or <5 cm 
from the anal verge), cT4 or cN2 rectal cancer were treated with preoperative CRT (25x2 Gy with 
capecitabine) and TME 6-8 weeks later. Central revision of histopathology followed and tumour 
regression grade (TRG) was scored with 4-tiers (pCR, near-pCR, response, no response). Uni- and 
multi-variable Cox regression were performed to identify prognosticators. 
RESULTS
With a median follow-up of 44 months, the 3-year distant metastasis-free interval (DMFI), DFS rate 
and OS rate were 82%, 73% and 87%, respectively. TRG consisted of 20% pCR, 11% near-pCR, 55% 
response and 14% no response. 6/21 patients with a pCR harboured nodal metastases. 5/12 patients 
with a near-pCR had ypT3 disease, while 6 harboured node metastases. Near-pCR was associated 
with a relatively poor outcome: 5/12 patients developed distant metastases. ypN and TRG were 
powerful discriminators of DMFI, DFS and OS. 
CONCLUSION 
pCR is associated with excellent outcome, while patients with a near-pCR fare poorly. The high 
number of near-pCR with ypT3 or ypN1/2 disease demonstrates that “wait and see” in LARC patients 
should be applied with extreme care. 




The treatment of rectal cancer has evolved immensely over the last 2 decades, resulting in improved 
local control and overall survival. The importance of tumour cells observed close to the inked 
circumferential resection margin68 (CRM ≤ 1 mm) in predicting local control and overall survival has 
led to refinement of the surgical technique and a neo-adjuvant approach. In the treatment of locally 
advanced tumours, where the risk of a positive CRM is high, short-course radiotherapy (SCRT) followed 
directly by total mesorectal excision (TME) will not suffice27;90;143. These patients require preoperative 
downsizing of the tumour with fluoropyrimidine-based chemoradiotherapy (CRT) and delayed TME 
for adequate local control4;29;30. Downsizing after SCRT followed by delayed TME surgery has also been 
observed144 and is currently being evaluated in the Stockholm III trial. Following improvements in local 
control, patient outcome in rectal cancer is nowadays determined by distant metastases, which are 
diagnosed in 30% of patients75. Adjuvant systemic chemotherapy seems to be the obvious means of 
attacking micro-metastases, but evidence for its use in rectal cancer is sparse and inconsistent29;38;75;79-81. 
The increasing use of neoadjuvant therapy in rectal cancer provides new challenges for pathologists. 
Tumours appear to respond heterogeneously to neoadjuvant therapy; mechanisms governing 
response or resistance remain unclear. For instance, certain tumours react with the formation of 
fibrosis completely replacing the tumour cells, while in others scattered tumour deposits are left 
behind. Other tumours are replaced by acellular mucin lakes. Unfortunately, some tumours are non-
responsive. The histopathological regression of tumour to the CRT is assessed by a semi-quantitative 
scoring of the relative proportion of residual tumour to stromal fibrosis, the tumour regression 
grade (TRG)74. It is conceivable that after CRT a highly responsive tumour is associated with superior 
treatment outcome. Published series38 demonstrate excellent outcome in those 8-24% of the cases 
in which no viable primary tumour cells are found in the resection specimen after CRT (pathologic 
complete response or pCR). The results after more intensive combination-regimens, however, have 
been disappointing, with more adverse effects33;145. Therefore, radiotherapy to a dose of 45-50 Gy with 
concurrent daily capecitabine, an oral prodrug of 5-FU, seems to have become the standard of care.
The concept of a pCR after CRT questions the need for additional resection. The group of Habr- Gama 
et	al39 have published multiple series on a non-operative “wait and see” policy in those patients in 
whom no residual tumour is detected at clinical assessment after CRT. Meticulous clinical, endoscopic 
and radiological follow up was implemented to guarantee a sustained clinical complete response 
(cCR). Using this policy, a locoregional failure rate of only 3% was reported in a series39 of distal rectal 
cancer patients (20% cT2, 70% cT3, 11% cT4 and 23% cN+), which is comparable to those with a pCR 
after resection. These excellent results have been confirmed in another series40. However, data are 
scarce regarding those in which the cCR is not sustained, and in which salvage resection is required 
due to locoregional failure. The risks of a non-operative (or local) treatment include under-treatment 
or treatment delay in those with residual lymph node metastases and those with undetectable tumour 




Differences in patient selection, indications for the treatment, definition of locally advanced rectal 
cancer (LARC), preoperative regimens, but also lack of standardized TME and pathology make 
comparisons between different series difficult. The aim of this study was to report histopathological 




In the period between June 2004 to February 2008 a total of 147 consecutive patients with LARC, 
defined as a cT4 tumour, a cT3 tumour <5 cm from the anal verge or threatening the mesorectal 
fascia (MRF) on magnetic resonance imaging (MRI) or cN2 disease, underwent preoperative CRT in 
the Netherlands Cancer Institute. MRI was used to evaluate tumour infiltration and the presence of 
lymph nodes larger than 1 cm or with clinical characteristics suspicious of metastases. A CT-scan of the 
abdomen and X-ray or CT-scan of the thorax were used to evaluate dissemination.
PREOPERATIVE CHEMORADIOTHERAPY
Preoperative radiotherapy consisted of 50 Gy in 25 fractions on week days. The clinical target volume 
included the primary tumour and the mesentery with vascular supply, containing the perirectal, 
presacral and internal iliac nodes. The recommended upper field border was at the level of the 
promontory. The perineum was included if an abdominoperineal resection (APR) was planned, whereas 
the lower border was 3 cm above the anal verge if the planned operation was low anterior resection 
(LAR). From April 2006 onwards, intensity-modulated radiotherapy (IMRT) substituted the three-field, 
three-dimensional conformal technique. Four patients received intra-operative brachytherapy using 
a 5-mm thick flexible intra-operative template. The radiation dose at 1 cm from the surface of the 
template was 7·5 or 10Gy. Capecitabine was administered orally and twice daily at a dose of 825 
mg/m2, starting on the first day and ending on the last day of radiotherapy, including weekends. The 
mean cumulative dose of capecitabine was 95% (range 32–100) of the prescribed dose, while 98% of 
patients received at least 45 Gy. 
SURGERY
Surgical resection followed 6-8 weeks later in the Netherlands Cancer Institute or in one of ten regional 
hospitals. Resection was performed according to the principles of TME and adapted upon indication: 
an APR or Hartmann procedure for distal tumours, LAR for mid or proximal tumours and exenterative 
surgery for infiltration into surrounding organs or structures. Preoperative clinical assessment of 
response with endoscopy or imaging was not standard treatment. Of 147 patients receiving neo-
adjuvant CRT, 138 were considered fit for surgery and underwent laparotomy after completion of neo-
adjuvant therapy. Of these, 131 were considered resectable intra-operatively. A further 19 patients 
were excluded because of synchronous distant metastases while in 5 patients pathology slides were 
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not available prohibiting pathological review. Thus, 107 patients were included for the analysis. 
Adjuvant chemotherapy is not standard of care in the Netherlands; four patients received adjuvant 
chemotherapy as part of a prospective trial. 
HISTOPATHOLOGICAL ANALYSIS 
Routine macroscopic and microscopic examination of the resection specimens was performed in 
the pathology laboratories of the participating hospitals according to the principles proposed by 
Quirke68. All H&E-stained slides of the resection specimens together with the original pathology 
reports were reviewed. Overall, a median of 14 blocks per patient were examined, while for pCR 
patients the median was 16 blocks. In 13 patients deeper levels were evaluated to facilitate accurate 
scoring. By reaching consensus two investigators (SB and MS), blinded to patient outcome, revised 
the histopathological diagnosis and scored additional tumour characteristics. In 37 (34%) cases 
uncertainties or discrepancies were resolved by consulting an independent colorectal pathologist (IN). 
The specimen was staged according to the 5th TNM staging system146, as is common practice in the 
Netherlands. Tumour characteristics included histological type and grade of differentiation, invasion 
depth (ypT), lymph node status (ypN), (circumferential) resection margin status, presence of acellular 
mucin lakes, presence and size of tumour deposits, intra- and extramural venous invasion, lymphangio-
invasion and perineural growth. Tumour deposits (TD) were defined as tumour nests demonstrating 
discontinuous growth from the primary tumour, with mesorectal fat or fibrosis separating the TD from 
the growth front of primary tumour. Furthermore, tumour nests sectioned as possible lymph nodes 
but with no signs of a lymph node or with a recognizable capsule but without a bordering layer of 
lymphocytes were considered a tumour deposit.
A tumour was considered mucinous when the mucinous proportion was ≥ 50%, and was not graded to 
further extent. Due to limited numbers venous invasion, lymphangio-invasion and perineural growth 
were grouped together into one factor, “neuro-vascular invasion”. Since no photos were available for 
revision/scoring of the completeness of the specimen, this information was not explored. 
Tumour regression was scored using a simple and practical 4 tier system as illustrated in Figure 1: 1) 
pCR, pathological complete response without residual primary tumour; 2) near pCR, only isolated 
residual tumour cells or small groups of residual tumour cells; 3) response: stromal fibrosis outgrowing 
tumour and 4) no response: no regression or those with stromal fibrosis outgrown by tumour.
LOCAL RECURRENCE, DISTANT METASTASES AND OVERALL SURVIVAL
Distant metastases were defined as systemic metastases of rectal cancer to another organ, to distant 
lymph nodes stations or by dissemination to the peritoneal surface. Local recurrence was defined as 
a radiological or histopathological determination of rectal cancer recurrence in the pelvis. Follow-
up information for local recurrence or distant metastasis and overall and disease-free survival 
was gathered by a comprehensive review of all patients files and contacting the patient’s general 




distant metastasis or last assessment. Disease-free survival (DFS) was defined as the time between 
surgery and the first event (local recurrence, distant metastasis, second primary or death) or last 
assessment. OS was defined as time between surgery and death or last assessment. 
Figure 1: Microscopic illustration of different grades of tumour regression.
STATISTICAL ANALYSIS
Associations between pre- or post-treatment factors and tumour regression was assessed using linear 
by linear or Fisher exact tests, as appropriate. The associations between these factors and DMFI, DFS 
and OS was performed using Cox proportional hazard regression. The proportional hazards assumption 
was tested using partial Schoenfeld residuals. Survival curves were constructed using the Kaplan-
Meier technique. In the multivariable regressions, missing data on pre- or post-treatment factors were 
imputed using the largest subgroup. The level of significance was set at 0.05 in all analyses. 
RESULTS	
PATIENT DEMOGRAPHICS 
The study involved 107 patients, 64 male and 43 female with a median age of 64 years (range 38-82). 
Baseline characteristics are listed in Table 1. On MRI, in 62 patients the tumour (58%) was located in 
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the distal rectum, 42 (39%) patients were staged as cT4 and in 29 (27%) patients extensive lymph node 
involvement was suspected (cN2). Forty (37%) patients underwent a LAR, 15 (14%) patients underwent 
a Hartmann procedure, while in 52 (49%) patients an APR was required due to close relation to the 
sphincter complex. Total exenteration was required in 6 patients, while partial exenterative surgery 
was performed in 25 patients.
RESPONSE TO CHEMORADIOTHERAPY
Table 2 presents associations between tumour regression and other histopathological factors. 
Downstaging to ypT0-2 occurred in 43 (40%) patients. After CRT, lymph node metastases were still 
present in 40 (37%) patients. Tumour deposits were identified in 28 (26%) patients, the majority of 
whom had a single deposit (median = 1, range = 1-12). The median size of the deposits was 7 mm 
(range 0.5-30 mm). Resection resulted in a CRM + rate (defined as primary tumour or lymph node 
metastases ≤ 1 mm from the CRM) of 15%. In 11 patients the primary tumour defined the positive 
CRM, while in 5 patients a positive node defined the positive CRM. In 8 of the 16 patients the inked 
margin was infiltrated (CRM = 0 mm) by the primary tumour while in 2 patients a positive lymph node 
infiltrated the CRM.
Twenty-one (20%) patients achieved a pathologic complete response (pCR) of the primary tumour 
and in 12 (11%) patients a near pCR was observed. Seven of the pCR patients and 6 of the near pCR 
patients initially had a cT4 tumour. Response was seen in an additional 59 (55%) patients, while in 
15 (14%) patients the tumour showed no response to CRT. Of note, 6 of 21 (29%) pCR patients had 
mesorectal lymph nodes metastases.
In the univariate analysis no pre-treatment factors (age, cT, cN, and distance from the anal verge) were 
significantly associated with tumour regression. Regression grade was associated with decreasing 
invasion depth (ypT, p<0.001) and the absence of neurovascular invasion (p=0.03). A positive CRM 
occurred more frequently in those showing no regression (p=0.01). Neither TRG nor ypT were 
associated with pathological node status (p=0.47 and p=0.24, respectively). 
ASSOCIATION BETWEEN RESPONSE AND OUTCOME
After a median follow-up period of 3.7 years (95%CI 3.3-4.2), 87 (81%) patients were alive, of whom 
75 (70%) were free of cancer, 5 (5%) developed a local recurrence only, 19 (18%) developed a distant 
metastasis only and 4 developed both (2 synchronously, 1 local recurrence first and 1 distant metastasis 
first). Four patients died due to other causes. The overall 3-year distant metastasis-free interval (DMFI) 
was 82%, the disease free survival (DFS) rate was 73% and overall survival (OS) rate was 87%. Neither 
preoperative tumour nor nodal stage influenced outcome (DMFI, DFS or OS). Table 3 displays the 
associations between histopathological features and outcomes. Due to small numbers (n=9) of local 




Table 1: Baseline patient demographics 
Demographics (n=107) n %
Age Median 64 (38 - 82)
Sex Male 64 60
Female 43 40




Distance from anal verge 0-5 cm 62 58
5-10 cm 30 28
>10 cm 15 14









Interval CRT and TME 3-5 weeks 16 15
5-7 weeks 65 61
>7 weeks 26 24
*WHO	 Performance	 status:	 0	 –	 Asymptomatic,	 1	 –	 Symptomatic	 but	 completely	 ambulatory	 2	 –	
Symptomatic,	<50%	in	bed	during	the	day.
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Table 2: Uni-variable associations between histopathological factors and the 4 tier tumour regression grade (TRG). 
Total pCR Near pCR Response No Response p-value
n=107 n=21 n=12 n=59 n=15
n % N % n % n % n %
ypT <0.001
T0 21 20 21 100 - - - - - -
T1 3 3 - - 2 17 1  2 - -
T2 19 18 - - 5 42 13 22 1 7
T3 59 55 - - 5 42 42 71 12 80
T4 5 5 - - - - 3 5 2 13
ypN 0.47
N0 67 63 15 71 6 50 37 63 9 60 0.26*
N1 28 26 5 24 4 33 15 25 4 27
N2 12 11 1 5 2 17 7 12 2 13
Tumour Deposits 0.15
No 79 74 17 81 10 83 43 73 9 60




> 1mm 90 85 21 100 10 83 50 85 9 64
≤ 1mm 16 15 - - 2 17 9 15 5  36
Missing 1 - - - - - - - 1 -
Histological type 0.42
Adenocarcinoma 76 88 - - 9 75 54 92 13 87
Mucinous 10 12 - - 3 25 5 8 2 13
Not applicable 21 - 21 - - - - - - -
Grade of  
Differentiation
0.11
Well/moderate 59 78 - - 8 89 43 80 8 62
Poor/undiff 17 22 - - 1 11 11 20 5 39




No 69 80 - - 11 92 49 83 9 60
Yes 17 20 - - 1 8 10 17 6 40
Not applicable 21 - 21 - - - - - - -
Acellular Mucin  
Lakes
0.38
No 71 66 15 71 8 67 40 68 8 53
Yes 36 34 6 29 4  33 19 32 7 47





The tumour regression grade (TRG) was a significant prognosticator of the DMFI (p=0.002). In addition, 
ypN (p<0.0001), presence of tumour deposits (p<0.001), ypT (p=0.002), acellular mucin lakes (p=0.007), 
histological type (p=0.01) and grade of differentiation (p=0.02) were all significantly associated with 
DMFI. TRG (p=0.02) and ypT (p=0.004) both retained their prognostic value for DMFI after adjusting for 
ypN. Due to the limited number of patients with distant metastases (n=23), no further multivariable 
analysis towards independent prognostic factors for DMFI could be performed. 
The TRG was a significant prognosticator of the DFS (p=0.001). Post-treatment pT (p=0.02) and ypN 
(p<0.001), presence of tumour deposits (p=0.004), histological type (p=0.03), grade of differentiation 
(p=0.03), acellular mucin lakes (p=0.03), and CRM (p=0.02) were also significantly associated with DFS. 
After adjusting for ypN, TRG (p=0.02) and ypT (p=0.04) retained prognostic value. 
Regarding overall survival, TRG was a powerful prognosticator (p<0.001). Histopathological factors 
predicting OS included ypN (p=0.004), CRM (p=0.04), TD (p=0.01) and histological type (p=0.03), but 
only TRG retained significance after adjusting for ypN. 
EXCELLENT OUTCOME IN THE PCR GROUP
In Figure 2, time to recurrence, second primary or death has been displayed for the separate TRG 
groups, illustrating that, with a median follow-up of 3.7 years (95% CI: 2.8 - 4.7), the 21 patients with 
a pCR have an excellent outcome, with no local recurrences and only one (5%) patient developing 
a distant metastasis. This patient was one of the 6 patients with a pCR still harbouring lymph node 
metastases. 
POOR PROGNOSIS IN THE NEAR PCR GROUP 
A summary of all near pCR patients is presented in Table 4. Three-year DMFI, DFS and OS rates for near 
pCR patients were 65%, 50% and 67% respectively, which are comparable to those with no response 
(64%, 60%, 79%). Of the 12 patients with a near pCR, 7 died (4 within two years), of whom 6 with 
disease progression. Five near pCR patients developed distant metastases. After 3 years, one near 
pCR patient developed a local recurrence on the anastomosis. In 6 (50%) of the 12 near pCR patients, 
nodal metastases were still present (of which 2 ypN2). In 5 patients isolated tumour cells were found 
invading the fat (ypT3), while in 2 patients the CRM was positive. 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2: Survival durations and event types for the four different TRG groups.
DISCUSSION
In this series of 107 patients with LARC, defined as cT4, cT3 threatening the MRF or <5 cm from the 
anal verge or cN2 on MRI, we confirm the excellent outcome in those with a pathological complete 
response after CRT and curative resection. However, the subgroup with a near complete response 
seems to fare poorly. Furthermore, we identified prognosticators for the development of distant 
metastases. 
Mechanisms governing the heterogeneous response to neoadjuvant CRT and their effects on patient 
outcome remain unclear. In our series, 20% of patients achieved a pCR after CRT. One third of these 
were clinical T4 tumours. Patients with a pCR have an excellent outcome with no local recurrence 
while one patient developed a distant metastasis. This is in line with the literature38;147 and raises 
the question whether more aggressive neoadjuvant strategies should be implemented to increase 
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the pCR rate and improve prognosis. Some studies have shown an increase in pCR rate with a longer 
interval between radiotherapy and surgery. So far, however, it remains unclear whether this translates 
into an outcome similar to patients with pCR after shorter intervals. Other options include increasing 
the radiotherapy dose or adding radiosensitizing drugs33 or biologicals148. Neo-adjuvant chemotherapy 
prior to CRT might be an attractive option to simultaneously decrease distant metastases149. 
Provided that clinical assessment after CRT is accurate and robust the concept of a pCR has introduced 
opportunities for less radical surgery, such as local excision of the tumour and even for omission of 
surgery all together (the “wait and see” policy). Avoiding surgical morbidity and subsequent decrease 
in quality of life as a result of organ resection are obvious advantages of this approach. However, 
the “wait and see” policy has only been analysed in a few single centre series39;40, is questioned by 
others41;150;151 and therefore requires further validation. Since the clinical imaging modalities at hand 
still lack diagnostic accuracy, omitting surgery in patients with undetected (nodal) disease may worsen 
prognosis. This study confirms these concerns and demonstrates potential risks involved in LARC 
patients treated with CRT in particular. In line with Gosens et	al71 studying a similar population of LARC 
patients, but in contrast to others152;153 nodal response after CRT was not related to primary tumour 
regression in our series, suggesting independent modes of response to CRT. Even in patients with a 
ypT0, nodal metastases were still present in 6/21 (29%) patients in our series of strictly defined locally 
advanced cases and in 5-19% of patients in the literature8;38;71;150;151;154. In a recently published series of 
ypT0-2 patients after CRT, Park et	al151 demonstrated that 17% of ypT1 and 21% of ypT2 patients still 
harboured nodal disease after TME. The impact on prognosis of not removing these lymph nodes, as is 
the case with both the “wait and see” policy and local excision procedures, is as yet unknown.
Another major concern is the effect of microscopic tumour deposits in the mesorectal fat, since those 
cannot be assessed by re-staging endoscopy and are difficult to discriminate from fibrosis on MRI. A 
recent publication by Duldulao et	al demonstrated that 17 of 53 ypT3-4 patients after CRT revealed 
tumour cells in deeper layers but not in the mucosa or submucosa150. In a review41, of 208 patients 
with a cCR approximately 30% were actually confirmed to be a pCR after resection, indicating the 
need of more accurate re-staging. Of note, the prognostic importance of these tumour deposits after 
neoadjuvant therapy is unclear155;156 and a topic of on-going discussion. Tumour deposits form part of 
the pathological T or N stage in the TNM 5th edition, depending on their size, and have been correlated 
with poor outcome155. Their presence showed to be a firm predictor of distant metastases in our 
series, possibly indicative of more aggressive tumour biology. 
The relatively poor outcome of the near pCR cases in our study is not a universal finding. Others 
have reported excellent outcomes in near pCR patients152;157 or in those with >95% regression158 and 
even reported outcome comparable to those with a pCR. In our series, 12 patients exhibited a near 
complete response of the primary tumour with only isolated tumour cells or islands of cells spread 
throughout the bowel wall and mesorectal fat (Table 4). In contrast to others, these near pCR patients 
were associated with an unexpectedly poor outcome (DMFI, DFS and OS), which was comparable to 




pCR patients harboured nodal metastases while in 5 patients isolated tumour cells were found in 
the mesorectal fat (ypT3). In recent series poor outcome is also reported in near pCR: Gosens et	al71 
reported an overall survival of 66% after a near complete response which was comparable to the poor 
responders, while Rödel153 described a similar trend of decreased disease- and distant metastasis-free 
survival for their group of good responders (73%) as compared to their moderate responders (83%). 
The prognosis of those with a near pCR is probably multi-factorial and this, once again, underlines the 
potential risk involved using a “wait and see” policy. 
In the last decade, local control in LARC patients has improved immensely with an intensified 
neoadjuvant approach4;29;30 and further refinement of surgical technique159-162. However, few studies 
focus on distant metastases after CRT, which develop in up to 39%163 of LARC patients and have become 
the event governing outcome. In our series, distant metastases developed in 21% of patients indicating 
the need of a more thorough understanding of factors predicting DMFI. Two studies have reported 
a correlation between TRG and distant metastases. Rödel et	al153 reported a univariate association 
between TRG, using a 3-tiered regression grading system, and distant metastases. Vecchio et	 al152 
reported a series of 144 patients with mainly cT3 tumours receiving neoadjuvant therapy (84% CRT) 
and observed that the four TRG groups, as used in the present series, significantly predict those at 
risk for distant metastases. TRG, together with ypT and ypN stage, retained prognostic power in their 
multivariable analysis. This is in line with our observations: when adjusting for ypN, we observed that 
both ypT and TRG were still significantly associated with a decreased DMFI, suggesting independent 
prognostic value of TRG next to nodal status. 
To our knowledge this is the largest cohort of well-defined LARC patients selected using state of the art 
staging, consistently receiving 25x2 Gy RT and capecitabine followed by TME 6-8 weeks later. Central 
revision of the resection specimens assured quality of histopathology thereby minimizing inter-
observer variability. Apart from shortcomings inherent to retrospective analyses, other shortcomings 
include the absence of a full model multivariable analysis due to low number of events and that no 
correction for multiple-testing was performed, thereby categorizing our data as hypothesis generating 
and in need of further validation. 
In conclusion, CRT followed by TME for LARC patients is effective and leads to an acceptable outcome. 
Histopathological assessment of tumour regression after CRT can, amongst other factors, be used to 
predict the risk for distant metastases. Near complete responders have a significantly worse outcome 
compared to complete responders. We demonstrate the relevance of tumour deposits and residual 
lymph node metastases in near pCR patients in particular and stress that a “wait and see” policy should 
be applied with extreme care. A significant subgroup of patients with LARC develop distant metastases 
after CRT and TME, demonstrating room for improvement, for instance with the implementation 
of neoadjuvant chemotherapy during the delay to surgery as is currently being investigated in the 
RAPIDO trial (ClinicalTrials.gov: NCT01558921).
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ABSTRACT
BACKGROUND
The spectrum of clinical indications for the use of endoscopic clips (endoclips) is rapidly expanding. 
As retention rates of endoclips have only been reported in animal models, we evaluated the long-
term attachment of two types of endoclips in the human gastrointestinal tract. 
METHODS
In this prospective observational study, endoclips were placed and followed-up during endoscopies 
or using fluoroscopic images as part of a prospective feasibility study evaluating external beam 
radiotherapy (EBRT, wk 1-3) followed by high dose rate brachytherapy (HDRBT with an endoluminal 
applicator once a week for three weeks, wk 9-11) in medically inoperable rectal cancer patients. 
Initially, type and number of endoclips were chosen randomly and later refined to 1 Resolution® 
clip (Microvasive) proximal and 2 Quickclips® (Olympus) distal to the tumour. Nine consecutive 
patients, included between September 2007 and August 2008, were analysed. Retention rates were 
evaluated over three different observational periods (period 1: pre-HDRBT (wk -2 - 8), period 2: 
during HDRBT (wk 9-11) and period 3: post-HDRBT (wk 12-16). 
RESULTS
In this study a total of 44 clips were placed during endoscopy, either at the beginning or at the end of 
period 1. The Resolution clip had a higher overall retention rate than the Quickclip (P = 0.01). After a 
median period of 81 days after placement (in period 1), long-term retention rates for the Resolution 
clip and Quickclip clip were 67% and 35%, respectively.
CONCLUSION
The Resolution clip has a high retention rate and is useful in situations where long-term attachment 
to the human gastrointestinal mucosa is warranted. 




In 1975, Hayashi	et	al were the first to describe the metallic endoscopic clip as an alternative means 
to control bleeding by mechanical pressure164. Since then, design and clinical indications have been 
refined. Nowadays, endoscopic clips are frequently used for haemostasis of arterial non-variceal 
bleeding of the upper gastrointestinal tract165;166. Other reported indications for endoscopic clip 
placement include the fixation of enteral feeding tubes167, stent anchorage168;169 and the management 
of small fistulas, perforations and anastomotic leaks170. Utilizing their radiopaque characteristics, 
endoclips have recently been used to mark tumours or anatomical structures to facilitate intervention 
radiology47, to locate the tumour peroperatively50 and to delineate tumour volume for radiotherapy48;49.
Several types of endoscopic clips are commercially available. Most studies involve those from Olympus 
(Olympus Ltd., Tokyo, Japan), available in preloaded (Quickclip) and reloadable devices (HX-5L). Once 
the clip has been opened, re-positioning is not possible as the jaws cannot be closed and reopened. 
The Resolution clip (Microvasive, Boston Scientific Corp, Massachusetts, US) has the ability to reopen 
its jaws for repositioning, which may result in superior positioning and tissue grasping. 
The ability of an endoclip to remain attached for a longer period could facilitate procedures in which 
a tumour needs to be located routinely during the treatment period or when the clip anchors feeding 
tubes or stents. Retention rates have, however, only been evaluated in canines and pigs and have not 
yet been reported in the human gastrointestinal tract. The aim of this study was to evaluate the long-
term attachment of two endoclips, the Quickclip and the Resolution clip, to human rectal mucosa.
MATERIAL AND METHODS
STUDY POPULATION
The 9 consecutive patients analysed in this study were patients with medically inoperable rectal cancer 
who participated in a prospective feasibility study in the Netherlands Cancer Institute. The primary 
objective of this on-going study is to evaluate the feasibility of external beam radiation therapy (EBRT) 
followed by high-dose rate endorectal brachytherapy (HDRBT) as definitive treatment in patients not 
suitable for surgery due to co-morbidity, old age or for those refusing surgery. The study gained ethical 
approval from the Medical Ethics Committee of the Netherlands Cancer Institute. Written informed 
consent was obtained from all patients. Patient accrual commenced in September 2007. 
TREATMENT PROTOCOL
The treatment regimen (Figure 1) consists of 39 Gy administered in 13 fractions of 3 Gy over 3½ weeks. 
After a further six weeks, HDRBT is applied once every week for three weeks. HDRBT dose level will be 
elevated (starting at 5 Gy/fraction) after every 6 patients depending on experienced toxicity. HDRBT 




consisting of a flexible tube with 8 channels (Figure 2). The applicator is 2 cm in diameter and is 
inserted via the anus prior to each brachytherapy treatment. 
Figure 1 Treatment plan: Patients first receive external beam radiotherapy followed by high dose rate brachytherapy. 
Abbreviations: EBRT: external beam radiotherapy. HDRBT: high dose rate brachytherapy. wk: week
ENDOCLIPS
The rectal tumour was marked (Figure 3a) with Quickclips (Olympus Ltd., Tokyo, Japan) and/or 
Resolution (Microvasive, Boston Scientific Corp, Massachusetts, US) endoclips to facilitate tumour 
localization during the HDRBT procedure. Endoscopy was performed before EBRT (baseline), before 
HDRBT (week 8-9) and after HDRBT (week 16-17). The tumour was marked before EBRT and, if 
necessary, additionally (when clips had been dislodged) before HDRBT. Initially, type and number of 
endoclips were chosen randomly. Later on, this was refined to one Resolution endoclip at the proximal 
and two Quickclips at the distal border of the tumour. 
Figure 2: Depicts the endorectal applicator (Oncosmart®, Nucletron, Veenendaal, the Netherlands) used to apply 
High Dose Rate Brachytherapy.




A CT-scan, with the unloaded applicator inserted, was performed for delineation and treatment 
planning purposes before the first HDRBT fraction. A 3D reconstruction of the applicator and radio-
opaque endorectal clips was made and the target volume delineated on the CT-images. A 2D anterior-
posterior projection of applicator and clips was reconstructed as a reference for C-arm fluoroscopy 
guided reinsertion of the applicator prior to each HDRBT session (week 9-11, Figure 3b). 
DATA ANALYSES
We evaluated retention rates between the two clip types over three different observational periods 
(period 1: pre-HDRBT (week -2 - 8), period 2: during HDRBT (week 9-11) and period 3: post-HDRBT 
(week 12-16)) (Figure 1). The percentage and absolute number of clips still attached during follow-
up endoscopy and on the fluoroscopic images were determined. To assess the retention rates of the 
two clip types (Quickclip or Resolution) a logistic mixed effects model was constructed with clip type 
as a fixed effect. To account for the influence of both the different periods (different in length and 
use of an endoluminal applicator) and the duration of attachment prior to assessment we included 
placement (beginning of period 1 or 2) and assessment period as fixed effects. The assessments of 
clip retention was assumed to be correlated when they relate to the same clip (assessed for different 
periods) or from clips within the same patient. To account for this cluster correlation we included clip 
and patient id as random intercepts. Due to insufficient events in period 2 a logistic model was unable 
to be constructed; hence the comparison of the retention rates of the two clip types in this period was 
performed using a Mantel-Haenszel test. Where appropriate, two-sided p-values are reported with a 
significance level set at 0.05. 
Figure 3 Imaging of the endoclips: A) Shows endoscopic images of an attached Resolution clip on the left (with a 
recognizable silver part at the loose end) and 2 attached Quickclips on the right (with a recognizable silver part at 




B) Shows a fluoroscopic image as made for HDRBT planning purposes and in between HDRBT fractions. Four 
Quickclips are still attached (arrows).
RESULTS
Six male and three female patients were evaluated. Median age of patients was 81 (range 57-93) years. 
Seven of the nine patients completed the treatment. One patient did not receive HDRBT after the EBRT 
due to an ulcer located in the brachytherapy field, while the other patient not completing treatment 
died due to a non-treatment related cardiac arrest after the first HDRBT treatment. Retention rates for 
the different observational periods are depicted in Table 1. 
In this study a total of 44 clips were placed during endoscopy, either at the beginning or at the end 
of period 1. At the beginning of period 1 (before EBRT), 26 clips were placed. The median duration of 
period 1 was 81 (49-90) days. Of the 20 Quickclips placed, 7 (35%) were visualized during the follow-
up endoscopy at the end of period 1. Four of the 6 (67%) Resolution clips placed were visualized at 
this second endoscopy. During the same endoscopy at the end of period 1, 18 clips were additionally 
placed (15 Quickclips and 3 Resolution clips) to replace dislodged clips. Median time between 
placement/visualization at the end of period 1 and the next follow-up endoscopy (end of period 
3) was 72 (range 33-91) days. No Quickclips survived all three periods, while 1 additionally placed 
Quickclip was visualized at the end of period 3. One of the 6 Resolution clips placed at the beginning 
of period 1 survived all three periods and was still visible at last follow-up after 231 days. One of the 
3 additionally placed Resolution clips was visualized at the end of period 3 as well. Therefore, at the 
follow-up endoscopy after HDBRT (end of period 3), 1 (7%) Quickclip and 2 (40%) Resolution clips were 
visualized.






























































































































































































































































































































































































































































































































































































































































































































































































































































































Retention rates gathered from the fluoroscopy images, acquired every week during the HDBRT, are 
depicted in Table 1. After 1, 2 and 3 weeks, these were 80%, 60% and 63% for the Quickclips versus 
83%, 80% and 75% for the Resolution clip. In case no image was available, the clip was censored which 
explains why the 3 week Quickclip retention rate is higher than the 2 week rate. The retention rates 
after 1, 2 and 3 weeks in period 2 did not differ significantly between the 2 types of clips (p=0.17, 
Mantel Haenszel test). The Resolution clip had a higher overall retention rate than the Quickclip [Odds 
Ratio: 96 (2.5-3614), p=0.01]. In comparison to the first period, long-term retention rates deteriorated 
significantly in the third period when the endoluminal applicator had been inserted [Odds Ratio: 0.01 
(0.0003-0.2), p=0.003]. 
DISCUSSION
In this study, we found the Resolution clip to be superior to the Quickclip in situations where long-
term attachment is warranted. The Resolution clip remained attached longer than the Quickclip, with 
encouraging long-term retention rates of up to 67% for the Resolution clip after nearly 12 weeks. In 
contrast, only 35% of the Quickclips remained attached.
Recently, Eun Ji Shin	et	al compared the attachment duration of two endoscopic clips (the Quickclip’s 
predecessor, the HX-5L, versus the Resolution clip) in the gastric mucosa of 5 pigs. They also found 
that the Resolution clip had the longest rate of retention, being visualized during follow-up endoscopy 
after 1, 2 and 4 or 5 weeks (range of retention rates: 4-5 weeks) and concluded that it be preferred 
over the HX-5L clip (80% dislodged within 2 weeks) when long-term attachment is important171. 
Similar results were reported in a randomized controlled study of 3 types of endoscopic clips used 
for haemostasis in bleeding gastric ulcers in 7 canines. In their study, the median clip retention time 
was 2 weeks for the Quickclip (maximum duration of attachment of 3 weeks) and 4 weeks for the 
Resolution clip (maximum duration of attachment of 18 weeks)172. The nature of our study enabled the 
first report in humans in vivo and is in line with these reports, favouring the Resolution clip when long-
term attachment is required. Furthermore, we describe retention after almost 12 weeks follow-up. 
Long-term attachment of an endoscopic clip was first described in 1994 when Iida	et	al reported clip 
retention (HX-3L, Olympus, total number of clips placed unknown) of up to 26 months after placement 
in a patient during a colonoscopic polypectomy173. In our study, 1 Resolution clip was even visualized 
33 weeks after placement, while the longest measured attachment of a Quickclip was 15 weeks. 
Clinical indications that would benefit from long-term attachment include the fixation of stents and 
feeding tubes in the oesophagus and bowel, respectively.
Regarding the effect of mechanical exertion on the endoscopic clips, we found the following: overall, 
the resolution clip survived the continuous passing of stools more effectively than the Quickclip. 
However, in our study, the retention rates of both the Resolution clip and the Quickclip deteriorated 
during the second and third period (during and after HDRBT) in comparison to the first period, where 
patients underwent external beam radiotherapy (Table 1). As suggested earlier, one probable cause 
for this decreased retention is the fact that an endorectal brachytherapy applicator was placed in the 
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second period in order to plan and perform the HDBRT (4 times in total), which could have mechanically 
dislodged both types of clips in the process. Another plausible reason could be that some of the clips 
(7 Quickclips and 4 Resolution clips) evaluated in period 2 were placed during the first endoscopy. 
With a grip that theoretically deteriorates due to cell renewal and mechanical pressure of passing 
stools during defecation, these clips could possibly have been on the verge of dislodgement, leading 
to the decreased retention rate over periods 2 and 3. Regarding the subgroup of endoscopic clips 
in our study in which attachment was determined after 1, 2 and 3 weeks, retentions rates (Table 1) 
are at least in line with those reported in the abovementioned study by Jensen	et	al	(Quickclip: 74%, 
30% and 11% versus the Resolution clip: 65%, 58% and 45% after 1,2 and 4 weeks)172. Interestingly, 
when one only looks at the retention of the two clip types during these periods (at 1,2 and 3 weeks) 
in our study the Quickclip retention rate did not significantly differ from that of the Resolution clip 
(p=0.17). That in contrast to what Jensen et	al describes, although this could be due to a lack of power 
for this sub-group analysis in our study. Our result implies that short-term attachment directly after 
external mechanical exertion (endorectal applicator) is not significantly superior for the Resolution 
clip, but that does seem to be the case in the period thereafter in which 40% of Resolution clips 
were visualized, versus 7% of the Quickclips. This suggests that if the clip survives the applicator, the 
Resolution clip seems to survive longer. 
Finally, we found the endoscopic clips to be useful in locating and marking the tumour borders for 
radiotherapy volume delineation and for optimizing the position of the endorectal brachytherapy 
applicator. Pfau et	al48 recently reported similar promising results in optimizing radiotherapy volume 
delineation in oesophageal cancer patients. However, a possible downside for the clinical use of 
endoclips is the fact that they are not MRI-compatible, having caused artefacts on MRI in our series. 
In conclusion, in this small prospective study we evaluated long-term attachment of the Quickclip and 
the Resolution clip to human rectal mucosa. We found that up to two thirds of Resolution clips were 
visualized at follow up after a median of nearly 12 weeks illustrating their superior value in situations 
where long term attachment is warranted.

CHAPTER 7
Quantitative intra-operative assessment of peritoneal 
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ABSTRACT
BACKGROUND
Selecting patients for cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy 
(HIPEC) remains challenging. We compared the predictive power of three intra-operative assessment 
tools of peritoneal involvement of colorectal cancer. 
METHODS
Ninety-two procedures (1999-2005) were prospectively scored using the Simplified Peritoneal 
Cancer Index (SPCI) and 7 Region Count. The Peritoneal Cancer Index (PCI) was retrospectively 
scored using the SPCI tool, operative notes and pathological reports. Endpoints were completeness 
of cytoreduction and overall survival. Logistic regression and Receiver Operating Characteristic (ROC) 
curves were applied to compare the predictive value of the three scoring systems on completeness 
of cytoreduction.
RESULTS 
After a median follow-up of 31 months, the median overall survival was 25.6 months. It decreased 
to 7.3 months, when cytoreduction was incomplete (p = 0.001). An increased PCI, SPCI or number 
of regions were all associated with a decrease in probability of complete cytoreduction (p < 0.05). 
With complete cytoreduction as outcome, the ROC areas for the PCI, SPCI and 7 Region Count were 
0.92, 0.94 and 0.90, respectively (p = 0.14). Using a cut-off value of 16 in the PCI system (p = 0.03), 
13 in the SPCI system (p = 0.04) and 6 regions in the 7 Region Count (p = 0.0002) the probability of 
complete cytoreduction decreased significantly.
CONCLUSION 
The PCI, SPCI and 7 Region Count are useful and equally effective prognostic tools predicting 
completeness of cytoreduction and associated improved survival. The 7 Region Count may be 
preferred due to its practical simplicity.




Peritoneal carcinomatosis (PC) is a manifestation of colorectal cancer being present in roughly 10% of 
patients at time of initial diagnosis and in approximately 25% of patients with recurrent disease174-176. 
The natural history of PC is associated with a median survival of approximately 6 months177;178. A 
prospective randomised phase III study86 and a multi-institutional study179 have both demonstrated 
that cytoreductive surgery followed by Hyperthermic Intra-PEritoneal Chemotherapy (HIPEC) improves 
survival in patients with peritoneal carcinomatosis of colorectal origin. These results have encouraged 
many surgical teams worldwide to embark on this relatively new treatment modality. Several studies 
show that HIPEC only works in patients who have undergone complete cytoreduction86;180. Long-term 
survival only seems to be reserved for this subset of patients, as reported in the long-term results of 
the abovementioned randomized controlled trial. After a median follow up of almost 8 years we found 
a 5-year survival of 45% in this subset of patients181. 
Patient selection is crucial to restrict this complex and potentially toxic treatment to patients in who 
complete cytoreduction is feasible. Cytoreductive surgery combined with HIPEC is associated with 
high costs, a treatment related morbidity of 27-35% and a mortality of 1.5-5%182-184. Furthermore, early 
disease progression has been observed in up to 30% of patients182. 
Consensus has been reached regarding pre-operative selection criteria. Patients with signs of extra-
abdominal disease, with inoperable intra-abdominal disease, or with poor performance status are 
generally excluded from this extensive treatment. However, the low sensitivity of CT185;186 or MR imaging 
of PC, especially when tumour deposits are smaller than 1cm, makes pre-operative selection difficult 
and inaccurate. Exploratory laparotomy is often the only way to reliably assess and select patients. 
At present, five quantitative intra-operative abdominal assessment tools have been described for 
this treatment modality: Gilly Staging187, Japanese Gastric Cancer P score188, Peritoneal Cancer Index 
(PCI)189, Simplified Peritoneal Cancer Index (SPCI)180 and the 7 Region Count180. Comparison between 
these prognostic tools with regards to their power to predict complete cytoreduction and long-term 
survival has yet not been attempted.
In this study, we compare 3 tools namely: the PCI, as introduced by Sugarbaker at the Washington 
Cancer Institute, the SPCI and the 7 Region Count, as used at Netherlands Cancer Institute, in a series 
of 92 patients with peritoneal carcinomatosis of colorectal origin treated at the Netherlands Cancer 
Institute between 1999 and 2005.
PATIENTS AND METHODS
SCORING TOOLS
The Peritoneal Cancer Index (PCI) was established at the Washington Cancer Institute by Sugarbaker189 




producing a quantitative score with a maximum of 39. Two transverse and two sagittal straight lines, 
together with a division of the small bowel, artificially divide the abdomen into 13 regions. Each region 
is defined by the anatomic structures situated in that region. Figure 1 describes how lesion size and 
distribution are scored.
The Simplified Peritoneal Cancer Index180 (SPCI) was established in the Netherlands Cancer Institute. 
The SPCI, like the PCI, calculates the tumour load, incorporating the tumour thickness with extent 
of peritoneal dissemination. However, the abdomen is, for practical convenience, divided into 7 
anatomical regions. Each region incorporates certain anatomical structures and scoring is based on 
the visualized maximum thickness of tumour nodules in each region. The SPCI adds up to a maximum 
score of 21 (Figure 1). 
The more user friendly 7 Region Count180 (Figure 1) was introduced by the Netherlands Cancer Institute 
following the SPCI and solely describes the number of affected regions out of 7 in the SPCI system, 
regardless of the tumour volume. Since 2002, 6 or 7 affected regions has served as a contra-indication 
for the combined modality treatment in the Netherlands Cancer Institute. 
DATA COLLECTION
Ninety-two patients with peritoneal carcinomatosis of colorectal origin were treated by cytoreductive 
surgery and intra-operative HIPEC, between 1999 and 2005, at the Netherlands Cancer Institute. 
Procedures were performed as described by our group previously184. Patients with pseudomyxoma 
peritonei or other malignancies were not included. 
During laparotomy, involvement of 7 peritoneal regions, as well as tumour nodule size per region 
was prospectively recorded using the SPCI registration form190. With the help of operative notes and 
pathological reports, procedures were subsequently retrospectively scored using the PCI scoring 
system. In cases where information on regions and/or tumour load was incomplete, missing data 
were translated from the SPCI scoring sheet to the PCI scoring sheet. The PCI lesion size (LS) groups 
differ in magnitude from the SPCI groups (Table 1). LS-0, -2 and -3 are convertible from SPCI to PCI. 
However, when directly converting the LS-1 score from the SPCI score (<2 cm) to the PCI score (<0.5 
cm) lesions measuring 0.5-2 cm in the PCI tool would be underscored (1 instead of 2). We corrected for 
this underscored PCI group 0.5-2 cm by allocating 1.5 instead of 1 point to the PCI group LS-1. When 
tumour location in the small bowel was in conclusive it was scored as follows: the distal ileum was 
scored when only isolated lesions were recorded which did not require partial bowel resection. The 
proximal and distal ilea were scored when the small bowel mesentery was involved or when partial 
resection was recorded. The distal jejunum was added to the combination when multiple small bowel 
resections were recorded and all four regions were scored when extensive small bowel infiltration was 
recorded to have created a surgical dilemma.




Figure 1: The 3 prognostic tools: Peritoneal Cancer Index (PCI)*, Simplified Peritoneal Cancer Index (SPCI) and 7 




Table 1: Scoring of the lesion size 
Lesion Size (LS)
Lesion Size Score PCI SPCI
0 None None
1* < 0.5 cm <2 cm
2 0.5-5 cm 2-5 cm
3 >5 cm >5 cm





Completeness of cytoreduction was recorded as follows; R1: no macroscopic residual tumour, R2a: 
residual tumour ≤ 2.5 mm and R2b: residual tumour > 2.5 mm. Complete cytoreduction was defined 
as a R1 or R2a result in this study.
STATISTICAL ANALYSIS
Logistic regression and Receiver Operating Characteristic (ROC) curves were applied to compare the 
predictive value of the 3 scoring systems on completeness of cytoreduction, e.g. R1 or R2a and R2b. 
Statistical level of significance in predicting complete cytoreduction was set at p=0.050. Overall survival 
was calculated from date of HIPEC procedure until date of death or date of last follow-up. Progression 
free survival was calculated from date of HIPEC procedure until date of progression or recurrence, date 
of death or date of last follow-up. Overall and progression free survival were investigated by a Cox 
regression. A uni- and multivariate analysis was performed for the following factors: gender, affected 
region, number of affected regions, result of cytoreduction, SPCI score and PCI score.
RESULTS
QUANTITATIVE ASSESSMENT ANALYSIS
Ninety-two procedures were performed and analysed in 49 women and 43 men. The median follow-
up was 31 months (range 0-67). The median PCI score was 8.8 (range 0-26) and the median SPCI score 
was 6 (range 0-18). The mean number of affected regions was 3.8 of the 7 regions while in 20 patients 
more than 5 of the 7 regions were affected. The mean number of affected regions in the PCI system 
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was 5 of the 13. In 58 patients a recurrence or progression developed. Forty-five patients died of which 
42 due to disease and 3 due to complications.
Results of the PCI system showed that the pelvis was the most affected region (80 of the 92 patients), 
followed by the central abdomen affected in 72 patients and the lower ileum affected in 65 patients. 
Volume of tumour was also found to be the greatest in the pelvis region followed by the central 
abdomen with a lesion size of >5 cm in 24 and 14 patients, respectively. In the 7 regions used in the 
SPCI and the 7 Region Count similar results were noted in the pelvis and omentum/ tranverse colon 
regions. The least affected regions in the PCI system were the lower jejunum (7 patients) followed by 
the upper jejunum together with the left flank, both affected in 8 patients. In the SPCI/ 7 Region Count 
the left subphrenic space was least affected (16 patients). 
After cytoreductive surgery, no residual tumour (R-1) was left in 58 patients while in 26 patients 
residual tumour deposits measured less than 2.5 mm (R-2a). In 8 patients the cytoreduction was 
grossly incomplete (R-2b). In the latter group the PCI score ranged between 13-21 with a median of 
18 while the SPCI score ranged between 10-18 with a median of 12. The median number of affected 
regions in this group was 6.5 of the 7 regions.
LOGISTIC REGRESSION ON RESULT OF CYTOREDUCTION
In the univariate analysis, both an increased PCI and SPCI, as well as an increased number of affected 
regions, were significantly associated (p<0.05) with a decrease in probability of complete cytoreduction 
(Figure 2). Using, in the literature described, cut-off values of <16 in the PCI system (p=0.0002), <13 
in the SPCI system (p=0.0011) and <6 regions in the 7 Region Count (p=0.0018) the probability of 
complete cytoreduction decreased significantly when the cut-off was exceeded, as shown in Table 2.




Figure 3 shows the ROC curves for the three prognostic tools. The ROC areas for the PCI, SPCI and 7 
Region Count tools were 0.92 (95% CI 0.84-0.98), 0.94 (95% CI 0.89-0.99) and 0.90 (95% CI 0.83-0.97), 
respectively. By nearing the maximum value of 1, these estimates of the ROC areas indicate that all 
three prognostic tools are highly accurate in predicting a complete cytoreduction result. The difference 
between the three was not significant (p=0.14), suggesting that the three systems are similar.
SURVIVAL ANALYSIS
The median overall survival was 25.6 months (95%CI 20.9 - 29.4), with a median progression free 
survival of 13.6 months (95%CI 11.2-16.4). The overall survival decreased from 26.2 to 7.3 months 
when cytoreduction was incomplete (p=0.001, hazard ratio 3.9, 95%CI 1.7-8.8). In all three tools the 
quantitative scores were significant prognostic factors for overall survival, whereby a higher score/
number of affected regions correlated with a decreased survival. Using the cut-off values of <16 in the 
PCI system (p=0.03), <13 in the SPCI system (p=0.04) and <6 regions in the 7 Region Count (p=0.0002) 
the overall survival decreased significantly when the cut-off was exceeded, as shown in Table 2.
In univariate analysis, 3 of the 13 PCI regions [right upper (Hazard-Ratio 2.7), epigastrium (HR 3.9) and 
lower ileum (HR 2.3)] and 4 of the 7 SPCI regions [small bowel and mesentery (HR 2.5), right lower 
abdomen (HR 2), subhepatic space (HR 4.1) and left subphrenic area (HR 2.7)] were, when affected, 
significantly associated with decreased overall survival and progression free survival (except small 
bowel and mesentery).
In the multivariate analysis of affected regions and result of cytoreduction, the epigastric region (HR 
3.3) in the PCI system and the subhepatic space (HR 2) in the SPCI system were independent significant 
prognostic factors for overall survival.
Table 2: Prognostic tools with associated probability of complete cytoreduction and overall survival
PCI SPCI 7 region count
<16 ≥16 <13 ≥13 0-5 regions 6-7 regions
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Figure 3: Receiver Operating Characteristic Curve 
DISCUSSION
PRIME OBJECTIVE IS COMPLETE CYTOREDUCTION
The results of this study are in line with previous studies with regard to poor overall survival in patients 
in whom cytoreduction is incomplete. Prime objective in the selection of patients for this therapy must 
therefore be the probability to achieve complete cytoreduction. Our results show that the PCI, SPCI 
and the 7 Region Count scoring systems are equally effective in this respect. The 7 Region Count is, 
however, the easiest to implement, and may therefore has some advantage over the other systems. 
CUT-OFF VALUES FOR THE PCI
The Washington Cancer Institute, pioneering the treatment modality, established the Peritoneal 
Cancer Index189 and implemented it in the assessment of peritoneal involvement of sarcoma191, 
mesothelioma192, ovarian193 and colorectal cancer194. Sugarbaker194 reported that the 5-year survival of 
approximately 100 colon cancer patients was 50% with a PCI less than 10, 20% with a score of between 
11-20 and 0% in those with a score of more than 20. They suggest a cut-off PCI of 20 above which 




described that a PCI of less than 16 resulted in a significantly more favourable prognosis. In a series 
of 64 patients with peritoneal involvement of colorectal cancer they reported a 3 year survival of 
60% versus 33% using this cut-off value. Our study confirmed these results whereby a PCI score < 16 
was associated with a median survival of 25.6 months while it was 11.3 months for a score of 16 or 
more (p=0.03). Remarkably, there was no survival advantage of a PCI cut-off of >20 versus >16, as no 
patients in our study survived 30 months with a PCI of >16 or >20. The following critical comments 
regarding the PCI should, however, be addressed. Firstly, the numerous amount of 13 regions makes 
the tool tedious to implement. Secondly, the negative effect of small bowel involvement on prognosis 
is together with other crucial anatomical sites a well-known and important fact. However, the desired 
advantage by encompassing this fact (dividing the small bowel into 4 regions) is neutralized by the 
increased chance of an inaccurate overestimation of this region. The subjective and vague transitional 
point of the proximal and distal small bowel creates a possibility to under or overestimate tumour load 
and distribution. Resectable tumour nodules situated on transitions or if one small lesion is resectable 
on each of the four small bowel regions should leave the patient with sufficient functional small bowel 
but would receive a highly overestimated PCI. 
CUT-OFF VALUES FOR THE SPCI AND 7 REGION COUNT
Our group180 previously described important factors predicting poor outcome including poor 
differentiation, signet cell histological type and primary location of tumour in the rectum. 
Furthermore, no long-term survival has been achieved in patients where complete cytoreduction 
failed, acknowledging that complete cytoreduction is a basic necessity for a positive outcome190. We 
introduced a simplified version of the PCI scoring system to maximize simplicity and practicality and 
proved that it was useful in patients with colorectal cancer. Using the simple seven anatomic regions 
we observed that patients where more than 5 of the 7 regions are affected or with a SPCI greater than 
12, the possibility of treatment benefit significantly diminished and was related to an increased rate 
of post-operative complications resulting in a higher morbidity and mortality rate184. We then went 
on to suggest that a SPCI of greater than 12 or 6-7 regions affected should serve as an intra-operative 
exclusion criterion. The results of this study confirm these previous reports. A SPCI score of lower 
than 13 was associated with a significantly increased overall survival (overall 25.6 versus 20.9 months, 
p=0.04) compared to patients with a higher SPCI. Furthermore, patients in whom up to 5 regions 
were affected had an overall survival of 27.7 months. This decreased drastically to 12.6 months when 
6-7 regions were affected. A shortcoming of these two versions of the SPCI tool is the inadequacy to 
encompass the additional negative prognostic value of anatomical crucial sites.
OTHER SCORING SYSTEMS
The assumption underlying the PCI and SPCI is that tumour size, additional to tumour distribution 
predicts outcome. This is in line with the TNM system widely used in oncology and validated 
for many types of cancer, which shows that more cancer predicts poorer prognosis. So why does 
it seem to be different in peritoneal carcinomatosis of colorectal origin? A clue may be that many 
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of the high volume regions recorded in our patients were ovarian metastases, omental metastases 
and primaries or recurrences around the cecum. These tumour deposits usually are technically easy 
to resect. In this series, high volume disease in these areas did not adversely affect completeness 
of cytoreduction or survival. On the other hand, even small tumour deposits in the porta hepatis 
and around the pancreas are difficult to resect completely. This may explain why tumour deposits 
in these areas related significantly to poorer survival. It must also be emphasized that both PCI and 
SPCI are including both unilocular big masses and confluent multiple small deposits as high volume 
disease. It seems clear that these two categories of high volume disease represent a different tumour 
biology, and probably a different prognostic impact. In this respect Gilly probably has a point when he 
emphasizes the prognostic significance of the distinction between localized and diffuse presentation 
of PC. He introduced the Gilly Peritoneal Carcinomatosis Staging187 which incorporates implant size (<5 
mm, 5-20 mm, >20 mm) and distribution (localized or diffuse). It’s efficacy was demonstrated in the 
EVOCAPE178 study investigating the natural history of peritoneal involvement in patients with amongst 
others gastric, pancreatic, liver and colorectal cancer (n=118). The tool was also implemented in a 
study of 56 patients receiving the combined modality treatment196. The prognostic efficacy of the tool 
in the 26 colorectal cancer patients included in this study was, however, not reported. Unfortunately, a 
shortcoming of this simple prognostic tool is that the distribution is unspecific and incomplete in stages 
3 and 4. The tool is inadequately capable of discriminating stages 2, 3 and 4. Stages 3 and 4 incorporate 
only the size of a lesion, without describing distribution. With the likelihood of cytoreduction being 
a chief prognostic indicator, a technically resectable solitary large tumour mass of 4 cm on the 
descending colon (stage 4) is related to a better prognosis than small nodules diffusely spread over the 
abdomen (grade 2). Finally, the Japanese188 established and validated a relatively simple tool to assess 
peritoneal involvement of gastric malignancy. Patients are divided into 4 groups after exploration and 
cytological tests. To our knowledge, no reports have been made on the implementation of this tool in 
colorectal cancer patients. Because we studied patients with PC of colorectal origin in this series, we 
chose to exclude the latter two scoring systems in our study.
STUDY LIMITATIONS
Due to its design, this study has its limitations. Although the SPCI and the 7 Region Count were 
prospectively recorded and are probably accurate, the PCI was retrospectively assessed. This may 
have led to some underscoring, especially regarding tumour distribution and tumour size on the small 
bowel. Another weak point is the fact that from 2002 onwards, patients with 6 or 7 affected regions 
were excluded from the treatment causing a selection bias in our study population. It is, however, 
difficult to foresee any new studies that will neglect the important lessons for selection that have been 
learnt the hard way during the past decade, both by our group and others. A prospectively designed 
study would more accurately be able to compare the scoring systems. A large disadvantage, however, 





Notwithstanding this, the message from this study is clear: Intra-operative selection for cytoreduction 
and HIPEC in patients with peritoneal involvement of colorectal cancer should be based on early 
assessment of the extent of the peritoneal deposits. A PCI ≥ 16, a SPCI ≥13 and a 7 Region Count >5 are 
indications to abort the attempt to complete cytoreduction and scale back to palliative approaches. 
These three staging tools are equal in their accuracy.
Financial contributions or potential conflicts of interest: none.
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DISCUSSION AND FUTURE PERSPECTIVES
EVOLVING TREATMENT MODALITIES IN RECTAL CANCER
Patients who undergo curative rectal surgery are at risk for local or distant disease recurrence. 
Local recurrence within the pelvis is especially feared since this outcome is often unresectable and 
patients, as a result, can suffer a slow, painful death. Over the last few decades treatment of rectal 
cancer has evolved immensely resulting in local recurrence rates after 5 years dropping from 20%-
38%24;197 to approximately 5-10%18;19;198, while overall survival after 5 years has increased from 50% 
to 65%24;198. The most important risk factor for local recurrence is a positive circumferential resection 
margin(CRM)68. CRM involvement is also associated with poor distant control and decreased overall 
survival68;70. Therefore, attaining a negative CRM has become one of the primary goals in the treatment 
of rectal cancer. 
Improvements started with the introduction of a different surgical approach69, the so-called total 
mesorectal excision (TME), which consists of sharp dissection under direct vision along the mesorectal 
fascia. Simultaneously, neoadjuvant short-course radiotherapy (SCRT 5x5 Gy) was introduced24;199 
originally to compensate for poor local control after conventional surgery but later also proved to be 
effective in optimizing local control in resectable rectal cancer treated with TME surgery20. However, 
those with positive margins after preoperative SCRT and TME remain at significant risk for local 
recurrence. Patients with locally advanced rectal cancer (LARC) receive chemoradiotherapy (CRT) 
consisting of long-course preoperative RT with the addition of concomitant chemotherapy followed 
by a longer delay to surgery to allow for downsizing and downstaging of the tumour. Subsequently, 
local control in this subgroup with LARC has improved4;29;30;96. In the recent randomized (C)RT and 
TME trials these improvements in local control have surprisingly not translated into prolonged overall 
survival, possibly due to an increase in other unknown causes of death. Moreover, rectal cancer 
surgery (including TME) is associated with significant adverse effects with regards to long-term organ 
dysfunction and sexual dysfunction, and RT adds significant acute and long-term toxicity59-61;200. To 
maximise patient benefit these adverse effects need to be continuously weighed up against the 
numbers needed to treat to prevent a local recurrence. 
Meanwhile, with the introduction of the MRI, imaging has improved preoperative staging thereby 
facilitating a more patient-tailored approach12. Two radiological studies11;94 demonstrated that MRI can 
accurately predict involvement of the surgical CRM, thereby shifting the importance of an accurate 
T-stage on MRI to the more clinically appealing mesorectal fascia (MRF) at risk for a positive CRM after 
TME. With the MRI, tumours can nowadays be stratified according to the risk of a positive CRM, and 
treated accordingly. 
One of the most important factors governing prognosis in cancer is the presence of lymph node 
metastases201, which explains its inclusion in the TNM cancer classification system. Prior to surgery, the 
presence of positive mesorectal lymph nodes is indicative for the need of preoperative (C)RT. As yet, 




very convincing with 93% being positive202. A more in-depth understanding of the morphology of these 
pathologic lymph nodes will increase staging accuracy. For instance, size, inhomogeneity and border 
contour seem to be predictive factors that increase risk of involvement13. Promising results of special 
contrast agents, like gadofosveset, used to enhance and distinguish pathologic from benign lymph 
nodes have been reported but not yet implemented in clinical practice203. Unfortunately, the current 
available clinical staging modalities remain unreliable in detecting positive lymph nodes smaller than 
1 cm. Our results on accuracy of N-staging in those not undergoing CRT (whereby no downstaging is 
expected) demonstrate under- or over-staging of nodal disease in up to 37% of patients (Chapter	2). 
As a consequence of the introduction and refinement of these different treatment strategies, 
the treatment of rectal cancer has become a complex and multidisciplinary team effort. The 
multidisciplinary team (MDT) discussion plays an important role in preoperative stratification and 
also serves as a platform for decision making, for example to decide to deviate from evidence-based 
guidelines. A population-based study demonstrated the positive effect of an MDT by reporting 
a decrease in the positive CRM rate after the introduction of a MRI-based MDT discussion for all 
patients3. In our regional audit we demonstrated that in only half of patients documented discussion 
in a MDT took place (Chapter	2). Reasons for not discussing the patient or not documenting decisions 
would be interesting to know and could include practical problems, but also non-compliance by 
specialists not aware of the potential benefits. Ten per cent of patients receiving SCRT or no RT 
ended up with a positive CRM, indicating more advanced disease and the need for preoperative CRT. 
Improving the quality of the MDT and increasing the number of patients being discussed may perhaps 
lead to a decrease in unnecessary positive CRMs although an inadequate surgical technique, resulting 
in an incomplete TME specimen, may also lead to (unnecessary) positive CRMs. This emphasizes the 
importance of quality of surgery but also the feedback from the pathologist. Regarding pathology, 
our audit revealed that the CRM itself is underreported in the histopathological report. These results 
together emphasize the importance of quality assurance through audits of region- or nationwide 
treatment results, outside of randomized controlled trials, and also indicate the difficulty of translating 
the results gained in large trials to daily practice. 
A way to assure quality of care on a population level is to introduce evidence-based guidelines, 
standardize treatment according to risk stratification and close the loop of care with an audit which 
in turn generates hypotheses for further prospective research. Once proven in prospective studies, 
new evidence also needs to be properly embedded in common practice through workshops and 
uptake in the guidelines. In order to be able to assess the quality of care, both process and outcome 
indicators must be assessed and observed over time. In 2009, a national initiative arose to improve 
quality of care and the Dutch Institute for Clinical Auditing (DICA) was established. Under auspices 
of the DICA, the Dutch Surgical Colorectal Audit (DSCA) forms a prospective case-mix adjusted audit 
with feedback on quality of care as compared to the median. This has amongst others led to a rise 
of rectal cancer patients being discussed in a MDT from 80% in 2009 to 96% in 2011, and to stricter 
compliance to national guidelines89. With a database coverage of 94% of all diagnosed rectal tumours 
in the Netherlands in 2011, valuable information is being gathered which will facilitate benchmarking 
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and continuous evaluation of quality of care over time, be an incentive to the MDTs to improve quality 
of care and make analyses possible to optimize cost-effectiveness. 
SURGERY
QUALITY OF SURGERY
The paradigm “a surgeon has only one chance to cure the disease” is, due to the nature of the disease 
and its location deep within the bony pelvis, highly applicable to rectal cancer. Complete surgical 
resection using the TME technique, has led to improved local control and at present remains the 
cornerstone in the treatment of rectal cancer19;69;204. However, quality of TME varies and may result in 
differences in outcome92;93;205. A positive CRM after surgery can be caused by various factors, the most 
important of which being suboptimal quality of surgery, aggressive and progressive tumour growth, 
therapy resistance but also preoperative under-staging. Following the introduction of TME on a 
national level further steps have been made to decrease the rate of positive CRMs. More attention has 
been paid to the plane of surgery, which can be assessed by evaluating the macroscopic completeness 
of the specimen. The plane of surgery correlates with both local recurrence and overall survival92 
and deserves to be assessed and reported routinely. A more in-depth analysis of the TME study205 
and following pooled analysis206 of the randomized controlled trials showed that an APR in itself is a 
significant predictor of CRM involvement and subsequent local recurrence. In the distal rectum the 
mesorectum steadily narrows down at the level of levator muscles and this understanding has led to a 
change in surgical approach for distal rectal cancer by maintaining a “cylindrical” resection distal from 
the levator muscles to retain adequate circumferential margins. This more extensive extra-levator 
approach, which pays more attention to the perineal phase and sometimes includes direct muscle 
flap reconstruction techniques, has led to decreased CRM involvement at a cost of more perineal 
wound complications159-162. We confirmed this, with more perineal wound complications occurring in 
those requiring more extensive resections (Chapter	4). Finding a balance between oncologic safety 
and acceptable toxicity is vital, as possible downsides of more extensive surgery in locally advanced 
rectal cancer, in general, are an increased risk of surgical morbidity and mortality.
SURGICAL MORBIDITY
Surgical morbidity is a serious problem in rectal cancer surgery significantly affecting quality of life. 
To ensure uniform documentation and enable inter-institutional comparison, strict definitions of 
complications are however required. Regarding the definition of anastomotic leakage and perineal 
wound complications, it is remarkable how the reported definitions vary in the reviewed phase II 
studies123;125;126 and European randomized trials4;30;52;56;60;90;96;117;137 in rectal cancer. The scope of a 
definition and the way it is implemented largely determines the reported complication rate. It is 
comprehensible that surgical complications are underreported when they are not well defined or do 




and classified complications according to the modified Clavien-Dindo classification134;135 which has 
been validated to score surgical complications (Chapter	4).
In roughly 25% of patients the sphincter will be resected leaving a permanent colostomy. After TME 
only, almost 40% of patients in which the sphincter is saved will develop faecal incontinence61. Sexual 
dysfunction is also a common complication59 after TME indicating the different adverse effects of 
surgery on the pelvic anatomy. In LARC where surgery is often more extensive, we found that acute 
surgical morbidity following CRT is profound with 27% of LAR patients developing an anastomotic 
leakage, while after an APR perineal wound complications occurred in 37% of patients. Furthermore, 
20% of patients were re-admitted to hospital within 30 days after discharge, underlining the importance 
of thorough follow-up. Fortunately, surgical morbidity did not translate into mortality; however, long-
term functional results and quality of life were not evaluated in this series. 
Decreasing surgical morbidity is another aim of the recently initiated DSCA. By prospectively registering 
postoperative complications, rates thereof have now been benchmarked. Furthermore, the database 
can be implemented to identify predictive factors and identify and treat complications earlier on. A 
decrease in the relative risk of 14% for developing major complications was realized over the period 
2009 to 2011, whereby a major complication was defined as an event causing death, requiring a re-
intervention or causing hospital admission longer than two weeks89. Recently, guidelines have called 
for centralisation of LARC and locally recurrent rectal cancer treatment to further increase quality of 
complex surgery required across different anatomical compartments in the pelvis, but also to optimize 
multidisciplinary post-operative care. 
NEOADJUVANT TREATMENT 
CONTINUE TO INCREASE RESPONSE IN LARC
Neoadjuvant (C)RT has firmly established itself as an important therapy becoming more effective 
over the years. The favourable results with regards to local control and tolerable toxicity after the 
addition of chemotherapy to long-course radiotherapy have been demonstrated in randomized trials 
in LARC4;29;96. Furthermore, preoperative CRT resulted in significantly more downsizing, downstaging 
and more pathologic complete responders in comparison to RT alone28. At present, combinations of 
chemotherapy concomitant to RT give more toxicity without oncologic benefit compared to single 
5-FU-based CRT145, except one randomized trial presently awaiting mature follow-up but already 
demonstrating more complete responders (17% versus 13%) after adding oxaliplatin to the 5FU-
based CRT regimen207. An important next step would be to increase response rates to decrease CRM 
involvement rates of 16% in LARC (Chapter	 5). Theoretically, short-course RT (5x5 Gy) and long-
course RT (25x2 Gy) have a similar biological effective dose raising the question which is clinically 
superior. Only the latter presently includes a delay to surgery thereby allowing downstaging and 
downsizing. Recently, two studies have compared SCRT with direct TME and CRT followed by delay31;32. 
As expected, more downstaging was observed after CRT but no significant difference with regards 
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to local/distant recurrence or overall survival was found. However, the studies were underpowered 
for these endpoints, thereby limiting firm conclusions. The Stockholm III trial which has recently 
completed accrual is investigating the effect of different delays to surgery. Patients with resectable 
rectal cancer are randomized to SCRT (5x5 Gy) followed by surgery within one week or after 4-8 weeks 
or long-course RT (25x2 Gy) followed by surgery after 4-8 weeks. Participating hospitals were allowed 
to choose to randomize between 2 or 3 groups, and individualize this per patient which may introduce 
the risk of selection bias. Interim analyses on acute toxicity and surgical complications show no 
significant differences in the 3 arms208. It appears that post-operative stage was more favourable in the 
delayed surgery groups with no residual tumour found in 0.5% (5x5 Gy with direct surgery), 12.5% (5x5 
Gy with delayed surgery) and 5% (25x2 Gy with delayed surgery), indicative of downstaging. These 
interim results are in line with retrospective series reporting downstaging after SCRT and delayed 
surgery in patients medically unfit for CRT144;209. Hopefully the Stockholm III study will provide the 
answer whether SCRT followed by delayed surgery will match the response of long-course RT and 
delayed surgery. The delay may open up logistical opportunities to add systemic chemotherapy to 
eradicate micrometastases and possibly increase distant control and OS. 
Another promising option, implementing induction systemic chemotherapy followed by CRT and TME, 
demonstrated high complete and near complete response rates, again with considerable toxicity, in 
non-resectable rectal cancer patients in a British trial210. One study investigated dose escalation and 
addition of a platinum derivative by comparing treatment with 45 Gy radiotherapy in 25 fractions with 
concurrent capecitabine versus 50 Gy radiotherapy in 25 fractions with capecitabine and oxaliplatin, 
but reported no benefit with regards to complete response rates, LR, distant metastases or OS33;211. 
With regards to radiotherapeutic options to increase downstaging and downsizing, several studies 
have reported a dose-response relationship99;212-214 indicating that dose escalation, for instance, with a 
boost delivered with contact therapy, endorectal brachytherapy or during IMRT is clinically appealing. 
Results on the addition of biologicals targeting molecular markers, for instance vascular endothelial 
growth factor specific antibodies like bevacizumab215 or epidermal growth factor receptor antibodies 
like cetuximab216-219, as part of the CRT have been disappointing with regards to increased efficacy. 
LESS NEOADJUVANT THERAPY WITH ADEQUATE TME IN LOW RISK PATIENTS?
In subgroup analyses of the MRC-CR07 and the Dutch TME studies, LR rates doubled if no SCRT was 
used prior to TME in TNM stage III rectal cancer, thereby firmly establishing the absolute need of 
preoperative RT for these patients90;198. Of note, despite a significant reduction in local recurrences in 
TNM stage I patients, the benefit from preoperative SCRT may be questioned as an absolute reduction 
of 2,6% for all eligible patients implies that 38 patients have to be irradiated to prevent one local 
recurrence. Furthermore, no significant benefit from preoperative SCRT could be demonstrated for 
stage II patients in this study198. In the MRC-CR07 study90 the beneficial effect of RT was found in all 
stages of disease, but due to low incidence of recurrence in stage I and II the beneficial effect may 
not outweigh adverse effects, especially as no survival benefit was found. The concept of selectively 




European centres which reported a LR rate of only 2.3% in TNM stage II rectal cancer (n=43), staged 
with MRI and treated with TME only. Therefore, in patients with TNM stage I or II disease high quality 
TME only is a valid treatment option. 
LESS SURGERY AND MORE (C)RT? 
Another important question is whether it is more beneficial to scale down aggressive surgical 
resection, to avoid morbidity and organ dysfunction, by implementing more effective neoadjuvant 
therapies? As preoperative CRT causes downstaging, less invasive surgical options have become more 
clinically appealing, especially in lower stage tumours. Promising results of (C)RT followed by local 
excision instead of TME in good responders with cT2-3 disease indicate the possibilities221;222. If the 
excised specimen contains residual disease or downstaging is insufficient, additional TME may follow. 
This is also the design of the phase II CARTS study, where the proposed accrual has been reached, 
and patients with cT1-3 N0 M0 distal rectal tumour cancer are treated with CRT followed by TEM 
if downstaging is observed223. Furthermore, the toxicity of this combination will be evaluated, with 
special attention for dehiscence of the TEM wound after CRT. 
In the elderly population the concept of minimizing surgery related adverse effects is also actual 
as consequences of surgical complications are larger than in the middle-aged population and may 
even be lethal62. Definitive radiotherapeutic regimens, like external beam radiotherapy followed by 
endorectal brachytherapy, might gain ground in this fragile patient group224. Lastly, as more treatment 
options become available, patient information on advantages and disadvantages of treatment options 
as well as evidence-based quality of life will govern shared decision-making225;226.
CAN WE WAIT AND SEE? 
A pathologic complete response (pCR) diagnosed after preoperative CRT followed by delayed TME 
occurs in up to 30% of cases. These patients have been associated with an excellent outcome in 
numerous series38;147. Different factors play a role in determining the pCR rate. Firstly, rates of pCR are 
dependent on the extent of histopathological analysis, whereby thorough processing and sampling of 
deeper layers within the specimen in search for residual tumour cells may result in more accurate but 
lower pCR rates. Traditionally, surgery is performed approximately 6 weeks after completion of CRT 
to allow for response and patient recuperation from CRT-related toxicity. Emerging evidence suggests 
that the response to CRT is time-dependent, with more delay to surgery resulting in a higher rate of 
pCR227-229. Whether patients achieving a pCR after longer delays than 6-8 weeks also have the same 
favourable prognosis is unknown. Another factor affecting reported pCR rates is patient selection for 
CRT, as a cT2 tumour is obviously more likely to respond completely than a cT4 tumour. It is unclear 
whether the prognostic benefit of CRT induced regression is similar between less advanced and locally 
advanced tumours. However, the effect of pCR on long-term outcome was not affected by clinical T 
or N stage in a pooled analysis of pCR patients whereby response was assessed after 6-8 weeks after 
CRT38. 
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The concept of a pCR after neoadjuvant therapy questions the need for additional resection and may 
be a solution to decrease the surgical morbidity. The group of Habr-Gama et	al have published multiple 
series on a non-operative “wait and see” policy in those patients in whom no clinically detectable 
tumour is found after CRT39. They reported a locoregional failure rate of only 3% in a series39 of distal 
rectal cancer patients (20% cT2, 70% cT3, 11% cT4 and 23% cN+), which is comparable to those with 
a pCR after resection. These results have been confirmed by another small single centre experience40. 
The long term oncological outcome following wait and see is however unknown. A key limitation of 
this policy resides in the inability to assess response accurately with present day imaging. Chapter	5 
adds knowledge to this option by demonstrating that CRT with capecitabine is an effective regimen 
resulting in a pCR rate of 20% in LARC with 39% T4 tumours. In this study, with central revision of the 
pathology, we however also demonstrate the potential risks involved in this group of patients. Counter 
intuitively, we demonstrated poor outcome in those with a near complete response and a significant 
percentage lymph node metastases in those with a pCR, underlining the risks of a wait and see policy. 
Furthermore, with the rectum being left in situ during this organ sparing approach the applied RT may 
perhaps lead to long-term toxicity. 
RESPONSE PREDICTION
With regards to the assessment of response to neoadjuvant therapy itself, imaging will play an 
increasingly important role in the future as more interest is gained in organ sparing strategies and 
minimizing overtreatment in non-responders. At present it is difficult to distinguish (residual) fibrosis 
from tumour with the modalities at hand. Pathological analysis remains the gold standard, but 
functional imaging would be more practical in distinguishing responders from non-responders during 
the treatment itself. Diffusion-weighted MRI seems promising with responding tumours showing a 
higher apparent diffusion coefficient (ADC)230. However, further optimization and validation is required 
before this technique will reach clinical practice. 
The use of another promising tool, the 18FDG labelled PET, in combination with clinical variables, to 
predict pCR has been tested in a multicentre study231 including sequential PET-CT imaging one week 
before and 6-8 weeks after CRT. The resulting nomogram performed with a sensitivity of 0.62 and 
a specificity of 0.88 in the validation series. Although the optimal time point of imaging needs to 
be refined, accurate PET-based prediction has been shown already after 2 weeks232. Interestingly, 
associations between preoperative ADC measurements and SUV measurements half way during and 
after CRT have been demonstrated (but not yet validated) to have a sensitivity for predicting a pCR of 
up to 100% and a specificity of 94%, suggesting a synergistic effect of combining these tools233. 
In conclusion, at present a wait and see policy seems to carry too many risks due to limitations in 
response assessment. In the future, knowledge gained on genetic profiles and using blood biomarkers 
will hopefully contribute to optimizing the specificity and sensitivity of response predicting models. 
Ideally, an accurate re-staging model using different tools (DW-MRI and 18FDG-PET) could predict 




considered for less invasive surgical interventions or even a “wait and see” policy. On the other hand, 
based on the early predicted response, early modifications of the treatment protocol are possible, 
which in suboptimal responders could include dose escalation to improve response or necessitate 
direct extended surgery to prevent progression during neoadjuvant CRT. 
IMPROVING RADIOTHERAPY TECHNIQUES TO DECREASE TOXICITY
The clinical target volume (CTV) in rectal cancer not only includes the rectum but also the surrounding 
mesorectal fat, containing possible microscopic tumour extensions and regional lymph nodes. As the 
irradiated volume increases more healthy tissue is inevitably and unnecessarily at risk. As reported 
in Chapter	4, grade 3 acute toxicity occurs in 21% during CRT for LARC, with diarrhoea and radiation 
induced dermatitis being most prominent. At present, to ensure complete coverage of the CTV, 
uncertainties which include patient set-up errors, target volume definition uncertainties but also 
internal organ motion, are taken into account by delineating a generous CTV or adding a generous 
margin from CTV to the planning target volume (PTV). To minimize uncertainties and consequently 
decrease toxicity to surrounding healthy tissue, several measures can and have to be taken. 
Firstly, decrease the irradiated volume: more knowledge on recurrence patterns demonstrates that 
reduction of CTV in selected cases is probably safe66. Lowering the upper border of the CTV results 
in a significant reduction of the PTV volume and irradiated small bowel volume. Secondly, decrease 
delineation variation: the introduction of guidelines and a delineation atlas in combination with 
delineation workshops have shown to decrease inter-observer delineation variation106. Possibly, the 
addition of other high resolution imaging modalities such as MRI to the planning CT could reduce 
delineation variation even more in the future. Thirdly, with intensity-modulated RT (IMRT) more 
conformal treatment plans can be delivered largely reducing small bowel volumes treated with high 
doses101;234. A comparative study has demonstrated that when implementing IMRT, supine position 
with a full-bladder protocol (and without a belly board) maximises patient comfort and stability on 
set-up. Although bowel exposure was higher on the prone and supine scans without a belly board, 
unacceptable values predicting acute and late toxicity were on average not reached. This questions the 
need for the belly board next to IMRT with full bladder protocol234. As a consequence of the increased 
precision made possible with the use of IMRT it has become increasingly important to estimate and 
account for these uncertainties involved to prevent critical under-treatment of parts of the target 
volume, especially in hypofractionated treatment plans. The next step is to reduce margins but to 
make this possible, more knowledge on shape variation of the whole CTV during the whole treatment 
is required. 
In Chapter	3 we present data on inter-fraction shape variation, demonstrating that adapted CTV-PTV 
margins for different parts of the CTV are needed to ensure adequate coverage. In this way IMRT can 
be safely applied. For further margin reduction a more imaged-guided approach is warranted, with 
an online and adaptive approach to CTV delineation with images, acquired upon setup and before 
the fraction, supplying information on present patient anatomy. In patients treated with CRT a mean 
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reduction in rectal volume was observed over time during the treatment. A recent study has suggested 
that with one single plan adaption based on repeat-CT images gained during the first 4 fractions the 
difference between intended and treated volume (systematic error) and subsequent PTV margins can 
be reduced significantly235. 
In conclusion, radiotherapy is a valuable tool with additional value to surgery alone in the treatment of 
rectal cancer. Future refinement will include more accurate patient selection for those really in need of 
radiotherapy to reduce LR, while on the other hand understanding and quantification of uncertainties 
will lead to increased precision of dose delivery leading to a decrease in toxicity to surrounding healthy 
tissue but also opening up possibilities for dose escalation with boosts to maximize response. 
PATHOLOGY
RESPONSE ASSESSMENT
Following the introduction of preoperative CRT for rectal cancer, histopathological features have 
changed, and the impact of these changes is yet unknown. Furthermore, assessment of response 
has become an integral part of histopathological assessment. In Chapter	 5	we	 demonstrate that 
tumours seem to respond heterogeneously to CRT, but mechanisms governing response or resistance 
unfortunately remain unclear. 
The ypT stage can be used as a measurement for tumour shrinkage or downstaging if the pre-treatment 
staging was accurate. However, there is a large variability with regard to tumour load, some tumours 
respond with downstaging from a cT4 to a ypT2, while others show regression or fragmentation of 
the vital tumour with residual tumour deposits scattered throughout the mesorectal fat. Extent of 
regression of the tumour after CRT is assessed by semi-quantitatively scoring the relative proportion 
of residual tumour to stromal fibrosis, the tumour regression grade. A complete response (ypT0) is 
clearly associated with excellent disease control, but results of our series surprisingly show that a near 
pCR fares poorly (Chapter	5). Various systems have been suggested to grade tumour regression, but 
the majority are not able to demonstrate a relation with prognosis5;71;74;153. In addition, reproducibility 
of regression grading is poor71, especially those using many tiers, preventing the introduction of one 
particular system into daily practice. Our results suggest that the 4 tier regression grade may predict 
prognosis in a strictly defined group of LARC receiving a uniform treatment. However, further validation 
in a larger series is required to unravel the true prognostic meaning of different types of response. 
Of note, the length of the delay between radiotherapy and surgery influences observed response 
rates with more response being observed after longer delays. Dependant on their position in the cell 
cycle, some tumour cells go into apoptosis directly after RT while others take weeks to do so. After a 
longer delay to surgery, relatively more radiosensitive tumour cells will have gone into apoptosis and 
have been replaced by fibrosis. This is visible on a slide after resection, however, morphologically, 
differentiation between a viable and dead tumour cell is impossible on a slide. This also indicates the 




dead at resection but simply had not yet been replaced. In the future it would be interesting to find 
ways to differentiate between viable tumour cells and (pre-apoptotic) damaged cells after RT and 
elucidate prognostic importance thereof.
FUTURE OF THE TNM CLASSIFICATION
The TNM staging system was originally used to describe the resected tumour more extensively, 
provide information on prognosis and guide the use of adjuvant therapy. If all tumours are staged 
according to the same system, large databases can be constructed and combined for interinstitutional 
or international comparisons in which different treatments or outcomes can be compared. However, 
TNM editions have recently been changed in rapid succession, perhaps with lacking evidential 
support156;236-239. As a consequence, this very important function of pathological staging may be 
lost. An illustrative example is the way lymph nodes are diagnosed: TNM 5th edition staged tumour 
deposits in the mesorectal fat as a node if it measured more than 3 mm, while in TNM 6th edition 
size was unimportant while contour guided the decision. In TNM 7th edition, no rules apply giving the 
pathologist room to decide. A lack of standardization creates stage migration, poor reproducibility, 
and major uncertainty for pathologists. In some European countries, this problem has temporarily 
been solved by deciding to remain with TNM 5th edition. 
On the other hand, with new prognostic factors like the CRM at hand, the classification of rectal 
cancer needs to be refined236;237;240. In modern staging of rectal cancer there should be a place for 
treatment-related factors, given that the result of treatment strongly determines prognosis. Promising 
suggestions for replacing the TNM system (using only tumour related factors) with a combination 
of a tumour-related factor like nodal status, and a treatment-related factor like CRM, have resulted 
in improved prognostication with highly divergent survival curves241. Also, a nomogram has recently 
been developed as a result of a pooled analysis of 5 large European randomized trials in LARC with 
the aim of stratifying the risk of an event. The nomogram is able to predict local/distant control and 
overall survival after 5 years thereby serving as a tool to guide more intensive follow-up or adjuvant 
treatment in those at risk75. As MRI has become the standard tool for staging of LARC, the group of 
LARC patients treated in trials will become more uniform and well-defined, which raises possibilities 
for further refinement of these nomograms in the future. Last but not least, the role of molecular 
genetics is slowly being unravelled as an important marker for response prediction to neoadjuvant 
(C)RT treatment or to adjuvant treatment but also for prognosis. This will facilitate an even more 
patient tailored treatment using genetic information together with the abovementioned patient and 
treatment related factors. 
With the introduction of the microarray in molecular biology, large amounts of information on gene 
activity can be produced in a quick and orderly fashion. An example of success booked in this field 
is the Mammaprint242 which is able to distinguish a good and poor prognostic profile in lymph-node 
negative or minimal positive (1-3 nodes) breast cancer patients. Meanwhile, another study has 
reported the development of a 10-gene prediction model for intrinsic radiosensitivity, with a sensitivity 
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and specificity of around 80%243. Also, recent investigations into gene expression profiling and kinase 
activity profiling revealed the possibility to predict response to CRT in-vivo244;245. 
IN CONCLUSION
Rectal cancer treatment is a team effort. The different modalities with their specialists are inter-
dependent when providing care of high quality. Improvements in the different modalities have 
improved local control immensely. Now it is time to shift attention to increasing the distant 
metastases-free survival and to the possibilities of less invasive surgical strategies. As technology 
improves, imaging for (re-)staging and delivery of radiotherapy will improve, leading to possibilities 
for more accurate patient selection and more precise radiotherapy delivery of more effective doses, 
respectively. As new neoadjuvant regimens are explored and genetic backgrounds are unravelled, 
treatment will become more patient tailored. The recently initiated prospective audits will shed light 
on the quality of delivered care with the aim of improving outcome, whilst minimizing side effects and 
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In the first Chapter a general introduction and background is given on recent developments in the 
multidisciplinary approach to the treatment of rectal cancer. In the Netherlands, roughly 3500 patients 
are diagnosed with rectal cancer each year. Improvements across all modalities have decreased the 
number of tumour positive circumferential resection margins (CRM) and optimized local control. 
Approximately, 60% of patients are alive after 5 years, with local recurrences occurring in around 
5-10% and distant recurrence up to 30% of patients. 
Total mesorectal excision (TME) remains the cornerstone of treatment, while preoperative radiotherapy 
(RT) or chemoradiotherapy (CRT) further improves local control. Following the introduction of the 
MRI, patients with rectal cancer can be stratified into risk groups and treated accordingly, each with 
a different treatment approach based on the risk of a positive CRM and subsequent local recurrence. 
Patients with well differentiated, superficial tumours (T1N0) where treatment with local excision 
suffices, were excluded for the purposes of this thesis. The intermediate risk group consists of patients 
with mobile resectable tumours (T1- T3, N0-1) where the distance to the mesorectal fascia (MRF) is 
≥ 1 mm. These patients receive preoperative 5x5 Gy radiotherapy (short-course radiotherapy; SCRT) 
followed directly by TME. Recently, TME only has become a valid option in those patients without 
suspected nodal disease and in those with superficial mesorectal fat invasion of the primary tumour 
(≤ 5 mm). The high-risk group includes patients with locally advanced tumours, where the MRF or 
the consequent surgical CRM is threatened or involved (distance to MRF < 1 mm), or where extensive 
lymph node involvement (cN2) or extra-mesorectal pelvic lymph nodes are suspected. In this group, 
the treatment of choice consists of preoperative downstaging with long-course radiotherapy (25x2 
Gy) in combination with oral fluoropyrimidine-based chemotherapy (CRT), followed by delayed TME. 
After resection the pathologist evaluates the specimen, micro- and macroscopically, and gives 
feedback to other caregivers on response, lymph node metastases and resection margins, and other 
histopathological factors governing prognosis. 
CHAPTER 2
In Chapter 2 the present population-based multidisciplinary team (MDT) approach to (>T1N0) rectal 
cancer in the region was evaluated. According to national guidelines, all rectal cancer patients deserve 
preoperative MDT discussion with the aim to improve quality of staging and to optimize decision 
making. The value of the MDT discussion was evaluated in 210 patients diagnosed in the greater 
Amsterdam area. The hypothesis was that discussion in an MDT would lead to less positive CRMs. 
In actual fact, in only 55% of all patients documentation was found of a discussion in an MDT. In 
those discussed, MRI was implemented more often and TNM staging was more complete, while more 




in rectal cancer, was mentioned in the pathology report in only 61% of patients, and additionally 
measured for the purpose of this study in 34% of patients. The overall CRM rate was 13% and did 
not differ between those discussed and not discussed, probably because more advanced patients 
were selected for discussion. In theory, after accurate preoperative selection and discussion, patients 
undergoing SCRT or no RT should have a negative CRM after adequate TME, as otherwise preoperative 
CRT was probably the treatment of choice to induce downsizing and downstaging and facilitate radical 
resection. However, the positive CRM rate was still 10% in those judged to require preoperative 
SCRT (or no RT occasionally), indicating room for improvement in patient selection. In LARC patients 
receiving CRT, a positive CRM could unfortunately not be prevented in 20% of patients. 
Results of this retrospective study demonstrate room for improvement, especially in the selection of 
patients for SCRT or no RT. Standardized documentation of treatment decisions and pathology reports 
are needed. Since then, the latter has been effectuated in daily practice. Audits but also pathologists 
are an important source of feedback for quality control. 
CHAPTER 3
Following the establishment of the benefits of radiotherapy in the treatment of rectal cancer, 
radiotherapy-related side effects have to be kept to a minimum. The challenge is to minimize the 
dose to surrounding healthy tissue or organs at risk, whilst assuring adequate clinical target volume 
coverage. Internal organ motion causes shape variation of the clinical target volume (CTV) and forms 
a major uncertainty that governs and limits the accurate delivery of radiotherapy. To evaluate the 
magnitude of this uncertainty a prospective repeat CT study described in Chapter 3 was initiated. 
Aim was to quantify the inter-fraction shape variation of the full CTV in rectal cancer patients treated 
with SCRT (5x5 Gy) and CRT (25x2 Gy + daily capecitabine). Subsequently, new anisotropic planning 
target volume (PTV) margins, which take these uncertainties into account, were derived to replace the 
standard 1 cm PTV margin. 
For the 33 SCRT patients CT-scans were made daily, while for the 30 CRT patients a CT-scan was made 
daily in the first week and weekly thereafter. The full CTV was then delineated on a total of 482 CT-
scans. The calculated CTV shape variation was found to be a major and heterogeneous geometric 
uncertainty in both groups, with systematic and random errors ranging from 0.2 cm standard deviation 
(SD) close to bony anatomy to 1.0 cm SD at the upper-anterior border of the mesorectum. For the 
lateral lymph node regions smaller systematic shape variations were found. Male and female shape 
variation did not differ significantly overall. 
Subsequently, gained information on shape variation was used to develop a modified recipe for a new 
PTV. Required anisotropic margins ranged from 0.7 cm close to bony structures up to 3.1 and 2.3 cm 
in the upper-anterior region for SCRT and LCRT, respectively. This results in a suggested PTV which is 
approximately 20% smaller than the conventional combination of a generously delineated CTV with 





In the treatment of LARC, 5-fluoruracil (5-FU) -based CRT has been demonstrated as an effective 
modality to induce downstaging and downsizing. Capecitabine is an attractive radiosensitizer with 
ease of oral intake compared to intra-venous 5-FU. However, few studies have concentrated on the 
surgical morbidity and mortality resulting from this treatment modality. In Chapter 4 acute toxicity 
and surgical complications associated with preoperative chemoradiotherapy with capecitabine 
for locally advanced rectal cancer were evaluated. Toxicity was scored according to the Common 
Terminology Criteria (version 3.0) and Radiation Therapy Oncology Group scoring systems. Treatment 
related surgical complications were evaluated up to 30 days after discharge from hospital using pre-
determined definitions and the validated modified Clavien–Dindo classification.
Some 147 patients with strictly defined LARC (M0) were included. The preoperative CRT was tolerable, 
with a mean cumulative chemotherapy dose of 95%, while 98% of the patients received ≥ 45 Gy. 
Serious toxicity (grade 3-5) was observed in 22% of the patients, especially diarrhoea and radiation 
dermatitis. The post-operative morbidity was significant, but did not translate into mortality in 
this series. Anastomotic leakage was found in 28% of the patients after LAR, while perineal wound 
complications occurred in 37% of the patients after an APR. One in 5 patients needed to be re-admitted 
within 30-days after initial hospital discharge. 
These results indicate that preoperative CRT with capecitabine is associated with acceptable acute 
toxicity and surgical mortality but with significant morbidity. A review of the literature on morbidity 
revealed that our anastomotic leakage rates were higher than rates reported in randomized controlled 
trials and phase II studies. Complication rates were not the endpoint of these studies and definitions 
used were barely mentioned. Our series also contained more advanced tumours, similar to another 
study reporting similar rates of morbidity. An important conclusion from this study was the importance 
of uniform definitions to be able to inform patients on possible adverse effects and to facilitate inter-
institutional comparisons so that morbidity can serve as a quality of care parameter. 
CHAPTER 5
Following the introduction of preoperative CRT, the importance of histopathological parameters 
in rectal cancer has changed. Some rectal tumours undergo apparent complete tumour regression 
after CRT. Clinically undetectable residual tumour deposits or pathologic lymph nodes may remain 
in the mesorectum. In this Chapter efficacy of the CRT was evaluated. The objective of this study 
was to evaluate which factors determine outcome, focusing on the contribution of histopathological 
response after CRT. 
Slides of 107 patients were revised according to TNM 5th edition and response scored according to 4 
grades of regression. Results indicate that in this series with almost 40% cT4 tumours, CRT (25x2 Gy 
with capecitabine) is an effective regimen, and worth the experienced morbidity, with 20% revealing a 




adverse effects mentioned earlier. However, alarming rates of residual lymph node metastases 
occurred in those with a pCR (29%) or near pCR (50%). Furthermore, islands of tumour cells were 
found invading the mesorectal fat in 42% of near pCR patients. Regarding the distant metastases free 
interval, patients with a pCR show excellent outcome, however, those with a near complete response 
were associated with a relatively poor outcome with 5/12 patients developing distant metastases. 
With the inabilities of present day imaging to accurately identify lymph nodes metastases and 
distinguish fibrosis from tumour deposits, a ‘wait and see’ policy in LARC is associated with significant 
risks and should be applied with extreme care. 
CHAPTER 6 
As CRT results in near or complete remission in 30% of the patients, pre-treatment demarcation of the 
tumour location will become more important in the future. Furthermore, utilizing their radio-opaque 
characteristics endoclips can be implemented to aid target volume delineation during radiotherapy, 
aid clinical assessment of response or mark the tumour during endorectal brachytherapy. Retention 
rates have, however, only been evaluated in canines and pigs and have not yet been reported in the 
human gastrointestinal tract. In Chapter 6, long-term attachment rates of two modern, but different, 
endoclips used in the human gastrointestinal tract were evaluated as part of a study to evaluate 
the feasibility of external beam radiation therapy followed by endorectal brachytherapy. The rectal 
tumour was marked with Quickclips (Olympus Ltd.) and/or Resolution (Microvasive, Boston Scientific 
Corp) endoclips to facilitate tumour localization during the brachytherapy procedure. 
A total of 44 clips were placed in 9 patients during endoscopy before or after the external radiotherapy. 
The attachment was evaluated during repeat endoscopy after external radiotherapy or traced on 
fluoroscopy images acquired every week during the brachytherapy. Results demonstrated that the 
Resolution clip, which has the advantage of being able to open and close its jaws repeatedly, was 
superior to the Quickclip (unchangeable after firing) in situations where long-term attachment is 
warranted. The Resolution clip remained attached longer than the Quickclip, with encouraging long-
term retention rates of up to 67% for the Resolution clip after nearly 12 weeks. In contrast, only 35% 
of the Quickclips remained attached. A possible downside for the clinical use of endoclips arising 
from this study, is the fact that the endoclips are not magnetic resonance imaging (MRI) -compatible, 
causing artefacts on MRI. As MRI has become standard of care in staging and re-staging of rectal 
cancer, further research and development is required, for instance into the feasibility and retention of 
submucosal gold markers.
CHAPTER 7
This Chapter concerns the treatment of metastatic colorectal disease. For patients with peritoneal 
metastases a new treatment has been proved effective which includes extensive debulking or 
cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) to eradicate 




challenging. In the study reported in chapter 7, three prognostic tools are compared which are 
used at the beginning of the cytoreduction to select patients in which complete cytoreduction is 
possible, as only these patients benefit from the treatment. The peritoneal cancer index (PCI) and the 
simplified PCI (SPCI) both combine cancer implant size with cancer distribution. The PCI contains 13 
abdominopelvic regions divided artificially by lines, while the SPCI contains 7 regions dependant on 
anatomical structures involved. According to tumour load a score is given to each region. The 7-region 
count describes the number of affected regions out of 7 in the SPCI system, regardless of the tumour 
volume. 
Results of this study of 92 patients showed that an increased PCI, SPCI or number of regions were all 
associated with a decrease in probability of complete cytoreduction and subsequent overall survival. 
A cut-off value of 16 in the PCI system, 13 in the SPCI system and 6 regions in the 7 Region Count were 
most predictive of both endpoints. The three tools were equally effective prognostic tools predicting 
completeness of cytoreduction and associated improved survival. However, the 7 Region Count may 









In het eerste Hoofdstuk van dit proefschrift wordt ter inleiding een weergave gegeven van recente 
ontwikkelingen op het gebied van de multidisciplinaire behandeling van het rectumcarcinoom. 
Verbeteringen in alle afzonderlijke modaliteiten hebben er toe geleid dat het aantal positieve 
resectie marges en het aantal lokale recidieven flink zijn gedaald. In Nederland worden er jaarlijks 
3500 patiënten gediagnosticeerd met een rectumcarcinoom. Ongeveer 60% van deze patiënten leeft 
nog na 5 jaar, terwijl een lokaal recidief bij 5-10% en afstandsmetastasen bij 30% van de patiënten 
geconstateerd wordt. Het doel van wetenschappelijk onderzoek bij het rectumcarcinoom is enerzijds 
het ontwikkelen van “therapie op maat”, afhankelijk van tumor- en patiënteigenschappen. Anderzijds 
is het belangrijk dat elke therapie gestandaardiseerd gegeven of uitgevoerd wordt om optimale 
kwaliteit te waarborgen. Inmiddels zijn er in Nederland richtlijnen geschreven waarin deze twee 
facetten verwerkt zijn.
Centraal in de behandeling van het rectumcarcinoom staat het verwijderen van de tumor middels 
totale mesorectale excisie (TME). Deze operatie is een en	bloc resectie van de primaire tumor met 
omliggende lymfklieren in het mesorectum door middel van scherpe dissectie in het circumferentiele, 
avasculaire vlak van het rectum. Als aanvulling hierop, om de lokale controle verder te verbeteren, 
wordt voorafgaand aan de operatie bestraling (RT) of een combinatie van bestraling met chemotherapie 
(CRT) gegeven. 
Beeldvormende technieken, MRI in het bijzonder, bieden tegenwoordig de mogelijkheid om patiënten 
in 3 groepen onder te verdelen afhankelijk van het risico op een incomplete resectie (een positief 
circumferentiele resectie marge, CRM) en lokaal recidief. Laag risico patiënten, diegene met een 
oppervlakkig gelegen en goed gedifferentieerde tumor (T1N0) waarbij lokale excisie volstaat, worden 
in dit proefschrift buiten beschouwing gelaten. De intermediaire risico groep bestaat uit patiënten 
met een mobiele en resectabele tumor (T1-3N0-1) met een afstand tot de mesorectale fascie (MRF) 
≥ 1 mm. Deze patiënten ondergaan een korte preoperatieve bestraling gedurende 5 dagen (5x5 Gy) 
met als doel losse achtergebleven cellen te doden. TME volgt binnen een week. Onlangs is besloten 
de preoperatieve bestraling achterwege te laten bij patiënten zonder klinisch verdenking op positieve 
lymfklieren en bij patiënten met beperkte (≤ 5 mm) of zonder extra-murale vet invasie. Bij de hoog 
risico groep (cT2-3 met afstand tot de MRF < 1 mm of cT4, en/of hoge mate van waarschijnlijk op 4 of 
meer positieve lymfklieren binnen het mesorectum of positieve lymfklieren buiten het mesorectum 
op basis van MRI) is preoperatieve bestraling noodzakelijk om de tumor te verkleinen om de kans op 
een radicale resectie te vergroten. Dit betreft patiënten met een lokaal uitgebreid rectumcarcinoom 
die CRT ondergaan, een combinatie van een lang schema radiotherapie (25x2 Gy) en lage dosis 
chemotherapie (capecitabine). Hierna volgt een periode van rust om de tumor de kans te geven 
kleiner te worden, waarna chirurgie volgt 6-10 weken later met eventuele uitbreiding van de resectie 




Na de TME wordt het preparaat door de patholoog op macroscopisch en microscopisch niveau 
onderzocht. Informatie over de respons op de voorbehandeling, aanwezigheid van lymfklier 
metastasen en de resectie marges zijn belangrijke factoren die de prognose bepalen. 
HOOFDSTUK 2
In Hoofdstuk 2 wordt de multidisciplinaire aanpak van het (>T1N0) rectumcarcinoom in regio 
Amsterdam geëvalueerd. Volgens de geldende Nederlandse richtlijn ten tijde van het onderzoek 
behoren alle patiënten in een multidisciplinair team (MDT) bespreking besproken te worden met als 
doel stadiering en keuze van een optimaal behandelingsplan te bewerkstelligen. 
In deze studie werd de aanvullende waarde van de MDT bespreking geëvalueerd in 210 patiënten 
met als hypothese dat bespreking in een MDT zou leiden tot minder positieve resectie marges. Het 
bleek echter dat slechts iets meer dan de helft (55%) van de patiënten daadwerkelijk werd besproken. 
Van diegene die besproken werden was de TNM stadiering vaker compleet en werd de MRI vaker 
geïmplementeerd. Ook werden patiënten met een verder gevorderd stadium vaker besproken. 
De resectie marge (CRM) werd slechts in 61% van de gevallen genoteerd en werd door ons in de 
overige gevallen aanvullend gemeten. Het percentage positieve CRM’s was 13 % over de gehele 
studiepopulatie en verschilde niet tussen de besproken en niet besproken groep, waarschijnlijk omdat 
patiënten met een meer gevorderd tumorstadium met een hogere	a	priori kans op een positieve CRM 
juist geselecteerd werden voor de MDT bespreking. Theoretisch zouden patiënten na een accurate 
stadiering en adequate TME, na 5x5 Gy of zonder preoperatieve bestraling, geen positieve CRM 
moeten hebben omdat er geen sprake was van een bedreigde MRF. Het percentage positieve CRM’s 
was 10% in deze groep. In patiënten met lokaal uitgebreide ziekte bleek de voorbehandeling en de 
operatie in 20% van patiënten niet voldoende om een positieve marge te voorkomen. 
De resultaten van deze studie tonen aan dat er ruimte voor verbetering bestaat, vooraal in preoperatieve 
stadiering en selectie van patiënten voor kortdurende RT of geen RT. Gestandaardiseerde documentatie 
van behandelingskeuzes en PA verslagen zijn nodig. Dit laatste is sindsdien geïntroduceerd in de 
dagelijkse praktijk. Het uitvoeren van audits en implementeren van pro-forma’s, in het algemeen, zijn 
nuttig voor het terugkoppelen van informatie aan de MDT en kunnen gebruikt worden om de kwaliteit 
te waarborgen. 
HOOFDSTUK 3
Radiotherapie als (neo)adjuvante behandeling gaat gepaard met een verhoogde kans op bijwerkingen, 
op korte en langer termijn, zoals diarree, afwijkend ontlastingspatroon, fecale incontinentie en 
sexuele dysfunctie. Om de kans op bijwerking te minimaliseren moet de bestraling zo goed mogelijk 
aangepast worden aan alleen het te bestralen doel volume (“clinical target volume”, CTV) terwijl zo 
min mogelijk dosis gegeven wordt aan het omliggende gezonde weefsel. Er zijn echter onzekerheden 
waar rekening mee gehouden moet worden zoals variatie in de definitie van het te bestralen 




bestralingstoestel. Om te corrigeren voor deze onzekerheden wordt het CTV uitgebreid met een 
veiligheidsmarge en vormt dan het “planning target volume” (PTV). Naar mate we meer te weten 
komen over deze onzekerheden, door bijvoorbeeld in beeld te brengen hoe organen (en daarbij het 
doelvolume) bewegen tussen verschillende fracties, is de volgende stap het doelvolume en benodigde 
veiligheidsmarges te verkleinen. Dit was het doel van het onderzoek naar vormvariatie van de gehele 
CTV tijdens de preoperatieve bestraling in Hoofdstuk 3. 
In deze prospectieve studie werden tijdens de voorbehandeling (5x5 of CRT), dagelijks in de eerste 
week en daarna wekelijks bij de CRT patiënten, CT scans gemaakt. Het CTV werd volgens strikte 
definities ingetekend op in totaal 482 scans. De vormverandering was heterogeen, met grote variaties 
aan de voorzijde bij de blaas en dunnedarm (1 cm SD) en minder grote variaties aan de laterale zijde 
in de lymfklier regio’s (0.5 cm SD). Bij de benige structuren was de variatie het kleinst (0.2 cm SD). 
Tijdens de CRT behandeling nam het rectum volume in de tijd af, hetgeen resulteerde in een afname 
van het CTV aan de voorzijde met gemiddeld 0.5 cm. Tussen man en vrouw verschilde de variatie niet 
significant. 
De volgende stap na bepaling van de vormvariatie van het CTV was bepaling van de PTV marge. De 
algemeen bekende formules om onzekerheden te vertalen naar een CTV-PTV veiligheidsmarge zijn 
echter niet zonder meer te gebruiken. In hoofdstuk 3 is berekend hoe de formule moest worden 
aangepast voor gebruik in vormverandering en om voldoende dekking van het CTV te waarborgen. 
De voorgestelde marges in combinatie met een strikt ingetekend CTV resulteerde in PTV volumes die 
gemiddeld genomen 20% kleiner waren dan de “klassieke” klinische ruime intekeningen met een 1.0 
cm marge.
HOOFDSTUK 4
Preoperatieve CRT wordt gebruikt bij het LARC om middels verkleining van de tumor een radicale 
resectie te faciliteren. Verschillende beschrijvende studies laten een verhoogde incidentie van 
naadlekkage zien na neoadjuvant (C)RT. Dit wordt echter in gerandomiseerde studies niet bevestigd. 
Capecitabine, een orale vorm van het intraveneuze 5-FU dat in de gerandomiseerde studies werd 
gebruikt, is een aantrekkelijke vervanger van 5-FU. Het toxiciteitsprofiel hiervan is nog niet uitgebreid 
onderzocht. In Hoofdstuk 4 werd de acute toxiciteit en chirurgische morbiditeit van preoperatieve 
CRT met capecitabine in 147 patiënten met LARC geëvalueerd. Toxiciteit werd met behulp van de 
Common Terminology Criteria (version 3.0) en de Radiation Therapy Oncology Group scoring 
systemen geëvalueerd. Chirurgische complicaties werden gescoord tot 30 dagen na ontslag uit het 
ziekenhuis met behulp van vooraf bepaalde definities en de gevalideerde gemodificeerde Clavien-
Dindo classificatie.
De preoperatieve CRT werd goed getolereerd met een gemiddelde cumulatieve chemotherapie 
dosis van 95% van de geplande dosis, terwijl 98% van de patiënten tenminste 45 Gy van de 50 Gy 
heeft ontvangen. Ernstige toxiciteit (graad 3-5) werd door 22% van patiënten ondervonden, vooral 




sepsis overleden tijdens de CRT. De postoperatieve morbiditeit was aanzienlijk, maar dit liet zich niet 
vertalen in mortaliteit (0%). Naadlekkage werd bij 28% van de patiënten na een LAR geconstateerd, 
terwijl perineum wond complicaties werden gezien in 37% van diegenen die een APR ondergingen. 
Eén op 5 patiënten moest worden heropgenomen in het ziekenhuis binnen 30 dagen na ontslag. 
In deze relatief grote serie patiënten die preoperatieve CRT met capecitabine had ondergaan, was 
de acute toxiciteit acceptabel, de chirurgische morbiditeit aanzienlijk maar de mortaliteit laag. Een 
mogelijke verklaring voor de hoge morbiditeit zijn de ruime definities die gehanteerd werden in 
deze studie. Door een grote variatie in de gehanteerde definities van naadlekkage en perineumwond 
complicaties is vergelijking tussen studies moeilijk. Een uniforme definitie zal inter-institutionele 
vergelijkingen beter mogelijk maken.
HOOFDSTUK 5
Preoperatieve CRT gevolgd door TME 6-8 weken later geeft goede lokale controle, waardoor de 
ontwikkeling van afstandsmetastasen de prognose nu lijkt te gaan bepalen. Door de CRT veranderen 
echter de histolopathologische kenmerken na de behandeling, waarvan de prognostische betekenis 
nog onduidelijk is. Sommige tumoren gaan als gevolg van de CRT in volledige regressie met als 
resultaat volledige fibrosering van het gebied of vorming van slijmmeren. De literatuur beschrijft 
dat een complete respons geassocieerd is met een uitstekende prognose. Chemoradiotherapie 
zonder chirurgische resectie (of alleen lokale excisie) in geval van complete klinische remissie (het 
zogenoemde “wait and see” beleid) heeft geleid tot veelbelovende resultaten. Potentiële (negatieve) 
gevolgen hiervan, zoals achtergebleven microscopisch resten of klier metastasen die vooralsnog 
niet detecteerbaar zijn met de huidige beeldvormende technieken, moeten nog verder onderzocht 
worden. Doel van het retrospectieve onderzoek besproken in dit hoofdstuk was om de uitkomst na 
CRT te evalueren en de histopathologische voorspellers van tumor respons en uitkomst op langer 
termijn te evalueren.
De coupes van 107 patiënten werden gereviseerd volgens TNM 5de editie. Mate van respons van de 
primaire tumor werd gescoord (volgens ‘tumor regression grade’ of TRG) en ingedeeld in 4 groepen. 
In deze serie van bijna 40% cT4 tumoren bleek CRT zeer effectief te zijn; 20% van de patiënten had 
een pathologische complete respons (pCR), 11% een bijna complete respons (near-pCR), 55% liet een 
(partiële) respons zien en 14% liet geen respons zien. Lymfklier metastasen werden gevonden bij 29% 
van patiënten met een pCR en bij 50% met een near-pCR. Daarnaast werden bij de near-pCR groep 
kleine tumor restjes reikend tot in het mesorectale vet bij 42% van de patiënten gevonden. Patiënten 
met een pCR in onze serie hadden een zeer goede uitkomst. Diegene met een near-pCR hadden een 
onverwacht slechte uitkomst, 5 van de 12 patiënten ontwikkelden afstandsmetastasen.
Met de huidige beeldvormende technieken is het momenteel niet goed mogelijk lymfklier metastasen 
of microscopische resten in voldoende mate te kunnen identificeren of te onderscheiden van fibrose 




ondergaan is momenteel dan ook geassocieerd met de nodige risico’s en moet met terughoudendheid 
en voorzichtigheid toegepast worden. 
HOOFDSTUK 6
Aangezien 30% van patiënten na preoperatieve CRT een pCR of een near-pCR bereikt zal het markeren 
van de tumor in het rectum tijdens de behandeling van toenemend belang gaan worden. Endoclips 
die met röntgenstraling detecteerbaar zijn kunnen onder andere gebruikt worden om een tumor te 
markeren om klinische respons te meten of om een doelvolume te markeren tijdens brachytherapie 
(inwendige radiotherapie). Onderzoek naar hoe lang deze endoclips vast blijven zitten (retentie) blijft 
beperkt tot dierproeven en is niet eerder in het menselijke darmstelsel onderzocht. In Hoofdstuk 6 
werd de mate van retentie op lange termijn van twee moderne endoclips prospectief geëvalueerd als 
deel van een studie naar definitieve radiotherapie (gecombineerd uitwendig en inwendige bestraling) 
als behandeling bij medisch inoperabele patiënten. Het rectum tumor werd met Quickclips (Olympus 
Ltd.) en/of Resolution (Microvasive, Boston Scientific Corp) endoclips gemarkeerd om de tumor te 
lokaliseren tijdens de brachytherapie. 
In totaal werden er met de endoscoop 44 endoclips geplaatst in 9 patiënten voor of na de externe 
radiotherapie. Retentie van de endoclip werd bepaald bij vervolg endoscopie na de externe 
radiotherapie (echter voor de start van de brachytherapie) of met behulp van röntgenfoto’s tijdens 
de wekelijkse brachytherapie. De Resolution endoclip, die over de mogelijkheid beschikt herhaaldelijk 
zijn tanden te openen en sluiten, bleek gemiddeld langer te blijven zitten (retentie van 67% na 
bijna 12 weken) dan de Quickclip (35% retentie), die na eenmaal afgeschoten te zijn niet meer van 
positie kan veranderen. Een nadeel van deze endoclips is het feit dat ze niet bruikbaar zijn in de MRI, 
aangezien ze voor artefacten zorgen. Derhalve dient verder onderzoek plaats te vinden naar andere 
markeringstechnieken, bijvoorbeeld met behulp van submucosale goud markers.
HOOFDSTUK 7
Hoofdstuk 7 betreft de behandeling van patiënten met gemetastaseerde ziekte, in het bijzonder 
patiënten met peritoneale metastasen. Diverse onderzoeken hebben aangetoond dat cytoreductieve 
chirurgie gevolgd door Hypertherme Intraperitoneale Chemotherapie (HIPEC) een betere overleving 
geeft dan chemotherapie alleen bij patiënten met peritoneale metastasen van colorectale oorsprong. 
Echter, alleen patiënten bij wie een complete cytoreductie (residu na chirurgie <2.5 mm) is bereikt, 
blijken voordeel te ondervinden van deze ingrijpende behandeling. Momenteel worden er verschillende 
scoring systemen gebruikt om aan het begin van de operatie een schatting te maken of complete 
cytoreductie haalbaar is: 1) de Peritoneal Cancer Index (PCI), deelt het abdomen in 13 regio’s met 
lijnen en bepaald de hoeveelheid tumor per regio; 2) de Simplified Peritoneal Cancer Index (SPCI) 
gebruikt 7 regio’s die gerelateerd zijn aan anatomische structuren en bepaald ook de hoeveelheid 
tumor per regio; 3) en de 7 Region Count, die uit dezelfde 7 regio’s bestaat als de SPCI maar die alleen 




van de doeltreffendheid van de in Nederland gehanteerde SPCI met de 7 Region Count en de PCI. 
Vervolgens werd het voorspellende karakter van de 3 scorings systemen op complete cytoreductie en 
mediane overleving bepaald.
Uit deze studie met 92 patiënten bleek dat bij alle scorings systemen een oplopend aantal punten of 
aangedane regio’s geassocieerd was met een verminderde kans op complete cytoreductie. Met een 
afkapwaarde van 16 punten uit 39 bij de PCI, 13 uit de 21 bij de SPCI en 6 aangedane regio’s bij de 
‘7 Region Count’ waren de systemen het meest voorspellend en nam de overleving het sterkst af. De 
drie scorings systemen waren allen even effectief in het voorspellen van een complete cytoreductie 
en de resulterende overleving. De 7 ‘Region Count’ die, wegens zijn praktische eenvoud, de voorkeur 
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over 50 hospitals in three different countries. In January 2011 he started his surgical residency at the 
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